The effects of glyceryl trinitrate and ovariectomy on femoro-tibial articular cartilage, synovium and subchondral bone in normal and osteoarthritic ewes by Cake, Martin Andrew
   i. 
 
 
 
 
 
 
THE EFFECTS OF GLYCERYL TRINITRATE AND 
OVARIECTOMY ON FEMORO-TIBIAL ARTICULAR 
CARTILAGE, SYNOVIUM AND SUBCHONDRAL BONE IN 
NORMAL AND OSTEOARTHRITIC EWES 
 
 
 
Martin Andrew Cake BSc BVMS 
 
 
 
 
 
 
This thesis is presented for the degree of Doctor of Philosophy of Murdoch University 
 
 
 
 
2002    i. 
 
 
 
 
 
 
 
I declare that this thesis is my own account of my research, and contains as its 
main content work which has not previously been submitted for degree at any 
tertiary educational institution. 
 
 
 
 
Martin Cake 
8
th February 2002    ii. 
ABSTRACT 
 
Nitric oxide (NO) alters chondrocyte metabolism, and is thought to be a key catabolic mediator in 
osteoarthritis. NO is also an important modifier of bone metabolism, and may partially mediate the 
bone-sparing effects of oestrogen. Oestrogen has also been linked to the modulation of 
osteoarthritis, though its role is not clear. The aim of this study was to examine the structural and 
metabolic effects of ovariectomy and the NO donor glyceryl trinitrate (GTN) on (1) normal ovine 
femoro-tibial joint tissues, and (2) the progression of joint lesions in the established ovine 
meniscectomy model of osteoarthritis.  
 
Preliminary investigations tested a novel computer-assisted histomorphometric method of assessing 
osteochondral changes post-meniscectomy, in a trial of a putative disease-modifying osteoarthritis 
compound. Quantitative assessment revealed a subtle protective effect not evident by qualitative 
methods. These techniques were then used to test the experimental hypotheses in a combined trial 
involving 48 aged ewes, variously subjected to ovariectomy, bilateral lateral meniscectomy, and/or 
topical GTN therapy. At six months, joint tissues were analysed using histology, histomorphometry, 
dynamic biomechanical testing, serum markers, bone densitometry, and tissue culture of synovial 
fibroblasts and explants of cartilage and bone. Ovariectomy modified cartilage structure and 
chondrocyte metabolism, and induced subchondral bone remodelling. Prior ovariectomy altered the 
development of OA lesions post-meniscectomy, producing thicker but biomechanically inferior 
cartilage and elevated metabolic activity in subchondral bone. GTN treatment of normal sheep 
induced thinner, structurally-altered cartilage in normal sheep, and accentuated cartilage and 
subchondral bone lesions post-meniscectomy. These results support an important homeostatic role 
for oestrogen in joint tissues, and show that GTN, a commonly used angina therapy, can induce 
structural alterations in joint tissues and potentially accelerate the progression of concurrent OA. 
Results also advance understanding of the role of synovial and subchondral bone changes in the 
pathogenesis of this OA model.     iii. 
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VEGF    Vascular endothelial growth factor 
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PREFACE 
 
 
 
This thesis details the findings of sheep studies conducted between 1998 and 2002. Predominantly, 
these studies investigate the effects of ovariectomy, and the exogenous nitric oxide donor  glyceryl 
trinitrate, on the structural and metabolic integrity of joint tissues in normal and osteoarthritic 
(meniscectomised) sheep. A large number of techniques were used to fully investigate the effects of 
these interventions, encompassing histology, biomechanical testing, bone densitometry, serum 
markers, and extensive tissue culture. Most of these investigations were conducted by the author, 
the most notable exception being the dynamic biomechanical testing of cartilage, which was carried 
out in conjunction with Dr. Richard Appleyard of St. George Hospital, Sydney.  
 
Due to the length and scope of these studies, efficient use of time and subjects required that multiple 
hypotheses were tested within the design of a single large trial. For this reason, this thesis is 
composed of only four chapters: (Chapter 1) an introductory literature review and statement of 
hypotheses; (Chapter 2) a preliminary trial applying computerised image analysis methods to assess 
osteoarthritic changes in this sheep model; (Chapter 3) an extensive trial testing the main 
experimental hypotheses; and (Chapter 4) summary and conclusions. The testing of several 
hypotheses simultaneously within a single large trial may make it difficult for the reader to follow 
individual hypotheses through Chapter 3. It is important to note that the methods and results (3.2 
and 3.3) relating to multiple hypotheses (stated in 1.3) are presented together (i.e. all eight 
experimental groups), before discussing each hypothesis individually in 3.4. 
 
Reference is made within the text (and Appendix 1) to findings from another trial involving 
ovariectomised ewes, conducted simultaneously by our laboratories. Some of these findings have 
been presented in preliminary abstract form and are referenced as published work (i.e. Smith et al. 
(2000),
769 Parker et al. (2000),
611 Hwa et al. (2001)
367). Some of the findings of the present study are 
therefore described as confirmatory of these published works, but the reader should note these 
studies were essentially conducted in parallel.    1. 
CHAPTER 1 
INTRODUCTION 
 
 
1.1   LITERATURE  REVIEW 
 
1.1.1   OSTEOARTHRITIS 
 
1.1.1.1    Definition and Classification of Osteoarthritis 
 
Osteoarthritis (OA) is a disorder of moveable joints characterised by painful degeneration of 
articular cartilage and osteochondral remodelling, including osteophyte formation at joint margins.
17 
Cartilage degeneration leads to progressive fibrillation, fissuring, ulceration, and finally full 
thickness loss of cartilage, exposing the underlying subchondral bone.
618 In the earliest stages of 
OA, which are generally asymptomatic, cartilage lesions are small and focal and are accompanied 
by a hypertrophic response in the surrounding cartilage.
498 The term osteoarthritis implies a degree 
of inflammation in the synovial membrane, which is often grossly evident but may be confined to 
chronic low-grade inflammatory changes such as fibrosis. Similarly, the involvement of bony 
tissues is implicit in the nomenclature and subchondral bone sclerosis is thought to be an early and 
important change.
618 There is increasing evidence that the synovium and subchondral bone are not 
only the primary source of OA symptoms such as pain, but may also play an important role in the 
disease pathogenesis via feedback interaction with cartilage, and have even been proposed as the 
site of the initial lesion.
618,629 
  
A strict definition of OA is difficult, complicated by the surprisingly limited overlap between 
various subsets such as symptomatic, radiographic, and self-reported OA.
226 Classification by    2. 
radiographic criteria is problematic, as a large proportion of patients with radiographically-defined 
OA are asymptomatic. Despite this phenomenon, radiological criteria such as those proposed by 
Kellgren and Lawrence (1957)
414 and more recently Altman et al. (1995)
21 remain the standard, 
especially for epidemiological studies.  
 
The heterogeneity of OA presents inherent difficulties in the classification of the disease. Subgroups 
of OA have been identified by the joint involved (most commonly the hip, knee, hand, or spine in 
humans), or by the aetiological distinction of primary (idiopathic) versus secondary OA, where 
some predisposing cause is identified. A generalised form of primary OA has been described, 
generally involving the hands (proximal and distal interphalangeal joints), knees, and hips of elderly 
women.
578 However, given the heterogeneous nature of the disease, OA is better conceptualised as 
the final common pathway of a number of separate diseases, rather than being a single disease 
entity.
896 
 
1.1.1.2     Aetiology and Epidemiology of OA  
 
OA is the most common joint disorder in the world, with radiographic evidence of the disease 
present in over 80% of people over the age of 75.
224 The economic impact of OA is enormous; in 
the USA, arthritic conditions represent the leading cause of disability in people over 15 years of 
age, with a cost to the economy estimated at US$149 billion in 1992 alone.
924 OA is also the most 
common joint disorder in canine veterinary practice, with approximately 20% of dogs in the USA 
over the age of 1 year affected.
181,863 However, the prevalence of OA is imprecisely reported and 
dependent on definition.  
 
Risk factors for OA can be categorised into two broad mechanisms: those signalling a general 
predisposition to the disease, and those causing abnormal loading to specific joint locations.
724 
Alternatively, they can be divided into those aetiological factors placing abnormal stress on normal    3. 
cartilage, and those involving normal stress on abnormal cartilage. Consistently identified risk 
factors for human OA include aging, obesity, high bone mass, major trauma (e.g. cruciate ligament 
and meniscal injuries), repetitive use (often occupational), and developmental disorders such as 
congenital dislocation of the hip.
224  
 
Interestingly, smoking is thought to be protective.
722,724 Age is the most powerful predictor of OA 
for all joints. It is unknown whether this is due to the cumulative effect of mechanical damage, or 
intrinsic age-related changes in joint tissues.
422 Obesity has been shown to have a strong association 
with knee OA, but a less clear relationship with hip or hand involvement. In one Swedish study, 
women with a high body mass index (BMI) at age 40 had a relative risk of knee replacement 
surgery of 9.2.
722 Gender also has a major influence on OA, especially in older patients. The 
prevalence of OA is similar in men and women until about 50 years of age, after which females 
show more prevalent, generalised, and severe OA.
911 The coincidence of this observation with the 
timing of the female menopause suggests that changes in sex hormones levels may potentially 
influence the disease.  
 
1.1.2   STRUCTURE OF NORMAL AND OSTEOARTHRITIC JOINT TISSUES  
 
1.1.2.1   Articular Cartilage 
 
The articular surfaces of synovial joints are covered with a smooth, resilient layer of hyaline 
cartilage. This provides a durable weight-bearing surface with a very low coefficient of friction, 
which is sufficiently 'spongy' to minimise peak stresses transmitted to the underlying bone. 
Articular cartilage is a highly specialised tissue consisting of sparsely distributed chondrocytes 
(only about 5% of its total volume), embedded in an abundant extracellular matrix. This matrix, 
essentially a stiff fibre-reinforced gel, relies on two principal structural components for its 
biomechanical properties: large hydrophilic proteoglycan polymers known as aggrecan, and a    4. 
network of collagen fibrils, principally type II collagen. These two components provide cartilage 
with its distinctive viscoelastic properties, the collagen chiefly providing resistance to deformation 
and shear, while proteoglycans provide swelling pressure and pre-stress in the collagen network.
745 
 
Three cartilage layers, termed the superficial, intermediate, and deep zones, are arbitrarily 
discriminated by histology and more recently by magnetic resonance imaging (Figure 1.1).
158 These 
layers are alternatively named according to the predominant orientation of collagen network, as the 
tangential zone (fine fibrils densely packed parallel to articular surface), intermediate zone 
(apparently random, oblique fibril orientation), and radial zone (large fibrils oriented perpendicular 
to the cartilage surface). The cellular form of chondrocyte also varies by zone, from the elongated, 
parallel-aligned cells of the superficial zone to the spherical form of deep zone chondrocytes. 
Another classification of matrix compartments is defined by the alterations in the collagen network 
in the proximity of chondrocytes: pericellular matrix (little collagen), territorial matrix (defined by a 
fine collagen 'basket' around the chondrocyte), and interterritorial matrix (larger, more ordered, 
parallel fibres). A chondrocyte, its surrounding capsule, and pericellular matrix form a 'chondron' – 
regular spherical matrix units surrounding individual chondrocyte lacunae, which can be isolated by 
specific digestion methods.
647 
 
1.1.2.1.1   Chondrocytes 
 
Despite the avascular nature of cartilage, chondrocytes are very active metabolically. They 
synthesise all macromolecules of the cartilage matrix, and regulate continuous turnover of matrix 
components. The nutritional requirements of chondrocytes are met by passive diffusion, a process 
assisted by intermittent joint compression. They are therefore largely dependant nutritionally on 
synovial fluid;
824 the extent of diffusion via the underlying bone is unknown. Phenotypically, 
chondrocytes are not homogeneous but show regional variation in metabolic activity, particularly 
between superficial and deep zone chondrocytes.
329    5. 
Figure 1.1:   Schematic representation of articular cartilage zones as defined by chondrocyte 
morphology and predominant collagen orientation (reproduced, with permission, from Smith and Ghosh 
(1998)
771) 
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1.1.2.1.2   Cartilage  Matrix   
 
The extracellular matrix is composed primarily of water, which forms 70-80% of its wet weight, 
variable with depth. This water is loosely bound to the hydrophilic proteoglycan-collagen 
composite, and is able to extrude under compression. Such water movement is responsible for the 
elasticity and resilience of cartilage, and may play a role in joint lubrication. Proteoglycans make up 
approximately 22-38% of the dry weight of articular cartilage, the remainder being predominantly 
collagen.
502 The composition of articular cartilage is regionally variable; for example, the portion of 
the tibial plateau not covered by the meniscus is thicker, less cellular, and biomechanically inferior 
compared to that protected by the meniscus.
41    6. 
Figure 1.2:   Structure of an aggrecan monomer and its attachment to hyaluronan. N, N-terminal 
G1 domain; LP, link protein; HA, hyaluronic acid (after Lapcík et al. (1998)
451) 
                                            
 
 
Aggrecan 
 
Most proteoglycans within articular cartilage are present as large aggregates in association with a 
hyaluronic acid (HA) chain.
315 Proteoglycans forming such aggregates are termed aggrecan. Many 
individual aggrecan monomers are bound to a filamentous core formed by a single HA molecule; 
this non-covalent bond involves a specific HA binding region (the G1 domain) and is stabilised by a 
separate link glycoprotein (Figure 1.2). The proteoglycan monomers themselves have a similar 
bottle brush-like structure, with glycosaminoglycan side-chains (principally keratan sulphate and 
chondroitin sulphate) covalently attached to a central core protein.
314 
 
Due to their highly anionic nature, proteoglycans are very hydrophilic and expand greatly in volume 
when fully hydrated. When combined into the massive aggrecan complex and enmeshed within the 
Aggrecan core protein 
Keratan sulphate side-chains 
Chondroitin sulphate side-chains    7. 
collagen network, proteoglycans create significant swelling pressure which gives cartilage its 
turgidity, resilience and shock-absorbing capacity.
848 By retaining nearly all available water, 
proteoglycans also restrict water flow and sequester ions, and control fluid dynamics within the 
cartilage matrix.  
 
Non-aggregating Proteoglycans 
 
A minor subpopulation of cartilage proteoglycans do not form aggregates with HA. The role of 
these non-aggregating proteoglycans is unknown, though they are thought to be involved in 
collagen fibril organisation, inhibiting mineralisation, regulating matrix turnover, and facilitating 
interactions between chondrocytes and their surrounding matrix. Several small non-aggregating 
proteoglycans are well characterised and are thought to have important roles. Decorin has a 36.5 kD 
protein core and a single dermatan sulphate side-chain, and is thought to influence the morphology 
of type I and II collagens.
316 Fibromodulin, which has several keratan sulphate side-chains, localises 
to the cartilage surface associated with the large glycoprotein fibronectin. Fibromodulin may 
prevent the collagen interactions necessary for collagen auto-recognition and fibroblast adhesion.
589 
Biglycan has a small 38 kD core and a few dermatan sulphate side-chains. It is found mainly 
pericellularly, though its function is unknown.
316  
 
Collagens 
 
Articular cartilage contains the following types of collagen: 
 
Fibrillar collagens 
 
Type II collagen comprises 85-90% of the total collagen in articular cartilage. It is formed from a 
triple helix of three identical alpha polypeptide chains. As the primary structural collagen in    8. 
articular cartilage, it is responsible for the high tensile strength and ability to resist deformation 
characteristic of this tissue. It is a product of the well-studied COL2A1 gene; mutations of this gene 
have been associated with various connective tissue disorders such as achondroplasia.
15 
 
Type V and XI collagen are structurally similar, and are present in low amounts (<5% of total) in 
association with type II fibrils. These collagens form small fibrils that closely associate with the 
larger fibrils, and may function to modulate their diameter.
80 
 
Type I and III collagen are synthesised by chondrocytes in vitro but are minor components of 
mature articular cartilage.  
 
  Non-fibrillar collagens 
 
Type IV collagen is present in small amounts and may act to cross-link the larger fibrillar collagens. 
 
Type VI collagen comprises 1-2% of total collagen, and is found mainly in the form of a fine 
network which defines the pericellular capsule.
647 It is relatively resistant to collagenase 
degradation.
62 
 
Type IX collagen differs from type II in being the product of three separate genes, which code for 
distinct alpha chains. It may act as a stabiliser between adjacent type II fibrils, limiting their 
separation and aiding entrapment of proteoglycan aggregates (Figure 1.3).
189 
 
Type X collagen is normally synthesised only by hypertrophic chondrocytes of the calcified 
cartilage zone, and is presumed to play a role in mineralisation of this layer.
721,881 
 
    9. 
Figure 1.3:   Schematic representation of the interaction of various matrix components. Aggrecan 
proteoglycan monomers elaborated by chondrocytes form large aggregates with cell surface-
associated hyaluronan. Minor collagens such as type IX, together with small non-aggregating 
proteoglycans stabilise the network of larger type II collagen fibrils (reproduced, with permission, from 
Smith and Ghosh (1998)
771). 
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1.1.2.1.3   Cartilage  Changes  in  Osteoarthritis 
 
Conceptualisation of the pathogenesis of OA has altered over the past few decades, with recognition 
that cartilage is a metabolically active tissue, and the changes observed are not simple wear 
processes but are the results of imbalances in a dynamic equilibrium (Figure 1.4).
629 Importantly, it 
is now recognised that many of the processes of cartilage degradation can be mediated by the 
chondrocyte alone. An imbalance in matrix homeostasis occurs, such that the equilibrium between 
anabolic and catabolic events is shifted in favour of degradation. Anabolic activity increases 
steadily up to a certain stage of degeneration, then dramatically decreases as repair mechanisms 
become ineffective and cell death occurs.
498    10. 
Insert Figure 1.4 after 
177 
    11. 
Biochemically, OA progression is characterised by increased turnover and eventual net loss of 
proteoglycan, early disruption of collagen architecture, and an increased water content. This 
increase in hydration is one of the earliest detectable events in OA and implies failure of the elastic 
restraint of aggrecan swelling provided by the collagen network. In early stages of the disease, the 
anabolic repair response is predominant; however this is often defective, producing proteoglycans 
of abnormal composition, distribution, and aggregating ability. The sulphation state of 
glycosaminoglycans is increased, and the proportion of chondroitin 4-sulphate increases while that 
of chondroitin-6-sulphate and keratan sulphate is decreased.
499 Previously minor components such 
as dermatan sulphate, decorin, biglycan, fibronectin are also proportionally increased.
475 These 
changes in chondrocyte metabolic activity are probably the result of continued cytokine stimulation 
rather than a permanent phenotypic change, as they have experimentally been shown to reverse 
after a few days in culture.
864 
 
Collagen changes occur early in the OA process, within a few days in experimental animal models. 
Wider spacing of type II fibres is apparent, accompanied by the appearance of novel thinner fibres. 
An increase in type II collagen synthesis is one of the early anabolic responses of OA chondrocytes, 
which may also show abnormal production of type I, III and X collagens.
9,881 It has been shown in 
vitro that the key catabolic cytokine interleukin-1ß (IL-1ß)  selectively increases chondrocyte 
synthesis of type I and III collagens while depressing type II and IX collagen synthesis.
721 Collagen 
breakdown and turnover is also increased in OA cartilage. As the basal rate of collagen turnover is 
lower than that of proteoglycans, the loss of the collagen network is a less reversible change than 
aggrecan loss.
636  
 
Structurally, OA is characterised by the appearance of perpendicular clefts in the articular cartilage 
surface, which become progressively deeper and coalesce to form regions of overt fibrillation. Loss 
of proteoglycan staining progresses from the superficial layer into deeper zones with worsening 
disease.
498 Initially, hypercellularity is present with the formation of clusters of chondrocyte clones,    12. 
later progressing to hypocellularity and the appearance of empty chondrocyte lacunae. Cell death 
may be a central event in OA, a process possibly driven by chondrocyte apoptosis.
322 
 
Biomechanically, OA cartilage shows reduced static compressive stiffness, a change partly related 
to increased matrix permeability, which is normally very low.
455 Dynamic shear stiffness, measured 
as the dynamic shear modulus (G*), is often severely reduced due to fibrillation, rupture of collagen 
fibres and loss of proteoglycan-supplied collagen pre-stress.
935 Phase angle (), a vector of viscous 
and elastic properties ranging from 0° (perfectly elastic) to 90° (perfectly viscous), is increased 
suggesting increased frictional energy dissipation due to loosening of collagen-proteoglycan 
interactions.
745,746 
 
1.1.2.2     Synovial  Membrane 
 
1.1.2.2.1 Structure  of  Normal  Synovium 
 
The synovial cavity is lined by a thin layer of specialised cells, whose major function is to produce 
and regulate the synovial fluid which lubricates and provides nutrition to articular cartilage. Normal 
synovium consists of an intimal lining layer containing primarily those cells designated 
‘synoviocytes’, and a subintimal layer of fibroblasts, macrophages, lymphocytes, mast cells, nerves, 
and vascular elements in a loose connective tissue matrix.
339,558 The lining layer is 1-3 cells deep in 
normal synovium, with no basement membrane, though tight junctions between cells may be 
present. 
205,558,759,917 Decorin, biglycan, fibromodulin and fibronectin are co-distributed with collagen 
in the loose subsynovial connective tissue.
146,613 The synovial nerve supply was once thought to be 
sparse, but a good supply of nociceptive unmyelinated C fibres is now recognised.
501 Changes in 
synovial  membrane composition occur with age, with more numerous villi and increasing 
irregularity of blood vessel and cell distribution.
613 
    13. 
Synoviocytes are unusual in their mixed characteristics of a mesenchymal origin, immunological 
capability, and an epithelial role.
753 Barland et al. (1962)
58 was the first study to identify two distinct 
synovial cell types, on the basis of their transmission electron microscopic characteristics. These 
could be broadly characterised as phagocytic (type A) and secretory (type B) cells. This functional 
definition has lead to the suggestion by several authors that synoviocytes represent a single cell type 
with great morphologic flexibility.
221,280,423 Other studies have concluded the two cell types are 
totally distinct and no intermediate types exist.
279 
 
Type A  synoviocytes are thought to function as phagocytic cells with antigen processing 
capabilities. Phenotypically they resemble tissue macrophages, with a prominent heterochromatin-
rich nucleus, numerous peripheral cytoplasmic vacuoles, fine lamellar extensions of the cell surface, 
a prominent Golgi apparatus, and scant endoplasmic reticulum.
221,279,558 They express typical 
macrophage markers such as CD11, CD14, CD68, and class II major histocompatibility complex 
(MHC) antigens, as well as non-specific esterase activity.
558,900 Type A synoviocytes comprise 
approximately 30% of cells in the intima and subintima, with the proportion reportedly increasing 
with age and progression of arthritis.
138,288,613 However, a decrease in Type A synoviocytes has been 
reported as an early pathologic change in canine hip dysplasia.
289 In rheumatoid arthritis (RA), a 
distinct subpopulation of Type A cells is recognised, termed dendritic cells. These CD13/CD33-
positive cells interact with T lymphocytes as antigen-presenting cells.
48,558 
 
Type B synoviocytes resemble tissue fibroblasts, with a bipolar or spindle-shaped form, extensive 
rough endoplasmic reticulum with wide cisternae, less developed Golgi apparatus, pale 
euchromatin-rich nuclei with a number of nucleoli, and small cytoplasmic secretory granules, but  
fewer large vacuoles than Type A cells. 
221,279,558 These morphological features point to their 
primarily synthetic function, in the production of hyaluronan and matrix components such as 
collagen. Several distinctive features distinguish Type B synoviocytes from other tissue fibroblasts: 
(1) sustained release of interleukin-6 (IL-6) in culture;
128 (2) expression of vascular cell adhesion    14. 
molecule-1 (VCAM-1);
231,553,899 and (3) high activity of uridine diphosphoglucose dehydrogenase 
(UDPGD), an enzyme related to hyaluronan synthesis.
231,377,900 However, membranes lined with 
cells of high UDPGD activity have been shown to form spontaneously around prosthetic implants, 
especially where shear stresses occur.
205 Approximately 75-85% of the glycosaminoglycans 
synthesised by synovial fibroblasts is hyaluronan.
26,375 HA synthesis is continued by cells in tissue 
culture, forming a loose pericellular matrix around each cell.
242 Synovial fibroblasts also produce 
small sulphated glycosaminoglycans, mainly in the form of dermatan sulphate.
118,300  
 
While VCAM-1 does appear to be a distinctive feature of  synovial fibroblasts, expression is more 
consistent in arthritic synovia.
437,553,899 Intercellular adhesion molecule-1 (ICAM-1) is also 
expressed following cytokine stimulation; up-regulated expression of these adhesion molecules in 
RA has been linked to the binding of invading inflammatory cells.
553 Cells of the immortalised 
rheumatoid synovial fibroblast line RAMAK-1 constitutively express ICAM-1, but express VCAM-
1 only when stimulated by tumour necrosis factor- (TNF-).
409  
 
The formerly debated origins of Type A and B cells have been clarified by the studies of Edwards et 
al. (1994).
205 Following bone marrow implantation from beige mice into irradiated histocompatible 
normal mice, giant granules were identified only in cells with the characteristics of Type A cells. 
This suggests that, in common with other tissue macrophages, Type A cells are derived from bone 
marrow and subsequently migrate to the synovial intima to undergo maturation.
376 Expression of 
leucocyte common antigen by Type A cells also suggests their origin from haematopoietic stem 
cells.
48 Type B cells are derived either locally (by cell division), or from an unidentified stem cell 
population in the subintima. However, the rate of cell division in synovial lining cells is low under 
most conditions. 
 
Synovial fibroblasts (Type B synoviocytes) were once considered to be relatively inactive secretory 
and maintenance cells, but studies in RA have confirmed their potential for joint destruction when    15. 
activated.
558 Experiments in severe combined immunodeficiency (SCID) mice and refined in vitro 
systems have shown that synovial fibroblasts are capable of cartilage destruction completely 
independent of T-cell influence.
558,740  
 
1.1.2.2.2   Synovial Changes in Osteoarthritis 
 
Whilst OA is not historically considered an inflammatory disease, some degree of synovitis is often 
present and is likely to be important in the disease pathogenesis. It is becoming recognised that OA 
synovium can demonstrate the same inflamed and activated phenotype as rheumatoid tissue, and 
that the difference between the diseases is more quantitative than qualitative.
214,472 In an important 
study by Smith et al. (1997)
768 examining synovial biopsies from patients with early OA, a 
significant increase in thickness, vascularity, inflammatory cell infiltration, and cytokine production 
was consistently detected even in early stages of the disease. Altered synovial vascularity (dilation 
of existing vessels and angiogenesis) is a consistent change in OA. Despite this altered vascularity, 
synovial fluid can be hypoxic and acidic in inflammatory conditions.
797 Altered vessel permeability 
and subsequent leakage of serum proteins promotes synovial oedema, increased synovial fluid 
volume, and the accumulation of fibrin on the intimal surface.
243,888 The same changes also admit 
joint-derived HA into the circulation, and elevated serum HA levels have been shown to be 
predictive of OA progression and synovitis.
495,747 
 
Infiltration of inflammatory cells (especially T and B lymphocytes) is variable and generally focal 
in OA synovia, but can be considerable.
470,568 A subset of OA patients seem to show greater severity 
of inflammatory features, with prominent lymphoid aggregates.
682 However, the importance of T-
cells in synovial inflammation is questionable, as T-cell-specific cytokines are absent from both OA 
and rheumatoid synovia, and perivascular lymphoid aggregates are occasionally present in normal 
human synovium.
214,471,576 Mast cells are found in appreciable numbers in OA synovia, and may 
play a role in synovial inflammation and joint effusion.
94,337,640,652,680,681    16. 
Mild to moderate synovitis is observed in around 50% of biopsies from OA dogs.
863 Following 
experimental anterior cruciate ligament transection (ACLT) in dogs, synovitis develops rapidly.
567 
Hyperplasia and inflammatory changes (subsynovial lymphocyte and plasma cell accumulation) are 
prominent by 8 weeks post-operatively, and fibrosis develops within 13 weeks.
473 However, careful 
haemostasis during open surgery considerably reduces the incidence of synovitis when compared to 
a blind ‘stab’ technique.
567,569 In rabbit models of OA, synovial responses are rapid and severe, often 
preceding observable cartilage changes.
808 Synovial hyperplasia is a prominent event, observed 
rapidly following the Hulth procedure (ACLT and hemimeniscectomy),
484 joint immobilisation,
430 
10% NaCl injection,
862 or repetitive impulse loading.
880 
 
The cause of synovitis in OA has not been identified, but breakdown products of cartilage are 
assumed to play a role.
210,629 Cartilage-derived proteoglycans provoke synovitis when injected intra-
articularly in rabbits, suggesting the effect of cartilage wear products may be from chemical factors 
as much as the physical presence of particles.
83,252 Breakdown products of type II collagen are 
similarly antigenic.
436 Embedded macroscopic cartilage shards are commonly observed in the 
synovium in end-stage OA, but are absent in the initial phases and are not visibly associated with 
inflammatory changes.
571 Microcrystals of calcium pyrophosphate and hydroxyapatite are often 
present in OA synovial fluids, though their significance is unknown.
20,738,860 
 
1.1.2.2.3 Synovium-Cartilage  Interactions  in  Osteoarthritis 
 
In a landmark series of experiments, Fell and Jubb (1977)
222 demonstrated that normal synovium, 
when minced, was capable of inducing degradation of co-cultured explants of normal cartilage. 
Subsequent experiments showed that: (i) killed cartilage showed significantly less degradation, 
suggesting that any direct enzymatic action was only partially responsible; and (ii) direct contact 
was not required, highlighting for the first time the presence of soluble ‘chondrocyte activating 
factors’ (CAF) capable of inducing chondrocytes to digest their own matrix.
221 Meats et al.    17. 
(1980)
534 further showed that these synovial factors induced chondrocyte release of plasminogen 
activator and prostaglandin E2 (PGE2). More recently, Scott  et al. (1997)
740 showed using a 
rheumatoid synovial fibroblast / macrophage line co-culture system, that 90% of CAF activity could 
be abolished by blocking antibodies to IL-1ß and TNF-, though IL-6 antibodies had a surprisingly 
large effect. However, other studies have found a less dominant role for IL-1 and shown that other 
as yet uncharacterised cytokines contribute to synoviocyte-chondrocyte cross-talk.
57 The umbrella 
of synovium-derived CAF probably also includes various growth factors, which are less well 
characterised than catabolic cytokines, but may include transforming growth factor-ß (TGF-ß) and 
basic fibroblast growth factor (bFGF).
32,57,130 
 
Current evidence suggests that in OA, pro-inflammatory cytokines may potentially be produced 
first in the synovial membrane, then diffuse across the synovial fluid to affect chondrocytes.
618 
However, the true importance of such tissue cross-talk is unknown. In a study directly comparing 
OA cartilage and synovium within the same joint, chondrocytes were seen to be the primary source 
of the important mediators IL-1, TNF- and nitric oxide.
538 Immunohistological studies of OA 
synovia also demonstrate increased expression of matrix metalloproteases (MMPs) and their 
inhibitors, predominantly in the intimal lining layer, in levels which correlate with the histological 
severity of synovitis.
232,593 It has been demonstrated that synovial fibroblasts are a major source of 
these catabolic enzymes.
539 However, the role of synovial-derived proteases in cartilage degradation 
has not been clearly demonstrated, with current evidence suggesting they are less important than 
endogenous cartilage enzymes.
624 
 
1.1.2.2.4 Rheumatoid  Arthritis 
 
Rheumatoid arthritis is a chronic polyarthritis characterised by severe synovial hyperplasia and 
dense subsynovial lymphoplasmacytic infiltrate. The simultaneous involvement of multiple joints is 
strongly suggestive of initiation by some circulating factor; one hypothesis suggests localisation of    18. 
persistent bacterial or viral antigens to the joint as a causal pathway.
310 Genetic factors also seem 
important though it is unknown whether these relate to differences in systemic or local responses.
737 
Intimal hyperplasia is one of the earliest and most striking alterations in RA, and correlates directly 
with the severity of joint erosion.
339 Two main pathways seem to operate in RA: (i) infiltration of 
the subsynovium by various T-cell types, which may (or may not) play a central role in initiating 
and perpetuating inflammation through interactions with antigen-presenting cells;
857 and (ii) 
activation of synovial fibroblasts to form an extremely aggressive, transformed phenotype.
324 RA 
synovium often forms a vascular 'pannus' which adheres to and erodes affected bone and cartilage. 
Lymphoid elements may make up over 5% of the total tissue mass in RA.
765 It has been 
demonstrated that patients with focal lymphoid aggregates produce more inflammatory cytokines 
than patients with more diffuse mononuclear infiltration, suggesting this marks a greater degree of 
immune activation.
919 Certain characteristics of rheumatoid synovium, such as the invasive growth 
of synovial xenografts implanted into SCID mice, are suggestive of neoplastic transformation.
231 
Certainly, the oncogene products egr-1,  c-fos and c-jun are constitutively expressed in RA,
201 
though this is probably a reflection of chronic inflammation rather than any primary growth 
abnormality.
693 
 
1.1.2.2.5 Synovial  Fluid 
 
Synovial joints contain a small volume of synovial fluid, which nourishes and lubricates the 
articular cartilage. By forming a thin viscous film between congruent joint surfaces, synovial fluid 
opposes distraction but not shearing movement.
759 Though synovial fluid, and in particular its 
hyaluronan content, is known to be important in cartilage-on-cartilage lubrication, the exact mode 
of this lubrication is the subject of some debate, and may differ between high and low load states. 
Thin film lubrication,
485 boundary lubrication, “weeping” hydrostatic lubrication
657, and “boosted” 
lubrication (by squeeze-film entrapment and enrichment)
882 have all been proposed.  
    19. 
Synovial fluid is essentially an ultrafiltrate of plasma, supplemented with HA secreted by type B 
synovial lining cells.
889 Another synovial fluid protein not derived from plasma is lubricin, which is 
thought to be important in boundary-layer lubrication of cartilage. The pressure within healthy 
synovial fluid is normally sub-atmospheric, due to the swelling pressure exerted by the hyaluronan 
matrix.
759 In OA, the mechanisms allowing selective exclusion of serum components from synovial 
fluid fail, resulting in: (i) increased protein content; (ii) increased fibrinogen content, hence a 
tendency to clot; (iii) increased inflammatory cell content; and (iv) reduced viscosity due to dilution 
of HA, despite an increase in HA synthesis by the inflamed synovium.
567 The HA component of 
synovial fluid is crucial to its rheologic properties, resistance to fluid leakage out of the joint 
cavity,
148 and maintenance of sub-atmospheric joint pressures.
759 Reduction in both the quantity and 
quality of synovial fluid HA has a major influence of the progressive deterioration of OA joints. 
Locally-generated oxygen radicals may be another significant cause of HA degradation within 
inflamed joints.
730 
 
Certain synovial fluid markers have been investigated as diagnostic indicators of OA disease 
activity.
601 The cytokine content of synovial fluid has been examined by numerous studies.
465,678 IL-
6 and TNF- have shown promise as synovial fluid markers in anterior cruciate ligament (ACL)-
deficient dogs and humans.
105,328 Reported synovial fluid levels of IL-6 vary widely – from 1 to 
1000 pg/ml in OA patients, and up to 72,300 pg/ml in inflammatory arthropathies.
678 Synovial IL-
1ß levels are an unreliable marker: while Westacott et al. (1990)
898 found appreciable levels, other 
studies have failed to detect IL-1 in OA synovial fluids.
74,865 Cartilage-derived proteoglycan 
fragments are also promising synovial fluid markers of joint disease, measured either as 
glycosaminoglycan content by dye binding assays,
113,167,372,668 or by immunological methods 
recognising the HA binding region of aggrecan.
105,113,910 
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1.1.2.3     Subchondral Bone 
 
1.1.2.3.1   Normal Structure of Subchondral Bone 
 
The subchondral bone region is defined as the thin layer of cortical bone between the calcified 
cartilage and the supportive epiphyseal cancellous bone. The calcified cartilage layer provides a 
transition zone between the compliant cartilage and stiffer bone, freely traversed by type II collagen 
fibres which are anchored to the subchondral bone. The calcified layer is distinct in containing type 
X collagen, which is likely to be involved in the calcification process.
721 During growth, the deepest 
layers of calcified cartilage undergo endochondral ossification, while the superficial boundary, or 
tidemark, advances into the uncalcified layers above. The calcified cartilage and its supporting 
cortical bone form a functional unit often termed the subchondral bone plate. The irregular and 
convoluted interface between these layers greatly strengthens the bond created by the thin cement-
like layer between them.
388 The thickness of the subchondral plate is often proportional to the 
thickness of the overlying cartilage; this phenomenon is not easily explained, as the stresses 
responsible for modelling bone (chronic, low frequency) and cartilage (dynamic, high frequency) 
are potentially different.
545 
 
The basic unit of bone, an osteon, represents a central Haversian canal and its surrounding 
concentric lamellae of mineralised matrix.
155 There are two major groups of cells within bone: 
 
Osteoblasts are plump, strongly basophilic cells that line most bony surfaces. They arise from 
osteoprogenitor stem cells within the bone marrow.
71 Osteoblasts produce (and gradually become 
buried in) the non-mineralised collagenous matrix known as osteoid. As osteoid mineralises the 
enclosed cells lose much of their secretory activity and become phenotypically distinct as 
osteocytes, which extend long cytoplasmic projections into minute bone channels known as 
canaliculi.     21. 
Osteoclasts are large multinucleate cells with abundant cytoplasm, mitochondria, and ribosomes. 
Osteoclasts are distinct in their origin from the circulating monocyte-macrophage system.
696 They 
become activated on attachment to mineralised bone, forming a ruffled border in intimate contact 
with the exposed bone surface. Enzymes active under acid conditions are secreted to dissolve bone, 
producing resorption pits termed Howship's lacunae. 
 
Bone is not static but is continuously remodelled according to Wolff's Law, which states that the 
architecture of bone is dictated by the stresses acting upon it.
912 Classical remodelling involves a 
cycle of osteoclastic resorption, followed by deposition and eventual mineralisation of osteoid. 
Osteoid primarily consists of type I collagen, deposited within a ground substance of proteoglycan 
and non-collagenous proteins such as osteonectin and osteocalcin. Mineralisation involves the 
formation of hydroxyapatite crystals (Ca10(PO4)6(OH)2) in a poorly understood process apparently 
initiated by the osteocyte. 
 
1.1.2.3.2  Subchondral Bone Changes in Osteoarthritis 
 
Sclerosis and stiffening of the subchondral bone plate are well-recognised characteristics of OA, 
though thinning of the underlying cancellous trabeculae has also been demonstrated. Rapid 
appositional bone growth produces prominent layers of osteoid, while lagging mineralisation 
creates a relatively hypomineralised matrix.
39,293 Osteonecrosis is frequently observed, probably due 
to ischaemia secondary to microfracture or thrombus formation. Resorption of necrotic regions 
creates the large subchondral bone cysts commonly seen in some species. Calcified cartilage 
remodelling occurs, resulting in increased vascularity and irregularity and duplication of the 
tidemark. 
 
    22. 
Two recent studies have shown metabolic differences in bone cells derived from the subchondral 
region of human OA joints. Westacott et al. (1997)
897 found that supernatants from OA bone cells 
induced release of glycosaminoglycan from cartilage explants, whether they were viable or dead. 
Hilal et al. (1998)
350 found that both subchondral explants and primary cultures of osteoblast-like 
cells show an altered phenotype in OA, with increased release of urokinase-type plasminogen 
activator, insulin-like growth factor-1 (IGF-1), alkaline phosphatase, and osteocalcin. Such studies 
show that active local release of cytokines and other mediators may be at least as important in 
subchondral bone remodelling as mechanical mechanisms. They also raise the possibility that bone-
derived factors such as cytokines and catabolic enzymes might have a direct effect on overlying 
cartilage if able to diffuse across the bone-cartilage interface.
243 On the basis of these studies, 
Martel-Pelletier  et al. (1999)
505 recently proposed that up-regulation of the IGF / IGF binding 
protein (IGFBP) axis is central to the simultaneous events of attempted cartilage repair and 
subchondral sclerosis. Whether systemic release of growth factors (IGF-1, TGF-ß) might also 
mediate the differences in bone metabolism at distant skeletal sites that have been observed in OA 
remains an intriguing theory.
184 
 
Altered subchondral bone turnover and metabolic activity appear to be early and central changes in 
OA.
350 Dieppe et al. (1993)
194 demonstrated increased activity in OA subchondral bone by 
scintigraphy and, importantly, found that this was predictive of joint space narrowing. Observed 
elevations of type I collagen synthesis, MMP-2 and alkaline phosphatase activity, and integrin 
expression in OA subchondral bone similarly demonstrates altered metabolic activity.
54,107,500 A 
localised increase in concentrations of growth factors such as TGF-ß, as has been observed in 
similar tissue, may represent one stimulus for such changes.
500 Other cytokines that may be 
involved in OA bone remodelling (particularly bone loss) include IL-1, IL-6, IL-11, and TNF-. 
Receptor activator of NF-ß ligand (RANKL), a potent stimulus of osteoclast formation and 
activation,
355 is detectable in rheumatoid synovium, but not healthy tissues.
285 Fazzalari et al. 
(2001)
219 recently showed that while RANKL levels correlate strongly with bone turnover in normal    23. 
femoral heads, the same association is not evident in OA bone, suggesting inflammatory cytokines 
such as those mentioned above may assume a dominant role in the control of bone metabolism in 
arthritic conditions. 
 
1.1.2.3.3  Role of Subchondral Bone Changes in the Pathogenesis of OA 
 
Radin et al. (1972)
658 first proposed that sclerosis and stiffening of the subchondral bone plate may 
be central to the pathogenesis of OA. They proposed that repetitive impulse loading results in 
trabecular microfractures and subsequent remodelling and stiffening, which reduces compliance of 
the subchondral bone structure and increases the stresses applied to cartilage. Advancement of the 
tidemark effectively causes thinning of the uncalcified layer, which increases shear forces near the 
base of the cartilage.
363 Other authors have subsequently endorsed the theory that bone sclerosis 
plays a major role in the pathogenesis of OA.
412,505,506,618,656 However, whether this process truly 
initiates or is an early secondary feature of cartilage loss remains the subject of debate. Several 
observations complicate this hypothesis. Firstly, it is very difficult to separate cartilage and bone as 
a mechanical unit; for example, in a study of aging, the stiffness of bone and cartilage was found to 
be very closely correlated.
195 Secondly, multiple studies have demonstrated that increasing 
thickness of osteoarthritic subchondral bone is accompanied by hypomineralisation, due to 
excessive osteoid production.
39,293 This suggests a defect of the remodelling process, probably 
related to the alterations in cellular metabolism already discussed.
350,505 Thirdly, subchondral bone 
stiffness may be related to a more generalised alteration in skeletal bone quality, as suggested by 
Dequeker and coworkers.
184,185 
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Two large bodies of evidence suggest an integral link between bone density and OA, though the 
exact nature of this association is far from clear: 
 
Epidemiological Evidence 
Multiple studies have concluded an inverse epidemiological relationship between osteoporosis and 
OA.
312,779 In several large cross-sectional populations, women with hip,
153,580,798 hand,
319,778 
knee,
319,778 or spine
319 OA have been shown to have higher bone mineral density (BMD) than did 
non-arthritic subjects. In another study, women with radiographically-defined knee OA were found 
to have greater average BMD, less temporal change in BMD, and lower serum levels of osteocalcin 
than unaffected women.
779 However, the same may not hold for hand OA.
779 In the iliac crest, a site 
with no direct mechanical stimulus, bone density is increased in patients with hand OA, as are 
levels of bone IGF-1 and TGF-ß 
184 As it is difficult to conceive that this could be a secondary 
change, such findings support the notion that an inherent difference in bone quality may predispose 
to a form of primary OA in certain groups. Alternatively, if subchondral stiffening is an initiating 
cause in OA, perhaps it occurs as part of a more generalised increase in bone biosynthesis.
185 
Certainly, patients affected by osteopetrosis are prone to subsequent development of OA.
505  
 
However, most of these studies have used relatively severe radiographic criteria of OA. Patients 
with osteoporosis and osteoarthritis may also have lifestyle differences, such as greater exercise 
levels in earlier life.
403 The two populations also differ anthropometrically.
184 For instance, the 
higher body weight in the OA subset influences bone density not only mechanically, but also from 
higher postmenopausal oestrogen levels associated with increased body fat and peripheral 
conversion of androstenedione to estrone.
185 A recent study involving female twin pairs, one with 
hip OA and one without, found that hip OA was associated with a higher BMD of the ipsilateral 
femoral neck, but not any of the other sites tested.
31 This study, while confirming the presence of 
local bone changes in association with OA, suggests that the more general relation between OA and 
high BMD is likely to be due to shared genetic factors.    25. 
Several studies have suggested a link between dynamic bone loss and OA. Karvonen et al. (1998)
403 
found that patients with relatively mild knee OA had a significant decrease of periarticular BMD, 
despite no significant difference in spine or femoral shaft density. Local osteoporosis was found to 
be more severe in superficial rather than deep subchondral regions. In a long-term prospective 
study, Sowers et al. (1991)
780 found that despite greater baseline bone density, women who 
developed hand OA showed greater bone density loss than normal women. Such data argues against 
a primary role for trauma-induced subchondral sclerosis in the pathogenesis of OA.
403 Interestingly, 
low serum levels of 1,25-dihydroxycholecalciferol, a well-known promoter of bone mineralisation, 
are associated with increased incidence of hip OA
449 and more rapid progression of knee OA,
523 
though whether this is related to its skeletal influence or direct effects on cartilage metabolism 
remains to be established. 
 
Experimental Evidence 
Proof that subchondral bone changes play a primary initiating role in the pathogenesis of OA 
depends on the observation of very early bone changes in natural and experimental models. Indeed, 
in various animal models of spontaneous OA, such as in macaques and Dunkin-Hartley guinea pigs, 
subchondral bone changes are often the earliest detectable changes, preceding detectable cartilage 
fibrillation.
54,89 In rabbits subjected to impulsive loading, subchondral thickening and remodelling 
can be demonstrated within six weeks, prior to detectable changes in cartilage proteoglycan 
content.
659 However, surgical models (especially those involving unilateral surgery) are 
compromised by their effect on limb loading. In meniscectomised rabbits, a decrease in bone 
density is observed due to reduced limb usage post-surgery.
540 In the canine ACLT model, the 
subchondral region shows a pattern of early trabecular bone loss and later subchondral plate 
thickening.
179 Loss of trabecular bone mass can be demonstrated by micro-computerised 
tomography from 3 months post-operatively, well before subchondral sclerosis is evident, and 
persists to 54 months.
179 Histomorphometric analysis shows reduced bone mass and increased bone 
turnover as early as 6 weeks following ACLT.
931 Many critics attribute this trabecular loss to    26. 
decreased loading following surgery.
90,590 However, even if the joint is denervated by 
ganglionectomy (a procedure that also accelerates cartilage destruction), rapid loss of bone ensues, 
with increased porosity of the subchondral plate and trabecular osteopenia.
180 In this model, 
therefore, thickening of subchondral bone does not appear to be necessary for the development of 
cartilage changes, and occurs much later in the progression of disease.
90,179,180 In a long-term (54 
months) follow-up study of ACLT dogs, subchondral studies demonstrated a marked increase in 
bone volume and active bone formation, as demonstrated by fluorochrome labelling. Further, these 
changes were demonstrated only in the medial femoral condyle, not the lateral condyle.
90 However 
in a canine histomorphometric study of OA hip joints, greater subchondral trabecular area was 
found to correlate with an increasing degree of cartilage pathology.
800 
 
1.1.2.3.4 Osteophytes 
 
Osteophytes are bony outgrowths occurring at the margins of arthritic joints, which form by either 
endochondral or intramembraneous ossification. The stimulus for osteophyte formation is unknown, 
though cartilage damage, joint instability, inflammation, and stretching of the synovial membrane 
have all been proposed as mechanisms.
682 Experimental observations of osteophyte formation in the 
absence of instability argue against this as a primary cause.
388 The function of osteophytes is 
thought to be mainly protective, countering instability by decreasing range of motion, and reducing 
focal loading by expanding the effective weight-bearing surface.
14 However, they are also a 
significant source of pain due to periosteal stretching.
388 
 
1.1.2.3.5  Markers of Bone Turnover in OA 
 
Several studies have shown alterations of serum and urine bone turnover markers in OA patients. 
Pyridinoline (Pyr) and deoxypyridinoline (DPyr) are elevated in both OA and RA patients when 
compared to reported levels in control populations.
450,762,798 These molecules are important in cross-   27. 
linkage of mature collagen and are released during its degradation. In rheumatoid patients, levels 
are significantly elevated during active RA when compared with subjects with suppressed disease.
11 
Similar elevations are seen following intra-articular chymopapain injection in rabbits.
846 However, 
whether such markers reflect local changes or are associated with systemic changes in bone 
turnover is unknown.
54 
 
Plasma osteocalcin levels provide a useful marker of osteoblast function. Due to its specific origin 
in newly formed bone and short plasma half-life, osteocalcin levels reflect the current activity of 
osteoblast-like cells,
157 though variations in renal and extra-renal clearance rate also potentially 
influence plasma levels.
218 The lower serum osteocalcin levels seen in patients with incident hand or 
knee OA therefore suggest a reduction of bone formation and turnover during active OA.
779,798 
Similarly, serum osteocalcin levels are reduced in patients with active RA when compared to 
subjects with inactive or no disease.
11 However, other studies have shown elevated serum 
osteocalcin in patients with hand OA
350 or with active psoriatic arthritis.
240 
 
1.1.3    PATHOGENETIC MEDIATORS OF OSTEOARTHRITIS 
 
1.1.3.1    Enzymes and Enzyme Inhibitors 
 
The importance of enzymatic degradation of cartilage, rather than simple mechanical disruption, has 
been known for several decades.
275,625 Proteolytic enzymes secreted by chondrocytes are 
predominantly responsible for normal turnover of various extracellular matrix components. 
Hyaluronan may be an exception here, as it is thought to be internalised and degraded intracellularly 
after binding to CD44 cell surface markers.
209,833 Overproduction of these enzymes in OA causes 
structural degeneration through two main process: degradation and loss of proteoglycan, and    28. 
cleavage and loosening of the fibrillar collagen network. Cartilage appears particularly susceptible 
to protease attack, with even a single enzyme being able to cause major defects in its structural and 
biomechanical properties.  
 
1.1.3.1.1 Matrix  Metalloproteases 
 
While it must be recognised that matrix breakdown occurs through a complex cascade of proteolytic 
events, the enzymes most consistently implicated are members of the matrix metalloprotease family 
(Table 1.1). As well as the ability to degrade matrix components, MMPs share the following 
common features: (i) they contain a zinc atom at the active site; (ii) they require Ca
++ for full 
activity, and are inhibited by calcium-chelating agents; (iii) they display peak activity at neutral pH; 
and (iv) they are secreted as pro-enzymes which require proteolytic cleavage for full activity.
612 
Four MMP subclasses are elevated in OA: stromelysin (MMP-3), acting on proteoglycan and type 
IX collagen; collagenases (MMP-1,-8,-13), acting on native fibrillar collagen; gelatinases (MMP-2,-
9), acting on denatured collagen; and membrane-type MT-MMPs, which may play a role in cell-
associated protease activity. In addition to its role in activating MMP-2, MT1-MMP may also act as 
a collagenase in its own right.
618 The recently characterised aggrecanases, members of the related 
ADAMTS (A Disintegrin And Metalloprotease with ThromboSpondin motifs) family, specifically 
degrade aggrecan.
828 
 
Many of the MMPs are not constitutively produced, but are induced in chondrocytes by IL-1ß and 
other cytokines by complex mechanisms involving the AP-1 promoter element and the oncoproteins 
c-jun and c-fos.
291,420,444,467,620 Induction of collagenase has also been shown to involve Protein 
Kinase C and NF-ß induction, but is antagonised by Protein Kinase A.
115,192,872 Expression of 
stromelysin and collagenase is generally closely linked, but enough examples of discoordinate 
expression have been shown to suggest independent modes of regulation.
87,244,488,509 Collagenase and 
stromelysin levels are increased in OA cartilage in levels which correlate to histologic severity, both    29. 
regionally and between patients.
625 MMPs (especially stromelysin) are also markedly increased in 
arthritic synovial fluids and represent a promising marker of diseased joints.
144,432,477,879 
 
Synovial tissue is also an important source of MMPs.
932 For example, after partial meniscectomy of 
rabbits, synovial stromelysin production precedes that of cartilage.
536 It has been suggested that the 
synovium is the main source of synovial fluid collagenase.
323,366 Numerous in situ-hybridization 
studies have localised expression of collagenase, stromelysin, and tissue inhibitor of matrix 
metalloproteases (TIMP) mRNA to the synovial lining layer.
232,284,524,932 Synoviocytes are also 
known to produce collagenase-2
311 and collagenase-3.
895 However, synovial tissues produce 
abundant quantities of the endogenous inhibitor TIMP,
536 and it seems likely that synovium-derived 
MMPs have an effect only on the most superficial layers of cartilage, if at all.  
 
As MMPs are secreted as inactive pro-forms, activation by proteolytic cleavage is an important step 
in their regulation.
560 The complex cascade of MMP activation is only partially understood.
612 
Plasmin is thought to be an important activator of MMP-1, -3 and -9, but it inefficiently activates 
MMP-2.
893 Once activated, stromelysin itself activates MMP-1 and -9;
618 its role in MMP-1 
activation may be an obligatory step.
825 Similarly, collagenase-1 and -3 activate the gelatinases, and 
membrane-bound MT-MMPs are thought to be important activators of the MMP-2, -9, and -13. 
Endogenous inhibitors such as TIMP are also important regulators of MMP activity. Serum protease 
inhibitors such as 2-macroglobulin and 1-antitrypsin are not normally present within the joint, but 
may enter synovial fluid in inflammatory states.
871 
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Table 1.1: Classification of the matrix metalloproteases found in articular cartilage.
812,885 
 
Name   MMP   
Number 
Mass  
(kD) 
Native Substrates 
(*=major targets) 
Collagenase-1 
(interstitial collagenase) 
 
 Collagenase-2 
(neutrophil collagenase) 
 
Collagenase-3 
1 
 
 
8 
 
 
13 
55 
 
 
75 
 
 
65 
Collagens I, II, III*, VII, VIII, X 
 
 
Collagens I*, II, III, VII, VIII, XI; 
   proteoglycan core protein 
 
Collagens I, II*, III, IV, IX, X, XIV 
Gelatinase A  
 
 
 
Gelatinase B 
2 
 
 
 
9 
72 
 
 
 
92 
Gelatin*, collagen I, II, IV, V, VII, X,XI, XIV;  
   PG core protein, elastin, laminin, fibronectin; 
   pro-IL-1ß, pro-TNF- 
 
As for gelatinase A 
Stromelysin-1 
 
 
 
Matrilysin 
3 
 
 
 
7 
57 
 
 
 
28 
Proteoglycan core protein & link protein*; 
   non-helical regions of collagens III,IV,V,IX; 
   laminin, fibronectin; pro-MMP-1 
 
As for stromelysin-1 
MT1-MMP  14  63  Collagen I, II, III; fibronectin, laminin, 
   vibronectin; pro-MMP-2, pro-MMP-13 
Aggrecanase-1  
 
Aggrecanase-2  
ADAM-TS4 
 
ADAM-TS5 
? 
 
? 
Aggrecan core protein 
 
Aggrecan core protein 
 
 
 
Collagenase 
Collagenase-1, -2, and -3 are all up-regulated in OA cartilage.
625,671 The relative roles and 
importance of these enzymes are unknown, though some differences in distribution have been 
recognized, collagenase-1 being mainly expressed in the superficial layers of OA cartilage.
244,505 
Contrary to initial suggestions, recent studies indicate that collagenase-3 may play primarily a 
remodelling rather than catabolic role.
505 Supportive of this is the finding that TGF-ß preferentially 
induces collagenase-3 over collagenase-1.
820 However, collagenase-3 inhibitors effectively reduce 
cartilage collagen damage in arthritis without co-inhibition of MMP-1.
121 MMP-1 has not been 
identified in rodents, yet these are well-known experimental subjects for arthritis models.
121 Such 
studies suggest that the true culprit(s) of collagenase degradation in OA is yet to be elucidated.    31. 
Gelatinase 
The gelatinases are so named for their ability to cleave fibrillar collagens only after their triple 
helical structure is already disrupted. However, they may be involved in cleavage of minor collagen 
types, and collagen-associated molecules such as fibronectin. MMP-2 (Gelatinase A) and MMP-9 
(Gelatinase B) are unusual amongst MMPs in containing a fibronectin-like domain and a type V 
collagen-like domain.
812 They are regulated independently, with the 72kD MMP-2 being 
constitutively produced in cartilage, while the 92kD MMP-9 is selectively expressed in OA, in a 
distribution corresponding to fibrillated areas.
551 Similarly, MMP-2 is constitutively expressed by 
synovial fibroblasts, while MMP-9 is induced by pro-catabolic cytokines.
415 MMP-9 is therefore a 
useful marker, if not mediator, of cartilage damage and synoviocyte activation. 
 
Stromelysin 
Complete enzymatic digestion of proteoglycan is a complex process, probably involving multiple 
MMPs. Stromelysin (MMP-3) is thought to be a key enzyme in destabilising aggrecan, through 
proteolysis of both the core protein and associated link protein. It can also digest collagens, but 
only secondary to initial collagenase attack.
87 Stromelysin is found in normal cartilage, but is 
greatly elevated in OA to levels correlating with disease severity.
323,509,594 It is also expressed in 
inflamed synovia, though cartilage expression appears to be more sustained.
366 
 
Aggrecanase 
Loss of aggrecan from cartilage involves cleavage at the interglobular domain of the core protein. It 
was recently discovered that cleavage occurs at two major sites, Asn
341-Phe
342 and Glu
373-Ala
374, 
yielding the C-terminal neoepitopes VDIPEN and NITEGE respectively. While the VDIPEN 
epitope was associated with previously known MMPs, it was proposed that an uncharacterised 
enzyme ‘aggrecanase’ might be responsible for generating the NITEGE neoepitope. Aggrecanase-1 
and -2 have since been purified and cloned, and their specificity for aggrecan cleavage 
confirmed.
828 A recent murine study has demonstrated differential distribution of the two    32. 
neoepitopes in normal cartilage, with VDIPEN detected mainly around deep zone chondrocytes, 
while NITEGE was present mainly in the upper zones. However, both were expressed adjacent to 
the spontaneous OA lesions characteristic of STR/ort mice.
122 Fragments from aggrecanase 
cleavage are the major product of aggrecan catabolism detected in arthritic synovial fluid and 
cartilage explant conditioned media, suggesting these enzymes may be a major mediator of 
cartilage proteoglycan catabolism.
43,478,723 
 
1.1.3.1.2  Tissue Inhibitor of Matrix Metalloproteases (TIMP) 
   
Tissue inhibitors of matrix metalloproteases (TIMP) are proteins which specifically bind to and 
irreversibly inactivate MMPs.
885 Four forms are currently recognised; of these, TIMP-1, -2 and -3 
are found in articular cartilage.
509 TIMP-1 may be only form in synovium and synovial fluid,
336,505 
while TIMP-2 seems to be the primary form elevated in OA cartilage.
509 A special relationship has 
been shown between TIMP-2 and MMP-2, with the inhibitor binding with high affinity to a region 
separate from the enzyme’s active site, facilitating the formation of an MMP-2/TIMP-2/MT-MMP-
1 complex which may be important in MMP-2 activation.
270,612 TIMP-1 has a similar association 
with MMP-9.
612 TIMPs are elevated within the OA joint, but are relatively deficient in comparison 
to the proportionally greater increase in MMP expression.
479 This is surprising given they are 
induced by IL-1ß and similar cytokines via the same Protein Kinase C-dependant mechanisms as 
the MMPs.
192,193 Inhibition of TIMP expression by co-induced PGE2 may be responsible.
193 TGF-ß, 
as a particularly powerful inducer of TIMP, opposes this imbalance.
130 
 
1.1.3.1.3 Serine  and  Cysteine  Proteases 
 
The serine protease system of plasmin and its endogenous activator, plasminogen activator (PA), 
contributes to cartilage degradation (in vitro at least) by activation of latent MMPs.
98,150,533 In 
addition, both PA and plasmin are thought to directly degrade various matrix components.
533,548,744    33. 
Plasmin has been shown to activate latent forms of growth factors, to activate IGF by releasing it 
from IGFBPs, and to induce leukocyte recruitment independently of its proteolytic effects.
102,506,809 
PA is also likely to be involved in subchondral bone degradation.
695 The involvement of PA in joint 
degradation in vivo has not been proven, though Martel-Pelletier et al. (1991)
507 found a significant 
correlation between plasmin activity and active collagenase in human OA cartilage. In the only 
such trial reported, Kikuchi et al. (1987)
416 reported clinical improvement of RA patients following 
intra-articular injection of a PA inhibitor. 
 
Levels of PA and plasmin are both elevated in OA cartilage.
507 PA is induced by IL-1 and TNF- 
in chondrocytes
98,106,212 and synoviocytes.
308,459,529 PGE2 may partially mediate the effects of these 
cytokines, as non-steroidal anti-inflammatory drugs (NSAIDs) partially reverse PA 
induction.
306,459,549 Leizer and Hamilton (1989)
460 described a human monocyte-derived factor 
capable of inducing PA activity in synovial fibroblast cultures, which was immunologically and 
functionally distinct from known cytokines. This may have been TGF-ß, which can similarly 
induce PA without concurrent induction of PGE2.
307 Plasminogen is not produced by joint tissues.
98  
 
Two distinct forms of PA are generally described: urokinase-type (uPA) and tissue-type PA (tPA). 
Early experiments (using a radio-labelled fibrin assay) identified tPA as the more commonly 
induced form in IL-1-stimulated chondrocytes.
100,106,150 More recent studies have shown uPA to be 
the predominant form in OA cartilage and synovial fluid.
416,507 In OA synovia, uPA also appears to 
be the main form induced, while tPA is more commonly expressed by normal synoviocytes and 
may actually be down-regulated in OA.
102,535 This shift from tPA to uPA may reflect a change in 
the role of synovial PA from fibrinolysis to matrix degradation.
694 uPA can be activated at the cell 
surface by binding to uPA-receptors (uPAR), producing local pericellular proteolysis. uPAR are 
present on both synoviocytes and chondrocytes and are up-regulated in OA.
102,744 tPA is activated    34. 
by binding to fibrin.
102 In the inhibitor-rich environment of the normal joint, cell-associated uPA 
probably represents the most active pool.
694 With increasing cytokine stimulation, secreted PA 
comprises a greater proportion of total PA activity.
212,308 
 
Serine protease inhibitors are plentiful in cartilage.
261 Two forms of PA inhibitor (PAI) are present 
in joint tissues: PAI-1 which primarily inhibits tPA, and PAI-2 which more effectively inhibits 
uPA.
102,543 Synovial tissue produces an excess of PAI over PA, hence synovial fluid does not show 
fibrinolytic activity without extraction procedures.
416,626 PAI-1 levels are decreased in OA 
cartilage,
507 which possibly contributes to the increase in non-cell-associated PA described above. 
In addition, poorly characterised low molecular weight (12 kD) serine protease inhibitors are 
known to be endemic in cartilage.
30 
 
Interest is reviving in certain cysteine proteases such as cathepsin B, which is thought to be capable 
of activating plasminogen activator and stromelysin-1. Cathepsin B and Cathepsin D are both 
significantly up-regulated in OA synovia.
249,537 
 
1.1.3.2   Cytokines 
 
The importance of cytokines in the pathogenesis of OA has become increasingly clear over the last 
few decades of research. It is now thought that differences in the cytokine profiles of OA and RA 
are more quantitative than qualitative; the common practice of using OA-derived synovial fluids as 
a ‘non-inflammatory’ control is therefore dubious.
876,896 Current evidence strongly suggests that IL-
1ß, and to some extent TNF-, initiate many of the catabolic events in OA joint tissues, such as the 
production and activation of proteases, depressed or deranged matrix biosynthesis, and release of 
inflammatory mediators such as nitric oxide and prostaglandins. 
505 It is unclear whether IL-1 and 
TNF-  act in concert, or whether a functional hierarchy exists between these and other 
cytokines.
618 Some authors suggest that IL-1 is primarily responsible for cartilage destruction,    35. 
while TNF- primarily mediates joint inflammation.
505 Van den Berg (1998)
857 has demonstrated 
that the effects of cytokines on joint inflammation and cartilage destruction can occur uncoupled. 
For example, cytokines such as IL-4, IL-6, IL-10 and TGF-ß enhance inflammation but potentially 
reduce cartilage damage. As small soluble mediators, cytokines are central to the tissue 'cross-talk' 
that occurs between cartilage, synovium, and bone within the OA joint. However, this highlights a 
gap in current knowledge, in that the cytokine-driven model of OA fails to fully explain the focal 
cartilage damage so characteristic of the disease.
896 
 
Cytokines are generally absent or present in only low levels in normal tissue, but are dramatically 
up-regulated in response to stimuli such as cellular injury. The subsequent action of cytokines is 
tissue-dependent, and is potentially controlled by many different mechanisms, such as the type and 
quantity of specific cell-surface receptors. The presence of specific receptor antagonists, soluble 
'decoy' receptors, or antagonistic cytokines may act to block these responses.
394 Some cytokines 
also require enzymatic cleavage for full activity. Post-receptor signalling is thought to represent 
another important level of modulation, but remains poorly understood. 
 
1.1.3.2.1     Interleukin-1 (IL-1) 
 
Early experiments with conditioned media from cultured synovium
222,534 and peripheral blood 
mononuclear cells
172,275 demonstrated the existence of a soluble factor which induced the release of 
inflammatory and catabolic factors from cartilage and synovium. This 17kD factor was isolated 
from porcine synovium and named ‘catabolin’.
196 It was subsequently demonstrated in the early 
1980’s that this factor was probably interleukin-1.
175,529,712,831,913,914 Subsequent in vivo studies using 
recombinant IL-1ß have shown it is capable of inducing, even from a single intra-articular 
injection, many of the changes characteristic of OA such as loss of cartilage proteoglycan, reduced 
matrix synthesis, and cellular infiltration of synovial fluid.
42,528 Gene transfer-induced over-
expression of IL-1 in rabbits has been shown to produce a severe, RA-like disease.
254 Conversely,    36. 
blocking IL-1ß activity is extremely effective at preventing cartilage destruction.
855 IL-1 is 
currently recognised as the primary cytokine driving degenerative changes within the OA joint. 
Other cytokine systems may predominate in more inflammatory arthritides, as illustrated by a 
recent study showing significant differences in the relative importance of IL-1 in adjuvant arthritis 
and collagen-induced arthritis in rats.
70  
 
Two forms of IL-1 are recognised, IL-1 and IL-1ß, though they share little homology (~27%) and 
are products of separate genes.
459 IL-1 is thought to be mainly cell-associated, while IL-1ß is 
predominantly soluble and is the principal form produced within OA joints.
276,428,576,627 The effects 
of both are similar, though IL-1ß exhibits greater activity on an equimolar basis.
922 IL-1 
simultaneously suppresses cartilage matrix biosynthesis and stimulates matrix degradation, though 
chondrocytes are much more sensitive to the former effect than the latter, especially in human 
cartilage.
259,822 The mechanism of this suppression is unknown, but possibly relates to reduced 
expression of galactose-ß-1,3-glycuronosyltransferase I, a key enzyme in glycosaminoglycan 
synthesis.
278 IL-1 also suppresses synthesis of other matrix components, notably type II collagen.
684 
Conversely, IL-1 promotes chondrocyte production of the normally fibroblast-associated type I and 
III collagen, but only when concurrent induction of PGE2 is suppressed.
273 IL-1 is also a major co-
factor in inducing the IGF-1 hyporesponsiveness commonly present in OA, though this may be via 
indirect  means.
867 At higher concentrations, MMP and TIMP are simultaneously but 
disproportionately induced, resulting in an increased MMP/TIMP ratio.
508,684 A similar change 
increases the uPA / PAI-1 ratio.
507 IL-1 is also responsible for many of the inflammatory changes in 
OA synovium, inducing synthesis of collagenase, stromelysin, IL-6, PGE2, and 
hyaluronan.
114,301,435,627,684 IL-1 induces proliferation of synoviocytes, but simultaneously sensitises 
them (possibly via NO) to Fas-mediated apoptosis, hence its mitogenic action is variable.
427,773 
 
Cellular release of IL-1 is induced by such varied stimuli as mechanical alteration, soluble matrix 
breakdown products, collagen (in vitro), TNF-, and IL-1 itself (i.e. it is autoinductive).
130 IL-1    37. 
release is inhibited by PGE2. and certain leukotrienes.
92 Both chondrocytes and synoviocytes are 
capable of producing significant amounts of IL-1, creating debate as to which tissue is the more 
important source. IL-1 within synovial fluid is thought to derive from synovium, produced as part 
of a theoretical cartilage-synovium feedback loop in response to phagocytosed matrix breakdown 
products. Supportive of this view is the predominant immunolocalisation of IL-1ß within the 
superficial layer of OA cartilage.
511,620,830 IL-1 is diffusely expressed throughout the lining layer of 
OA synovia,
182,214,511 though it can also be detected in normal tissue.
182 However, several studies 
have shown very low or undetectable levels of IL-1ß in OA synovial fluid, suggest that synovium-
derived IL-1 is unlikely to drive cartilage damage.
74,105,865,896,898 Autocrine production by 
chondrocytes is now recognised as significant and represents a more likely source of cartilage IL-
1.
49,538  
 
IL-1ß requires proteolytic maturation for full bioactivity, a function performed by the unique 
cysteine protease interleukin-1ß converting enzyme (ICE).
428 The cellular effects of IL-1 are 
receptor-mediated. Cell membrane receptors of 80kD (Type I) and 68kD (type II) are recognised, 
the smaller form possibly acting as a ‘decoy’ rather than a true signalling receptor.
392 Only low 
levels of receptor occupancy are necessary for maximal catabolic responses.
627 Human 
chondrocytes primarily express the Type I receptor, with cells derived from the superficial zone 
expressing approximately twice the number of binding sites and are hence being more susceptible 
to the effects of IL-1 than those from deeper layers.
325 Receptor expression is also increased in OA 
chondrocytes relative to normal cells.
508,627 Human synoviocytes have been reported to express both 
receptor types, with up-regulation of Type I IL-1 receptors in OA.
709  
 
IL-1 receptor antagonist (IL-1Ra) was first characterised in 1990, at that time the first description 
of a naturally-occurring cytokine receptor antagonist.
206 Since then other (mainly intracellular) 
forms have been described.
56,493 A large excess of IL-1Ra over IL-1ß is required to reduce receptor 
occupancy sufficiently to block activity. IL-1Ra is induced in synovium by IL-1ß itself, a process    38. 
which is enhanced by other cytokines such as interferon- and IL-4.
133,510,741 However, IL-1Ra 
production is deficient relative to IL-1 release, increasing the agonist:antagonist ratio.
105,133,182,392,768 
 
The post-receptor signalling mechanisms of IL-1 are poorly understood. Its effects on matrix 
synthesis, matrix degradation, and PGE2 release all seem to be mediated through independent 
mechanisms, as reflected by differences in dose and time dependence. The induction of the MMP 
and plasmin systems involves Protein Kinase C-dependant mechanisms.
193 IL-1-induced 
suppression of proteoglycan synthesis is partially reduced by Protein Kinase C activation, though 
PGE2 release is unaffected.
44 Numerous tyrosine kinases and oncogene products (e.g. c-fos, c-jun) 
are also involved in IL-1 signal transduction. 
 
1.1.3.2.2 Tumour  Necrosis  Factor- (TNF-) 
 
TNF- is generally described as having similar effects to IL-1 but with lesser potency, inducing the 
release of MMPs, IL-6, PGE2, and superoxide by target cells.
8,12,814,922 IL-1ß and TNF  stimulate 
production of each other,
92,753 and it has been suggested that many of the IL-1-like actions of 
TNF  in vitro may actually be due to induction of endogenous IL-1. However, others have found 
this effect to be limited.
92,440 It has also been suggested that there is some synergy of their cartilage 
degradative effects when both IL-1 and TNF- are present.
340,542,550,713 While IL-1 and TNF-  are 
generally induced by the same stimuli, this may not always be the case in OA cartilage, as positive 
correlations between the two cytokines are surprisingly lacking.
896 
 
TNF-  is generally present in only low levels in OA joints,
627 though it is thought to be the 
dominant cytokine produced within rheumatoid joints.
220 It has been shown to be the major 
mediator of joint swelling and inflammation, but not cartilage destruction, in inflammatory rodent 
models of arthritis.
440,713,857 Intra-articular injection of TNF-  in rabbits induces profound 
(predominantly monocytic) cellular infiltration of the synovium, but causes minimal proteoglycan    39. 
loss.
340 Bryson et al. (1998)
98 found that while a uPA inhibitor was potent in preventing 
proteoglycan release from TNF- -stimulated cartilage, it was less effective against IL-1ß-induced 
degradation, suggesting a difference in the pathways by which these cytokines induce proteolysis. 
 
TNF- is synthesised in a latent form that requires proteolytic cleavage for activation. TNF--
converting enzyme (TACE), otherwise known as ADAM-17, is one of several MMPs capable of 
cleaving the membrane-bound latent TNF- into a soluble trimer of 17kD subunits.
320 Two 
receptors, TNF-R55 and TNF-R75, are described according to their molecular size of 55kD and 
75kD respectively. The 55kD form has been shown to mediate cellular responses to TNF-, and is 
up-regulated in OA chondrocytes and synovial fibroblasts.
13,886 Corresponding soluble forms are 
described, TNF-sR55 and TNF-sR75, with a relative increase in synovial fibroblast TNF-sR75 release 
seen following IL-1ß or TNF- stimulation. However it is currently unknown whether these 
binding proteins function to transport or to sequester active TNF- ligand, thereby promoting or 
antagonising its actions.
512  
 
1.1.3.2.3     Interleukin-6 (IL-6) 
 
This multi-functional cytokine is best known for its role in inducing hepatic release of acute phase 
proteins, and stimulation of B-lymphocyte proliferation. Given these effects, circulating synovium-
derived IL-6 may mediate some of the systemic effects recognised in arthritis, such as elevated 
levels of gamma globulins and acute phase proteins such as 1-antitrypsin.
296 In cartilage, IL-6 has 
been described as a natural chondroprotective agent that attenuates the actions of more catabolic 
mediators such as IL-1ß, and promotes chondrocyte proliferation and biosynthetic activity.
259 
However it is also potentially a catabolic mediator in that it promotes synovial inflammation and 
local bone resorption.
296 
    40. 
Serum levels of IL-6 are elevated in OA patients.
401 Similarly, patients with active RA have 
significantly higher serum levels of IL-6 than those with suppressed disease.
11 Synovial fluid IL-6 
is elevated following experimental canine ACLT, and correlates strongly with increased 
proteoglycan synthesis.
865 The synovial membrane is a rich source of IL-6,
64,296,547,698 especially in 
RA.
229,296,698 Immunolocalisation studies have found IL-6 is mainly associated with macrophage-
like (Type A) cells in the synovial lining,
229 but also correlates histologically with plasma cell 
infiltration.
229,547 Articular chondrocytes are also an important source of IL-6.
295 IL-1ß appears to be 
the most potent stimulus for its production in vitro,
132,295,627 though TNF-, TGF-ß, interferon-, IL-
4, IL-10, IL-13, insulin, and bFGF all increase IL-6 release.
259,295,296,583,698 Paracrine stimuli 
affecting IL-6 production appear complex - the addition of monocytes, but not monocyte 
conditioned medium (MCM), increases synovial fibroblast IL-6 production in the absence of 
detectable levels of IL-1ß or TNF-.
128 Studies of the IL-6 gene promoter have revealed control by 
multiple transcription factors including NF-ß, AP-1, and Protein Kinase A and C.
64,933  
 
IL-6 has multiple, somewhat pleiomorphic effects within the OA joint. It promotes the infiltration 
of inflammatory cells into synovium, and may also regulate synovial fibroblast proliferation.
296 In 
synovial fluid, levels of IL-6 correlate with inflammatory indices such as leukocyte count and total 
protein content.
74 However, IL-6 has no direct effect on PGE2, glycosaminoglycan, or collagen 
synthesis by synoviocytes.
375,480 The primary receptor IL-6R is reportedly absent from synovial 
fibroblasts; however, soluble receptor/cytokine complexes in synovial fluid have the potential to 
interact with the gp130 subunit, inducing cell proliferation.
64,375 In cartilage, IL-6 stimulates 
chondrocyte proliferation,
295,865 and may be a major stimulus for the formation of chondrocyte 
‘clones’ in OA cartilage. Its effect on proteoglycan synthesis is unclear, having been shown to both 
inhibit and increase synthesis under different conditions.
344,583 Nietfeld et al. (1990)
583 found that 
while IL-6 alone was a weak inhibitor of proteoglycan synthesis, blocking antibodies to IL-6 were 
able to significantly reduce the effect of IL-1 on matrix synthesis. Its role in proteolytic damage is 
similarly unclear. IL-6 alone increases TIMP production without increasing MMP production,    41. 
suggesting its net influence is probably to limit proteolytic damage.
375,480,618,865 However, IL-6 
augments IL-1ß-stimulated MMP production in a dose-dependant manner.
234,375 IL-6 also induces 
TGF-ß, IL-1Ra, TNF-sR55, uPA, and PAI-1 release, while reducing IL-8 production.
344,375,857 
Together, this suggests IL-6 may play an important regulatory role in amplifying the intermediate 
events which follow IL-1ß stimulation.
583 
 
1.1.3.2.4 Other  cytokines 
 
The following cytokines have also been identified as having a potential role in the pathogenesis of 
OA: 
 
Interleukin-4 (IL-4) exhibits predominantly anti-inflammatory effects on synovial fibroblasts, 
reducing IL-1ß, leukocyte inhibitory factor (LIF), IL-8, PGE2, collagenase and stromelysin release, 
while increasing expression of IL-1Ra.
85,133,178,741,823,857 IL-4 has been shown to reduce TNF-R55 
levels in rheumatoid synovial fibroblasts by promoting receptor shedding, and this may represent 
one mode by which this monokine antagonises the activities of pro-inflammatory cytokines.
823 
However synovial fibroblasts were found not to express IL-4 receptors in one study.
183 
 
Interleukin-8 (IL-8) is known primarily for its effects on neutrophil chemotaxis. It is released 
constitutively by OA synovial fibroblasts, but is greatly up-regulated after IL-1ß stimulation.
741 
Chondrocytes may also be an important reservoir of IL-8.
344 
 
Interleukin-10 (IL-10) plays a predominantly anti-inflammatory and immunoregulatory role in 
leukocyte cross-talk, and its over-expression by activated T-cells may contribute to the endogenous 
immunosuppression present in the rheumatoid joint.
147,408 IL-10 inhibits iNOS induction and 
increases proteoglycan synthesis in cartilage. While it increases collagenase and stromelysin 
production by skin fibroblasts,
677 IL-10 has been shown to reduce cyclooxygenase-2 (COX-2) and    42. 
phospholipase-A2 expression and increase IL-1Ra release by isolated synovial fibroblasts,
12,742 and 
to reduce synovial activation in the SCID mouse model.
557 
 
Interleukin-11 (IL-11) is elevated in synovial fluid of OA patients.
832 It may play a protective role, 
by inducing TIMP release.
596 
 
Interleukin-13 (IL-13) may be an important anti-inflammatory cytokine, at least in synovial tissue. 
It reduces IL-1ß, TNF-, stromelysin, COX-2 and PGE2 production by OA synovial fibroblasts, 
and increases IL-1Ra release.
12,394 
 
Interleukin-17 (IL-17) is a recently discovered cytokine induced by IL-1ß and TNF- in some cell 
types.
505 While it has been shown to increase iNOS expression in articular cartilage, its net role is 
OA in not known.
51,618 IL-17 may mediate the osteoclastic bone resorption associated with some 
forms of arthritis.
749 
 
Leukocyte inhibitory factor (LIF), though a member of the IL-6 superfamily, has a clearer catabolic 
role in cartilage, by stimulating proteoglycan resorption, MMP synthesis, and NO production. LIF 
is up-regulated in both OA synovia and chondrocytes, and is induced by IL-1 and TNF-.
309,482 LIF 
may potentially form a positive feedback loop with IL-1ß, which would naturally amplify the 
'activated' state of OA chondrocytes.
344 
 
1.1.3.2.5 Growth  Factors 
 
The degradative effect of catabolic cytokines is inhibited or antagonised by a range of anabolic 
mediators (generally termed growth factors) which act to promote connective tissue formation, and 
to maintain the proliferative and/or biosynthetic activity of connective tissue cells. In cartilage, the 
balance between anabolic and catabolic cytokines regulates the homeostatic turnover of cartilage    43. 
matrix components. In particular, TGF-ß and IGF-1 have been identified as potent promoters of 
cartilage anabolism, stimulating chondrocyte proliferation, matrix biosynthesis, and antagonising 
the deleterious effects of cytokines such as IL-1ß. It has been speculated that reduced production 
of, or responsiveness to, such growth factors may contribute to the increased incidence of OA in 
aged patients.
896 
 
Transforming growth factor-ß (TGF-ß) 
 
TGF-ß is abundantly expressed in normal and inflamed synovial tissue,
93,136,446,558,563,817,878 and is 
spontaneously produced by synoviocytes in culture.
446 IL-6 may be an important stimulus of its 
increased expression in arthritic synovia.
870 Synovial fluid levels of TGF-ß are elevated in arthritic 
conditions.
93,465,826 Cartilage also contains large quantities of TGF-ß, especially in OA.
864 TGF-ß 
has been described as pleiotropic in its actions, causing seemingly different effects depending on 
experimental conditions and target cell type.
670,754,857 TGF-ß is known to stimulate chondrocyte 
proliferation, collagen and proteoglycan synthesis,
650,653,672,673 and TIMP expression,
804 and to 
down-regulate IL-1 receptor expression.
675 Its effect in inducing proteoglycan synthesis is potent; 
however TGF-ß does not appear to have any additional effect in combination with IGF-1.
852 In 
cartilage, TGF-ß is protective of IL-1-induced degradation, partially reversing the inhibition of 
proteoglycan synthesis
29,124,268,852,857 and reducing proteolytic activity.
124 It causes similar responses 
in synoviocytes,
446,916 also reducing collagenase expression,
516 an effect which may be via down-
regulation of the c-jun family of oncogenes as has been proposed in dermal fibroblasts.
516 In 
gingival fibroblasts, TGF-ß independently reduces collagenase production and increases TIMP and 
PAI-1 levels, but increases production of MMP-2.
603 Synoviocyte production of hyaluronan, and its 
molecular weight, is decreased by TGF-ß in vitro.
410 It has also been shown to be a strong inhibitor 
of nitric oxide production in cultured rabbit synoviocytes and other cell types.
795,822 The net effect 
of these diverse activities in the osteoarthritic joint is difficult to determine. 
    44. 
As TGF-ß is secreted in latent form and most cells express TGF-ß receptors constitutively, its 
activation by proteases such as plasmin and cathepsin may be an important regulatory step.
446,506 
Various isoforms of TGF-ß have different distributions within the synovial membrane: TGF-ß1 and 
TGF-ß2 seem associated with synovial lining cells, fibroblasts, and endothelial cells,
136,563 while 
TGF-ß3 is localised to macrophages of the sublining layer,
563 and appears to be selectively induced 
by IL-1ß.
870  
 
Insulin-like growth factor (IGF) 
 
The insulin-like growth factors are small peptides highly homologous with pro-insulin.
506 In 
particular, IGF-1 seems to be one of the most important cytokines acting to maintain normal 
proteoglycan synthesis,
506,576,727 and has been shown to be the primary cartilage anabolic factor 
present in serum and synovial fluid.
245 Though it only partially antagonises IL-1ß-induced 
suppression of proteoglycan synthesis, it accelerates cartilage recovery when fluctuating IL-1ß 
levels fall below the threshold required for suppression.
576 IGF-2 has similar properties but is 
generally associated with embryonic stages of growth,
859 and may be involved in mechanical 
strain-related proliferation of certain cell types.
129 Chondrocyte production of IGF-1 is increased in 
OA, with elevated levels in arthritic synovial fluid.
202,735 IGF-1 has been shown to auto-induce 
further IGF-1transcription.
586 While IGF levels are up-regulated in OA cartilage, cellular 
responsiveness is concurrently reduced, a phenomenon often attributed to the presence of IGF 
binding proteins.
506,821 IGFBP-2, -3, and -4 are all increased in osteoarthritic cartilage, their 
expression induced by IGF-1 itself.
131,821 However, Chevalier and Tyler (1996)
131 found that 
recombinant IGFBP-3 improved anabolic responses to IGF in human cartilage explants. 
 
Epidemiological studies have found some evidence of an association between serum IGF levels and 
osteoarthritis. While two studies have found no association between high IGF levels and knee 
OA,
237,354 others have identified positive correlations with osteophyte growth
736 and more severe,    45. 
bilateral disease.
476 The latter study also found an association with OA of the distal interphalangeal 
joint, a common manifestation of so-called 'generalised OA'.
476 Any association between IGF and 
OA may relate to its role in promoting greater bone density, as circulating IGF-1 has been shown to 
correlate positively with skeletal bone mineral density.
868 Osteoporosis has been linked with low 
serum levels of IGF-1 and IGFBP-3,
506 though no association was found in the large Chingford 
study group.
476 IGF may be a particularly important mediator of the subchondral bone sclerosis that 
often accompanies OA.
184,506,896 
 
Exposure of vascular epithelium to IGF-1 causes rapid induction of nitric oxide release, apparently 
by induction of iNOS.
332,559,732,839 However IGF-1 apparently inhibits IL-1ß-induced iNOS 
induction within the circulation.
732,733 The opposite has been shown in renal mesangial cells.
294 The 
influence of IGF on iNOS induction in joint tissues has not been studied. 
 
Other growth factors 
 
Epidermal growth factor (EGF) has been detected in high levels in rheumatoid synovia, where it 
may contribute to thickening and neovascularisation of the lining layer.
214 In cultured fibroblasts, it 
increases hyaluronan synthesis
461 but antagonises the effect of TGF-ß on collagen synthesis.
687 In 
cartilage, EGF may decrease proteoglycan synthesis while stimulating chondrocyte proliferation.
650 
 
Platelet-derived growth factor (PDGF) is a potent stimulus for chondrocyte and synovial   
proliferation.
441,651 It prevents induction of iNOS by IL-1ß, but not TNF-.
795 Direct oncogene-
triggered 'transformation' of synovial cells has been demonstrated following PDGF exposure.
445 
 
Basic Fibroblast growth factor (bFGF) is an autocrine growth factor produced by both 
synoviocytes and chondrocytes.
558 It has both anabolic and catabolic functions in matrix 
homeostasis.
670    46. 
Vascular endothelial growth factor (VEGF) is secreted in significant amounts by rheumatoid and 
OA synovial fibroblasts, especially after induction by IL-1ß or hypoxia.
73,377 It is likely to be an 
important stimulus for synovial angiogenesis, which is important in sustaining chronic proliferative 
inflammatory states such as RA. 
 
1.1.3.3   Nitric  Oxide 
 
Nitric oxide (NO) is a highly reactive, gaseous free radical which is emerging as an important 
mediator in many physiological and pathophysiological processes, such as vascular tone, neuronal 
transmission, platelet function, immune function, and angiogenesis.
211,215,381,552,936 NO was initially 
identified as the long sought endothelial-derived relaxation factor (EDRF) and is probably the 
major influence on basal vascular tone, producing vasodilation. Its small size and unpaired electron 
make NO a highly diffusible and reactive molecule, which passes readily through cell membranes 
to act as a local signalling or effector mechanism.
381 It has a very short half life, in the order of 
seconds. However, associated products such as peroxynitrite and S-nitrosothiols have longer half-
lives and may mediate some of its effects.
292,329 Experimentally, the stable intermediates nitrite and 
nitrate are usually measured as an index of NO production itself. 
 
NO is generated enzymatically by nitric oxide synthase (NOS) by oxidation of L-arginine, yielding 
L-citrulline as a coproduct (Figure 1.5). To date three NOS forms have been recognized: a neuronal 
(nNOS) and endothelial form (eNOS), both of which are constitutively expressed and regulated by 
intracellular Ca
2+ concentration, and an inducible form (iNOS) found in many cell types, which is 
instead regulated at the transcriptional level.
211 iNOS is not normally present in cells, but is induced 
in inflammatory states in response to cytokines such as IL-1ß, TNF-, and gamma interferon, or 
bacterial products such as endotoxin.
381 NO production by iNOS is several orders of magnitude 
greater than that of constitutive forms.
215 
    47. 
 
 
 
 
 
 
Figure 1.5:   The enzymatic production of NO from arginine, as catalysed by nitric oxide synthase. 
NADP, nicotinamide adenine dinucleotide phospate. 
 
 
There is strong evidence that NO plays a role in arthritic conditions.
381 Synovial fluid levels of 
nitrite/nitrate are elevated in arthritic joints,
216,378,680,815 as is the level in serum and urine.
216,281,786,799 
The main source of NO within the OA joint appears to be chondrocytes themselves.
7,538,676 Standler 
et al. (1991)
791 first showed that like many other cell types, articular chondrocytes produce NO in 
response to cytokines. Many subsequent studies have confirmed the expression of iNOS in OA 
cartilage and chondrocytes in a number of species.
25,49,538,609,637,676 OA cartilage demonstrates 
greater capacity for NO production than normal cartilage, with IL-1ß apparently the main stimulus, 
though TNF- and the newly-discovered IL-17 may also be important.
51,538,637,785 Superficial 
chondrocytes produce significantly more NO than chondrocytes derived from deeper 
cartilage.
139,326,329  
 
Studies in rheumatoid patients demonstrate that synovial tissue also has the capacity for high output 
of NO given the correct stimulus.
532 Immunohistochemical studies have confirmed synovial iNOS 
expression but differ over the cell types involved.
282,538,714 McInnes et al. (1996)
532 clarified this 
issue by demonstrating, using an antiserum specifically raised against human iNOS, that synovial 
fibroblasts (Type B synoviocytes) were the major expressors of iNOS in human synovia. They 
showed substantial spontaneous and enterotoxin-stimulated NO production in primary synovial 
L-Arginine                                    L-citrulline + NO• 
O2 , NADPH                                                  H2O, NADP
+ 
NITRIC  OXIDE  SYNTHASE    48. 
cultures sourced from both RA and OA patients. Other studies have found NO production by 
synovial cultures to be inconsistent.
676,714,795 This may be due to species differences, or may 
indicate a requirement for a more complex cytokine stimulus than is usually provided 
experimentally.
894 
 
Cells within fibrous structures such as menisci may also represent an important source of intra-
articular NO production.
109,426,457,813 A recent rabbit study  observed that nitric oxide release by 
meniscal explants was much greater than that of synovial tissue.
813 Cao et al. (1998)
109 suggested 
that within menisci, chondrocytic cells were responsible for most cytokine-stimulated NO 
production. However, the observation of substantial NO release by canine cruciate ligaments 
confirms that fibroblasts may also contribute to intra-articular levels.
785 
 
1.1.3.3.1  Nitric Oxide and Cartilage 
 
The effect of NO induction within the arthritic joint is unclear. There is mounting evidence that it 
plays a catabolic role, but also some evidence of chondroprotection, suggesting that its effect may 
differ in matrix homeostasis and inflammatory states.
381 Taskiran et al. (1994)
822 first suggested 
that NO mediates much of the effect of IL-1ß in suppressing proteoglycan. Recently, transfection 
of rabbit chondrocytes with the iNOS gene confirmed the ability of NO to inhibit matrix production 
independently of IL-1.
801 However, the magnitude of this effect is not entirely consistent and varies 
between species,
349 culture systems,
393 and chondrocytes derived from different zones.
139,326,327,346,794 
The mechanism of inhibition is unknown, but may be via interference with glycosaminoglycan 
sulphation,
349 cytoskeletal integrin-signalling complexes,
141 or mitochondrial respiration.
386,827 
Alternatively, inhibition of matrix synthesis may be primarily by prevention of anabolic responses 
mediated by endogenous cartilage growth factors. Arthritic cartilage is known to be 
hyporesponsive to IGF-1 and recent studies have identified NO as a key element of this 
phenomenon, possibly by inhibition of receptor autophosphorylation.
803,858 NO also inhibits    49. 
chondrocyte TGF-ß production, to similar effect.
801,802 In addition to suppression of proteoglycan 
synthesis, Cao et al. (1997)
110 showed that NO reduces type II collagen production, possibly by 
inhibition of prolyl-hydroxylase. NO has also been reported to reduce IL-1ß receptor antagonist 
(IL-1Ra) expression and enhance cartilage MMP activity.
637 Murrell et al. (1995)
561 reported 
inhibition of collagenolytic and caseinolytic activity by the NOS inhibitor N
G-nitro-L-arginine 
methylester (L-NAME), and induction of activity by the NO-donor S-nitrosylacetylpenicillamine 
(SNAP), in cultured bovine chondrocytes and cartilage explants as well as tissue from a single 
human patient. However, Bird et al. (2000)
76 recently reported that NO inhibited proteoglycan 
degradation in equine cartilage explants, specifically demonstrating reduced production of 
aggrecanase-generated proteoglycan fragments  of the NITEGE neoepitope.  
 
Other cartilage studies have similarly demonstrated that NO may confer some protection against 
the degradative effects of IL-1ß. Stefanovic-Racic et al. (1996)
794 found that in bovine  cartilage, 
NO had no effect on PG synthesis, and that the competitive NOS inhibitor L-N
G-
monomethylarginine (L-NMA) enhanced early IL1-induced catabolism. This protective effect has 
also been demonstrated in human and rabbit articular cartilage,
327,793 and lapine menisci.
109 
Endogenous NO also downregulates chondrocyte production of IL-6 and IL-8, cytokines which 
themselves play both pro- and anti-catabolic roles.
346 These protective effects of NO may be due to 
disruption of anchorage-dependent integrin signalling, thus acting as a non-specific ‘brake’ in 
preventing both anabolic and catabolic responses.
140 
 
NO has also been linked to chondrocyte apoptosis.
78,321,481 However, in vivo evidence for this relies 
mainly on regional correlations between apoptosis and NO or peroxynitrate formation,
109,426 and as 
such remains circumstantial. In vitro evidence of NO-mediated apoptosis has not been entirely 
consistent, possibly due to co-dependence on other oxygen radicals.
79 Interestingly, Notoya et al. 
(2000)
588 recently suggested that PGE2 was necessary to sensitise human OA chondrocytes to NO-
induced apoptosis.     50. 
1.1.3.3.2  Nitric Oxide and Synovium 
 
The effect of exogenous NO on synoviocytes has not been adequately examined. NO certainly has 
the potential to be an important mediator of inflammation, by modulating events as diverse as 
blood flow, endothelial permeability, leucocyte migration, and immune cell activation. Via its 
actions on blood vessels, NO may be involved synovial hyperaemia and joint swelling.
282 However, 
its direct metabolic effects on synoviocytes are unclear. In rabbit synovial fibroblasts, L–NMA had 
no effect on PGE2, MMP or lactate production,
7 though NO was shown to enhance MMP-2 
production in rheumatoid human synoviocytes.
353 NO has also been shown to induce TNF- 
production in cultured synoviocyte and macrophage lines.
352,532 Were this to occur in vivo, NO may 
represent an important activator of synovial inflammation. 
 
1.1.3.3.3   Nitric  Oxide  and  Bone 
 
NO has recently been identified as an important regulator of bone, another in the long list of 
mediators involved in cell-to-cell signalling between osteoblasts and osteoclasts. Human and rat 
osteoblasts have been shown to produce NO in response to cytokine stimulation.
362,483,665 In mouse 
calvarial bone cultures, such induction of NO is associated with reduced bone resorption.
664 
Induction of high levels of NO may represent a protective mechanism against cytokine-stimulated 
bone resorption in pathological conditions.
483 Direct studies in cultured osteoclasts have confirmed 
that NO is a potent inhibitor of osteoclast function,
88,405,486 and of osteoclast differentiation from 
precursor cell types.
88 NO (in culture at least) may be partly responsible for cytokine-associated 
inhibition of osteoblast proliferation and activity,
171,362,665 and at high concentrations, osteoblast cell 
death.
170 However, as in osteoclasts, constitutive production of small amounts of NO appears to be 
needed for osteoblast growth.
211  
 
    51. 
While the in vitro effects of NO in bone are somewhat variable,
483,664 its dominant role in vivo 
appears to be tonic inhibitory restraint of bone resorption. This is supported by the observation that 
in rats, the iNOS inhibitor aminoguanidine potentiates loss of bone mineral density.
405 while 
Wimalawansa and co-workers have demonstrated that topical use of a NO donor (glyceryl 
trinitrate) alleviates ovariectomy-induced bone loss in rats.
903,905,906 A subsequent study showed that 
administration of exogenous NO also counteracts prednisolone-induced bone loss in rats.
904 NO 
may also be involved in the responses of bone to mechanical stimuli
134,644 and fracture healing.
199 
Evidence from iNOS deficient mice suggests that NO may also contribute to osteophyte formation, 
possibly via its influence on TGF-ß production.
858 NO is also thought to promote angiogenesis in 
some tissues, by feedback interaction with fibroblast growth factor-2 (FGF-2).
937 
 
1.1.3.4   Eicosanoids 
 
Prostaglandins are important mediators of classical inflammatory changes such as pain, 
vasodilation, increased vascular permeability, and immune responses.
542 Prostaglandins are 
generated from cell membrane phospholipids in an enzyme cascade involving phospholipase A2 
(PLA2)-generated arachidonic acid, which is converted by cyclooxygenase (COX) to various 
prostaglandins. As with NOS, both constitutively expressed and inducible forms of COX are now 
recognised. COX-1 is expressed under basal conditions in many cells, and is generally prescribed 
‘housekeeping’ functions, of particular importance in the gastrointestinal tract, platelets, renal 
medulla, and vascular endothelium. In contrast, a second form of cyclooxygenase, COX-2, is not 
expressed under normal conditions in most tissues, but is strongly induced by a variety of 
inflammatory stimuli.
575 
 
Production of eicosanoids by synovial tissue has been recognized and studied for decades.
530,534 
PGE2 is the predominant eicosanoid produce by synoviocytes, though others including PGI2 
(prostacyclin) are produced in appreciable amounts.
172,305,689,715 Early researchers noted that PGE2    52. 
production was increased in  synovial fibroblasts derived from rheumatoid joints, with IL-1ß 
subsequently identified as the major stimulus for its production.
56,95,114,175,480 Induction of COX-2 is 
currently thought to be the prime determinant of synovial PGE2 release,
371,618,688 though other 
mechanisms have been proposed, including increased expression of a secretory subtype of PLA2,
379 
and significant levels of COX-1 are also present.
159 
 
Though Meats et al.
534 first reported in 1980 that chondrocytes in culture could be stimulated to 
produce large amounts of PGE2, the potential importance of cartilage prostaglandin production has 
only recently been recognized. Subsequent studies have recognised that while some COX-1 activity 
is present in normal chondrocytes, COX-2 is indeed induced in cytokine-stimulated cartilage.
77 
Much interest was sparked by the report of Amin et al. (1997),
22 who found that COX-2 is 
‘superinduced’ in OA cartilage – to the extent that the spontaneous release of PGE2 by OA 
cartilage may be an order of magnitude greater than that of even IL-1ß-stimulated normal cartilage. 
This raises the prospect that cartilage may be the major source of PGE2 within the OA joint, though 
a recent study in horses suggested synovial tissue was instead the major producer.
874 The 
proportionately greater cell mass in synovium, particularly in inflammatory states, increases its 
contribution to synovial fluid PGE2 levels. 
 
1.1.3.4.1 Effect  of  Prostaglandin E2 (PGE2) on Joint Tissues 
 
In arthritic tissues, PGE2 has been traditionally thought of as a pro-inflammatory mediator. 
Certainly, it is a key driver of inflammatory changes in the synovial microvasculature, such as 
hyperaemia and increased permeability to proteins.
759 In culture, PGE2 induces some of the major 
phenotypic changes of synoviocytes derived from arthritic joints. A PGE2-mediated increase in 
intracellular cAMP seems to be responsible for the characteristic stellate or ‘dendritic’ morphology 
of cytokine-stimulated synovial fibroblasts in vitro.
55 Also, PGE2 is responsible for the reduced 
growth rate of rheumatoid synovial fibroblasts in culture, as IL-1ß or platelet-derived growth factor    53. 
(PDGF) are mitogenic only when cyclooxygenase is inhibited.
95,441 However, as PGE2-induced 
Protein Kinase A generally opposes the (mainly catabolic) Protein Kinase C dependant 
pathways,
193 the net effect of PGE2 is generally to oppose the actions of pro-inflammatory 
cytokines. In synovial tissue, PGE2 increases hyaluronic acid synthesis,
168 reduces TNF- 
expression,
188 and attenuates expression of MMP-1 and MMP-3.
191,192 However, PGE2 
simultaneously down-regulates the endogenous MMP antagonist tissue inhibitor of 
metalloproteinases-1 (TIMP-1),
193 increases synovial plasminogen activator activity,
549 and 
increases IL-6 and IL-8 production.
346 
 
In the avascular, aneural substance of cartilage, where prostaglandins cannot be involved in overt 
inflammation, it appears that they may yet play an important role in the regulation of chondrocyte 
metabolism. Surprisingly, the effects of PGE2 in cartilage are little explored in the literature. While 
evidence is not overwhelming, it is widely thought that PGE2 antagonises the cartilage effects of 
IL-1ß in a negative feedback loop, as it does in synovium.
259 There is some evidence that PGE2 
reverses IL-1ß-induced depression of proteoglycan synthesis, increases type II collagen synthesis 
(by a direct effect on COL2A1 gene expression), and decreases type I collagen 
synthesis.
197,259,272,273 Di Battista and coworkers have proposed a possible mechanism for this effect, 
involving an autocrine feedback loop with IGF-1 and the IGF binding proteins IGFBP-3 and -
4.
186,187,190 They hypothesised that the actions of locally synthesised eicosanoids in activating the 
IGF-1 / IGFBP system may be important during cartilage repair processes.
187 However, recent 
interest has focussed on the interaction between PGE2 and MMPs, particularly evidence that it may 
increase the release and activation of MMPs in certain tissues.
3,24,530 PGE2 has also recently shown 
to induce apoptosis in cultured chondrocytes, via a cAMP dependant pathway.
546,588 
 
In bone, prostaglandins are recognised as a potent inducer of bone resorption. PGE2 increases the 
size and number of osteoclasts, and COX-2 seems to be necessary in vivo for osteoclastogenesis. 
PGE2 may also repress osteoblast parathyroid hormone (PTH)-dependant responses.
351 Clinically, it    54. 
has been implicated in bone resorptive processes such as human RA
96 and equine subchondral cyst 
formation.
873 However, other models equally implicate prostaglandins in bone formation.
407,587 The 
response of bone to prostaglandins is complex and likely differs in physiological and 
pathophysiological states. The effect of NSAIDs on bone has been insufficiently examined, though 
interestingly, long-term use of aspirin has been associated with greater bone mass in 
postmenopausal women.
63 
 
1.1.3.4.2  Interaction Between Nitric Oxide and PGE2 
 
Numerous studies have shown that NO appears to regulate cellular PGE2 production, though the 
results obtained vary in different cell types, pathophysiological states, and experimental 
conditions.
22,789 In cartilage, the majority of studies suggest that NO augments PGE2 
release.
78,135,494,574,588,717 This is consistent with evidence that NO, via peroxynitrite, directly 
activates the cyclooxygenase enzyme.
448,716,717 However, other equally valid studies have shown 
either no effect,
383 or that NO instead shows an inverse relationship with PGE2 in cartilage.
22,346,791 
It has been suggested that NO may act at the level of COX expression.
381 Amin and coworkers 
have presented evidence that NO may differentially enhance COX-1-derived prostaglandins, while 
inhibiting those produced by COX-2.
24 However, Nedelec et al. (2001)
574 found that NOS 
inhibition specifically decreased induced but not basal COX activity. The subject remains a matter 
of considerable controversy despite numerous investigations. 
 
Conversely, the effect of PGE2 on NO production by joint tissues has received little attention. Onga 
et al. (2000)
599 recently examined the effect of PGE2 and forskolin, a direct adenylate cyclase 
activator, on bovine articular chondrocytes. While they did not affect basal NO production, these 
agents synergistically augmented IL-1ß-stimulated NO release and iNOS expression. This is 
consistent with the observation that in many cell types, NSAIDs suppress iNOS 
induction.
5,112,360,591,718 In cartilage however, this effect seems to vary between different NSAIDs,    55. 
suggesting that it is in fact unrelated to COX inhibition. For example, aspirin, diclofenac and 
tenidap inhibit NO release,
50,84 while naproxen, indomethacin and glucocorticoids have little 
effect.
3,628 
 
The interaction of the NO and prostaglandin pathways in bone is also potentially important, given 
the potent effects of each on bone resorption, but remains poorly understood. In an osteoblastic cell 
line, NO appeared to mediate cytokine-induced induction of PGE2, which in turn had an inhibitory 
effect on NO.
402 However, SNAP had no effect on PGE2 concentration in a bone organ culture 
system.
664 
 
1.1.4      OESTROGEN IN BONE AND JOINT HOMEOSTASIS 
 
A growing body of epidemiological, clinical, and experimental evidence suggests that sex steroids, 
particularly oestrogen, may modify the metabolic activity of joint tissues, and as such may be an 
important player in the pathogenesis of OA. The effects of oestrogen in promoting bone density are 
well known, and may represent one possible route by which it may influence the arthritic process. 
Its role in the immune system is also well studied, and it is possible it may modulate the immune 
processes of arthritis rather than cartilage events.
162 However, strong evidence also suggests that 
oestrogens have a direct influence on cartilage metabolism. 
 
Being steroid hormones, oestrogens are highly lipid soluble and pass freely across cell membranes 
to enter cells by passive diffusion. Binding to specific receptors occurs intracellularly; the exact 
location of these receptors has been the subject of debate, but is probably the nuclear 
compartment.
143,419,891 The oestrogen-receptor complex then binds directly to the promoter region of 
target genes.
602 Since the cellular actions of oestrogen vary in response time, there appears to be a 
cascade of gene responses. Recent evidence suggests that extremely rapid, non-genomic responses 
also occur.
433,602 Initial increases in nuclear proto-oncogenes c-myc, c-jun and c-fos suggest the AP-   56. 
1 pathway may be one important route by which oestrogen affects cellular proliferation and 
differentiation.
165 This promoter pathway is also involved in post-receptor mechanisms of IL-1 
activity. Oestrogen was found to be synergistic with lipopolysaccharides in enhancing IL-1ß 
promoter activity, via oestrogen receptor-mediated processes, in a macrophage cell line.
704 
However, other reports have shown the opposite both in vitro and in vivo.
704  
 
Two functional oestrogen receptors are currently known, ER and ERß, which are the product of 
separate genes.
439,602 It has been shown that the two receptors signal in opposite ways via the AP-1 
promoter element, suggesting they may have distinct and often opposite effects on cellular 
activity.
606 Therefore the ratio of ER to ERß is likely to be an important determinant of the cellular 
effects of oestrogen, in addition to total receptor number.
602,757 In discussing agonists/antagonists of 
these receptors, the term ‘selective estrogen receptor modulator’ or SERM has come into use, to 
reflect the highly tissue-specific action of such compounds 
298  
 
If oestrogens do play a role in joint tissue metabolism, local production or conversion from weaker 
oestrogens might be important. Bellino (1992)
68 examined rabbit cartilage and showed appreciable 
17ß-hydroxysteroid dehydrogenase activity (which converts weak oestrone to potent oestradiol), but 
not aromatase activity (required for de novo synthesis of oestradiol). This provides a mechanism for 
local conversion of peripheral oestrone in postmenopausal women. Recent studies suggest 
osteoblasts may possess both enzymes.
711 
 
Of particular relevance to discussion of the effects of oestrogen in joint tissues is its now well-
documented relationship with the IGF-1 system. Importantly, Fernihough et al. (1999)
227 showed 
that oestrogen supplementation of ovariectomised monkeys increased synovial fluid levels of IGF-1 
and IGF-2, and IGFBP-1 and -3. This effect was dose-responsive but was reduced by treatment in 
combination with progestogen.
227 Further, elevated chondrocyte expression of IGFBP-2 was 
demonstrated, in association with an increase in proteoglycan synthesis.
685 However, these findings    57. 
are somewhat contrary to previous observations that: (i) serum IGF-1 is known to increase five 
weeks after ovariectomy in rats;
811 (ii) oestrogen represses IGF-1 expression in HeLa cells and rat 
vascular smooth muscle cells by an ER-dependant mechanism,
728 while simultaneously 
potentiating the IGF-1 receptor signalling pathway;
398 and (iii) oral oestrogen replacement therapy 
in women has been shown to reduce total serum IGF-1, IGFBP-3, and the acid-labile subunit of the 
circulating ternary IGF-1 complex, though increases in IGFBP-1 and free IGF-1 have been 
recorded.
111,248,399,604,868 Interestingly though, oestradiol by either transdermal
111,399,604 or intranasal
248 
routes has no apparent effect on IGF-1 levels in women. Serological associations between oestrogen 
and IGF-1 have also been demonstrated in males.
142,458 In the osteoblastoid ROS and SaOS-2 cell 
lines, oestrogen-related proliferation has been associated with IGF-1,
129,573 while mechanical strain-
related proliferation has been shown to act separately via IGF-2 receptors.
129  
 
1.1.4.1    Evidence Linking Oestrogens and Arthritis 
 
1.1.4.1.1   Clinical and Epidemiological Evidence 
 
The epidemiological patterns of OA strongly suggest a link with oestrogen.
226 The incidence and 
prevalence of OA increases steeply in women after the age of 50, corresponding to the time of 
menopause.
225,578 OA involving multiple joints is more frequent and more severe in women.
556 A 
subset of OA has long been recognised in middle-aged women, occurring around the time of 
menopause, characterised by chronic recurrent “inflammatory OA” of multiple joints, especially the 
interphalangeal joints (causing classical Heberden’s nodes), carpometacarpal joints, and cervical 
spine.
20,154,782 This ‘generalised OA’ has a strong genetic influence, possibly through oestrogen 
receptor gene polymorphisms.
850 It is unclear whether short-term hormonal fluctuations and 
imbalances at the time of menopause, or the permanent decline in hormone levels which follows, is 
responsible.
578 In reviewing the subject, Spector and Campion (1989)
782 postulated that an absolute 
oestrogen excess, and/or a relative excess of oestrogen relative to progesterone during the    58. 
perimenopausal period, may cause this phenomenon. Oestrogen excess may also explain other 
epidemiological findings, such as the strong association between hysterectomy and OA (the 
commonest indications for hysterectomy being those associated with hyperoestrogenism),
781 the 
well-documented inverse relationship of osteoporosis and OA,
153,312,319,580,778,779 and the correlation 
of obesity and OA in non-weight-bearing joints (obesity in women is associated with 
hyperoestrogenism due to peripheral conversion of androstenedione to oestrone in adipose 
tissue).
782 However, results from studies directly measuring endogenous oestrogen levels have been 
inconclusive.
226,578,778 One study found a weak association between high oestrogen levels and 
advanced knee (but not hand) OA, and a negative association with testosterone levels.
778 Another 
study found that women with generalised OA had lower levels of sex hormone binding globulin, 
possibly allowing higher levels of free circulating oestrogen.
784 Synovial oestradiol levels are 
elevated in OA patients when compared to normal postmenopausal women, in levels correlated 
highly with OA severity.
838 
 
On the other hand, there is fair (but not total) agreement amongst epidemiological studies (reviewed 
by Felson and Nevitt (1999)
226) that hormone (i.e. oestrogen) replacement therapy (HRT) in women 
is associated with reduced incidence and prevalence of OA.
577,598,719,722,778,783,934 A meta-analysis of 
some of these studies found a pooled odds ratio of 0.76.
578 In the Framingham study cohort of 551 
elderly women, current use of oestrogen replacement therapy was found to have a moderate 
protective effect against progression of radiographic knee OA.
934 The same protective trend was 
noted in the middle-aged Chingford study cohort.
318,783 However, several studies have shown either 
no effect or an increased relative OA risk with HRT.
490,579,722,778 Adjustment for all confounding 
factors is difficult because women choosing HRT differ in many ways from those who do not, 
including frequency of utilisation of health services.
225,578,598 In addition, women with osteoporosis 
are more likely to be prescribed oestrogen, and osteoporosis is protective of OA.
225 Such conflicting 
lines of evidence are difficult to reconcile. It may be that the effect of oestrogen exposure depends 
on menopausal status or stage of OA.
225    59. 
Other forms of arthritis are also apparently modified by hormonal influences. RA is more frequent 
in females (gender ratio of approximately 2:1), and carries a worse prognosis in women.
452,724 While 
epidemiological studies remain inconclusive, there seems a consensus that oral contraceptives are 
partially protective of severe RA.
724,911 The anti-oestrogenic compound tamoxifen (commonly used 
to treat breast cancer) has been circumstantially associated with symptomatic improvement in 
rheumatoid patients, though it has also been suspected of causing inflammatory arthritis in its own 
right. One small cohort study (of 49 patients) examining this matter found no effect.
233  
 
1.1.4.1.2     Experimental Evidence 
 
To date, animal experiments investigating the effects of oestrogen on joint integrity are of 
questionable relevance due to the high doses of oestrogen, mode of administration, species and age 
of the animals used.
835 Silberberg and Silberberg (1963)
758 showed that oestrogen injections reduced 
the severity of spontaneous OA lesions in male inbred mice. Later studies by Rosner and coworkers 
demonstrated that subcutaneously administered oestrogen worsened osteoarthritic changes in both 
ovariectomised and entire hemi-meniscectomised rabbits.
699,701 Tamoxifen reduced erosive changes 
in the same model.
699 In a rabbit model of immune synovitis, tamoxifen also reduced gross and 
histologic pathology.
700  
 
Tsai and coworkers conducted another series of experiments in normal rabbits, demonstrating OA-
like changes after intra-articular injection of oestradiol benzoate, an effect which could be blocked 
by tamoxifen.
834,837 The effect was apparently cytotoxic, with cell necrosis, chondrocyte cloning, 
and pitting of cartilage.
837 However, the doses of oestradiol used in these studies (equivalent of 0.3 
mg/kg/day) are clearly supraphysiological.
578 Chander and Desa (1991)
123 also demonstrated that 
large doses of oestrogen accelerated the loss of glycosaminoglycan from rat femoral heads 
implanted subcutaneously into female mice, an effect which again could be blocked by tamoxifen. 
    60. 
1.1.4.2   Oestrogen  and  Cartilage 
 
It has been shown in many species that exogenous oestradiol depresses proteoglycan synthesis by 
chondrocytes,
582,699,701,782,835 though in bovine cartilage, this effect has only been demonstrated at 
supraphysiological concentrations.
487 However, it is not clear whether this suppression of synthesis 
leads to net loss of proteoglycan.
487,782 In vitro, 17ß-oestradiol inhibits chondrocyte proliferation, 
but increases production of collagen and other proteins.
487,739 This change may effectively signal 
chondrocyte differentiation, as has been shown in growth plate cartilage.
572 It is not clear whether 
these effects are direct (receptor-mediated) or are dependent on some second messenger. Oestradiol 
enhances IL-6 production by IL-1-stimulated chondrocytes.
295 17ß-oestradiol also reduces basal 
COX-2 expression in bovine chondrocytes, but has no effect on cytokine-induced levels.
720 
 
If oestradiol is an important regulator of chondrocyte metabolism, this implies inherent gender 
differences in cartilage. Male children have greater weight-adjusted cartilage volume than females, 
even from a young age.
390 In comparing femoral head cartilage from male and female rats, Larbre et 
al. (1994)
452 found that female cartilage contained less proteoglycan and collagen, showed greater 
spontaneous proteoglycan loss and lower proteoglycan synthesis, and was more sensitive to IL-1-
induced inhibition of matrix synthesis. However, as female cartilage was less sensitive to IL-1-
induced  loss of proteoglycan, the net effect on glycosaminoglycan content was similar in both 
sexes. Some gender differences in metabolic responses have been shown in human cartilage, such 
as in the effects of 24,25-dihydroxy-vitamin D3.
739 Hormonal influences must also account for the 
reduction in type II collagen, biglycan, TNF-, iNOS, and COX-2 expression seen in articular 
cartilage of pregnant rabbits relative to non-pregnant controls.
335 
 
Turner et al. (1997)
841 made the important observation that simple ovariectomy of normal, aged 
sheep has an adverse effect on the biomechanical integrity of cartilage, as evidenced by a reduction 
in aggregate modulus (compressive stiffness) and shear modulus. Räsänen and Messner (1999)
667    61. 
showed an increase in static stiffness and cartilage thickness in young rabbits after ovariectomy. 
Similarly, ovariectomy of young rats rapidly increases cartilage thickness in the temporomandibular 
joint.
597,918,923 These findings should be interpreted with some caution, as results based on pubertal 
growing animals may not be relevant to adult animals. Ovariectomy of adult rats increases cartilage 
collagen and protein content
4 and creatine kinase activity.
777  
 
The presence of high-affinity oestrogen receptors has been demonstrated in rabbit, sheep, rat, mice, 
dog, baboon, and human articular cartilage.
69,642,685,702,836,842,851,928 However, Mackintosh and Mason 
(1988)
487 were unable to demonstrate oestrogen receptors in bovine chondrocytes. Tsai et al. 
(1992)
838 examined oestrogen binding sites in human OA cartilage collected at knee joint 
replacement, and showed that levels were greater in femoral and tibial cartilage of the medial 
compartment than in equivalent tissues from the lateral joint compartment. In this small group of 
patients, oestrogen receptors were found to be significantly correlated with OA severity, but were 
absent from patients with traumatic OA secondary to articular fractures.
838 Both ER and ERß have 
been detected in human and monkey cartilage,
685,851 though a recent report suggested that ERß may 
be the predominant receptor present in human cartilage.
395  
 
One problem raised by the apparent importance of oestrogen in cartilage homeostasis is explaining 
how this may apply to male animals. In fact, oestrogen-dependant mechanisms may also exist in 
male tissues. Recent studies have shown that bone homeostasis in men appears to be oestrogen 
dependant.
669 Metabolites of dihydrotestosterone such as 5-androstane-3ß,17ß-diol have a good 
affinity for oestrogen receptors and may replace oestradiol in this function.
298 
 
1.1.4.3    Oestrogen and Synovium 
 
Several authors suggest that synovial tissue may also be a significant target of oestrogen, not least 
its influence on disease activity in rheumatoid arthritis.
164,849 Given the known modulating effects of    62. 
androgens and oestrogens on cytokine synthesis by monocyte/macrophage populations, synovial 
macrophages may be a major target of sex hormones within the joint.
161,164 Ushiyama et al. 
(1995)
849 demonstrated oestrogen binding and expression of oestrogen receptor-related protein 
(p29) in human synovium. Cutolo et al. (1996)
163 used kinetic binding studies to confirm the 
presence of specific oestrogen receptors in cells characterised as synovial macrophages. Both Type 
I (high affinity, low capacity) and Type II (lower affinity, high capacity) receptors were observed. 
Ghosh and Seshandri (1986)
266 reported ‘large amounts’ of oestrogen and progesterone receptors in 
a rheumatoid synovial cell line.  
 
The effect of oestrogen stimulation in synovial tissue remains poorly examined. The addition of 
oestrogen caused a mild increase in IL-1ß-stimulated IL-6 production by human rheumatoid 
synovial fibroblasts.
411 Oestrogen has been shown to increase IL-1 production in peripheral 
macrophages, though this effect may be biphasic at higher concentrations.
161,361 This seems feasible 
given the close association of oestrogen and IL-1 via the AP-1 promoter. 
 
1.1.4.4    Oestrogen and Bone 
 
The exact mechanisms by which oestrogens exert their well-known effects on bone metabolism are 
unclear. Multiple pathways and mediators appear to be involved, as reviewed by Oursler (1998).
602 
Firstly, oestrogen modifies the proliferation and cellular responses of osteoblasts. Oestrogen 
receptors are known to be present in osteoblast-like cells.
46,208,711 In osteoblastic precursor cells, 
oestrogen has been reported to both stimulate and inhibit proliferation in vitro, suggesting the effect 
may be dependant on maturation state.
602 Similarly, osteoblast matrix production is promoted by 
oestrogen, but only under certain experimental conditions. Oestrogen also modulates the release of 
growth factors such as IGF-1 and TGF-ß, and osteoblast responsiveness to other hormones such as 
vitamin D3, progesterone, growth hormone, and parathyroid hormone.
207 It has been shown in vitro 
that oestrogen promotes the proliferative response by osteoblasts to mechanical strain.
169 This may    63. 
explain why the homeostatic strain-related adaptive responses of bone fail to compensate for 
postmenopausal bone loss. 
 
Secondly, oestrogen influences osteoclast differentiation and activation, probably via complex 
cytokine networks including IL-1, TNF- and IL-6.
356,602 Evidence for such interactions is multiple 
but somewhat confused. IL-6 is known to be important in osteoclastogenesis,
385 and may represent 
an important pro-resorptive factor released by osteoblasts and other cells. Oestrogen has been 
shown to inhibit IL-6 production in osteoblast-like cell lines.
267,404,429 In one murine study, a 
blocking antibody to IL-6 was able to prevent any post-ovariectomy increase in 
osteoclastogenesis.
385 Similarly, ovariectomy has no effect on bone mass in IL-6 knockout mice.
645 
However, other studies have found that blocking IL-6 antibodies fail to prevent bone loss in 
ovariectomised rats and mice.
418 The response may be site-specific, or other cytokines, such as IL-1 
and TNF- may be involved.
602 Both are potent inducers of bone resorption and their production by 
certain cell types appears to be suppressed by oestrogen. Peripheral blood monocytes (PBM) from 
patients with osteoporosis produce greater amounts of IL-1 and TNF- than those from age-
matched patients.
691 This effect appears to be oestrogen-dependant, as the same effect has been 
shown in ovariectomised women,
605 and PBM cytokine production is normalised (and IL-1Ra 
release increased) by oestrogen replacement therapy.
691 This is somewhat surprising, as in other 
experimental systems using monocyte cultures, oestrogen has been found to potentiate the basal 
production of IL-1ß.
161 Both IL-1 and IL-6 increase RANKL expression by osteoblasts,
287 and 
blocking antibodies to IL-1 and TNF- are able to prevent bone loss in ovariectomised mice.
418 
However, the relative importance of such cytokines in oestrogen-deficient bone loss is debatable. 
Such second messengers may not be necessary, as oestrogen has been shown to suppress 
differentiation of osteoclasts from blood precursors through a direct receptor-mediated 
mechanism.
748 Direct associations between oestrogens and the RANKL/osteoprotegerin (OPG) axis 
have recently been reported, and may prove to be important. For example, oestrogen may decrease 
responsiveness of osteoblastic precursors to RANKL.
748,788    64. 
Thirdly, oestrogen may modulate the activity of mature osteoclasts directly.
602 It has been shown 
that osteoclasts express oestrogen receptors,
600 and that oestradiol produces a dose-dependant 
reduction in resorptive activity when added to cultures of osteoclasts. In addition to down-
regulation of resorptive enzymes, rapid non-genomic effects may be involved, via specific trans-
membrane oestrogen receptors.
602 Oestrogen also appears to induce osteoclast apoptosis.
400 
 
Another possible mechanism by which oestrogen regulates bone metabolism is by influencing nitric 
oxide production. The known protective effects of oestrogen in the cardiovascular system are 
suspected to be mediated by NO. For example, the aorta of female rabbits has higher basal NO 
production than that of male animals.
330 Oestrogen has been shown to increase production of NO in 
a range of guinea pig tissues, including uterine artery, heart, skeletal muscle, and brain.
884,890 
Oestrogen is also known to cause vasodilation, an effect can be partially blocked by the NOS 
inhibitor L-NMA.
666 A link is also suggested by the observation that circulating nitrate levels in 
women increase with follicular development,
676 and after administration of exogenous 
oestradiol,
370,666 though the exact source of this nitrate is unknown. 
 
More recently is has been proposed that NO may mediate the bone-sparing effects of oestrogen. 
Wimalawansa et al. (1996)
906 showed that while both glyceryl trinitrate and exogenous oestrogen 
alleviated ovariectomy-induced bone loss in rats, oestrogen was totally ineffective in the presence 
L-NAME, suggesting that much of the effects of oestrogen on bone resorption may be mediated by 
NO. Other researchers have shown in vivo that oestradiol increases osteoblast NOS activity and 
expression approximately two- to three-fold, probably via induction of the eNOS isoform.
36 As NO 
has been shown to reduce osteoclast formation and activity, this link seems entirely 
plausible.
483,486,664 
 
Whilst oestrogen appears to increase constitutive NO synthesis, there is some evidence that it may 
reduce NO production via iNOS. Ovariectomised rats demonstrate a greater increase in plasma    65. 
nitrate levels following endotoxin treatment than entire animals, and this increase can be attenuated 
by pre-treatment with oestradiol.
406 Oestrogens may therefore be beneficial in pathological 
conditions associated with iNOS induction.  
 
1.1.5       ANIMAL MODELS OF OSTEOARTHRITIS AND OSTEOPOROSIS 
 
1.1.5.1     Animal Models of OA 
 
While the degeneration of articular cartilage is an early event in OA and is of central importance to 
its pathogenesis, this process is generally asymptomatic. Radiographic evidence of the disease may 
not be evident until cartilage disruption is well advanced.
258 Similarly, symptoms of pain and 
stiffness may be present only in advanced disease, and correlate poorly to radiographic or 
pathologic indices. As joint tissues are only feasibly obtained from clinical end-stage disease, study 
of early events is difficult and properly matched control tissues are difficult to obtain. The use of 
animal models therefore provides the only practical method for sequential evaluation of the factors 
initiating (and perpetuating) the complex morphological, biochemical, metabolic, and molecular 
alterations seen in OA.  
 
Brandt (1999)
89 recognises three broad categories of animal OA models: (i) spontaneous or genetic 
OA (e.g. Dunkin Hartley guinea pigs, STR/ort mice, canine hip dysplasia); (ii) chemically-induced 
OA, generally by intra-articular injection of an irritant substance (iodoacetate, papain, hypertonic 
saline); and (iii) physically-induced OA, including anterior cruciate ligament transection (ACLT), 
immobilisation, myectomy, and meniscectomy procedures. Each method has its own advantages 
and pitfalls. Because the aetiology of OA is unknown, particularly with respect to the importance of 
overt inflammatory processes, models involving inflammatory responses are of questionable use. 
Spontaneous models are caused by specific genetic defects and hence relate to specific subsets of 
OA. Similarly, surgical models may be more relevant to post-traumatic OA than primary    66. 
(idiopathic) OA, and it is unknown whether ideal treatment modalities may differ between these 
subgroups.
89 One criticism which has been applied to all animal models is the short time scale 
required to establish advanced disease, compared to the decades-long progression of human OA.
260 
 
Models based on surgical disruption of the stifle joint have most frequently employed rabbits or 
dogs. Rabbit models have involved partial or total meniscectomy, ACLT, or combined procedures 
such as the Hulth procedure.
152,364,430,927 The utility of rabbit models may be limited due the different 
range of motion and stresses on the knee joint compared to that of bipeds, and the particularly labile 
nature of lapine cartilage.
260 Even injury as slight as intra-articular injection of sterile physiological 
saline is able to induce proteoglycan defects in rabbit articular cartilage.
246  
 
The canine ACLT or Pond-Nuki model is widely utilised and well described.
646 However, it has 
been demonstrated that the blind 'stab' technique usually employed creates intra-articular 
haemorrhage and subsequent inflammation which significantly contributes to the pathologic 
process.
569 Hypertrophic repair of cartilage is predominant in this model, and long experimental 
periods are required for progression to full-thickness cartilage lesions, though this can be 
accelerated by neurectomy.
89,90,412 It has been proposed that many of the joint changes characteristic 
of this model may be attributable to the decrease in loading following unilateral surgery, rather than 
any intrinsic OA-like disease process.
590  
 
1.1.5.2  The Ovine Meniscectomy Model of OA 
 
The knee joint menisci are fibrocartilaginous semi-lunar pads interposed between the femoral and 
tibial condyles. They are composed predominantly of a dense type I collagen framework and 
hydrated aggrecan, with the majority of collagen fibres oriented circumferentially. The menisci 
function to improve congruity between the convex femoral condyles and the comparably flat tibial 
articular surface, hence increasing the effective contact area of the articulation and reducing focal    67. 
peak forces.
67 It has been estimated that 50-70% of the total transarticular load may be transmitted 
via the menisci.
541 The menisci also have roles in shock absorption, stabilisation, joint lubrication, 
and possibly in providing sensory feedback during joint compression. 
 
It has long been recognised that total meniscectomy results in eventual cartilage degeneration and 
joint remodelling in human patients.
541 Experimental meniscectomy of sheep reliably creates a 
useful model of OA, which primarily develops secondary to altered joint congruity and load 
distribution in the meniscus-deficient femoro-tibial compartment.
258,260,264,474 Medial meniscectomy 
in sheep has been shown to reduce the mean area of femoro-tibial contact from 78.6 mm
2 to 24.8 
mm
2.
67 Biomechanical alterations also cause wide-ranging changes to more distant sites such as the 
patella and even the femoral head.
33 Synovitis, synovial fluid alterations, and subchondral bone 
remodelling accompany cartilage changes and may play a role in disease progression.
38,474 The 
advantages of the sheep model are multiple: husbandry practices in Australia allow purchase of 
genotypically and phenotypically homogenous groups of animals from a single source, and the use 
of food animals is ethically and financially preferable to companion animal or primate models. The 
large joint permits serial collection of synovial fluid, and allows both topographic division and the 
harvest of large volumes of cartilage for multiple analyses.
258 The anatomy of the ovine stifle is 
comparatively similar to the human knee, and is relatively extended in normal stance, compared to 
the more flexed posture of rodents and rabbits.
520 The lesions induced are reproducible, slowly 
progressive, and correspond faithfully to the pathological changes found in naturally occurring 
human OA. Focal cartilage fibrillation or erosion develops within a few months, accompanied by 
matrix proliferation and marginal osteophyte formation.
474 Increased loss of proteoglycans from 
cartilage, reduced incorporation of 
35S-labelled proteoglycans, increased chondroitin-4-sulphate, 
and changes in proteoglycan epitopes have all been documented.
258,474 
 
The differences between ovine medial and lateral meniscectomy models have been examined in 
detail.
264 The ovine lateral meniscus covers a greater proportion of the tibial condyle than the    68. 
medial, as has been demonstrated in the human knee (Figure 1.6).
41,143,541 The medial compartment 
is reported to bear a greater proportion of total load than the lateral compartment in the human knee; 
the greater bone density of the medial compartment suggests this is probably also true in sheep.
39,41 
Contact stresses are therefore lower in the intact lateral compartment than the medial under 
conditions of normal weight-bearing. The higher stresses therefore imposed on articular cartilage 
following lateral meniscectomy may explain the more rapid cartilage deterioration when compared 
to that following medial surgery.
264 
 
 
 
 
 
 
 
  
  
  
  
 
 
 
 
Figure 1.6:   Dorsal view of the ovine tibial condyles with menisci intact. Note the difference in the 
caudal attachments of the medial (menisco-tibial ligament) and lateral (menisco-femoral ligament) 
menisci, and the close association between the lateral meniscus and the popliteus tendon. MED, 
medial; LAT, lateral. 
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1.1.5.3    The Ovine Ovariectomy Model of Postmenopausal Osteoporosis 
 
Osteoporosis is a systemic skeletal disease defined by loss of bone volume and bone mineral 
density, and micro-architectural deterioration of bone, leading to an increase in bone fragility and 
incident fracture. Women are prone to a postmenopausal form of osteoporosis, characterised by 
rapid bone loss in the 5-10 years following menopause, as distinct from the slower age-dependant 
loss of bone density occurring in both sexes.
615 BMD is the variable most often measured, and is 
highly correlated with bone strength.
615 However, recognition of the importance of other factors 
such as trabecular connectivity has lead to the view that densitometry may be inappropriate as a 
single predictor of fracture risk in osteoporosis.
616 The most important osteoporotic changes occur 
in trabecular bone, though cortical bone loss is also important in certain types of osteoporosis and is 
often overlooked.
686 
 
Newman et al. (1995)
581 reviewed the application of the ovariectomised sheep model to the study of 
osteoporosis. Sheep represent a promising model as they have similar oestrus and hormonal cycles 
to women, with the exception of a short period of anoestrus during the winter months. Turner and 
coworkers have characterised this model in extensive studies.
127,290,581,840-845 Most bone 
histomorphometric parameters change slowly, with only a slight decrease in bone mass at six 
months post-ovariectomy, accompanied by a slight increase in trabecular separation and decrease in 
wall thickness.
845  
 
Plasma osteocalcin is potentially a useful measure of osteoblast function in sheep,
217,581 though it is 
reduced by low dietary phosphate,
156 pregnancy,
217 and long term administration of 
adrenocorticotropic hormone (ACTH) or corticosteroids.
157,236 Plasma values in both growing and 
mature animals are at least 6-10 times that of equivalent human subjects, probably reflecting the 
genetically selected higher growth rate in these production animals.
157 In contrast to humans, there 
is no significant circadian variation
157 or rapid pulsatile variation of circulating osteocalcin in    70. 
sheep.
156 However, plasma alkaline phosphatase has limited value as a marker of ovine bone 
formation.
156 
 
1.1.6   IN VITRO INVESTIGATION OF SYNOVIAL TISSUE 
 
1.1.6.1    Culture Methods of Synovial Tissue in vitro 
 
In the past, researchers used a variety of in vitro culture methods (reviewed by Henderson (1981)
337) 
to examine the metabolic changes evident in synovial tissue in different disease states. Fraser 
(1965)
241 first described an enzymatic method of harvesting synovial cells, involving intra-articular 
injection and aspiration of trypsin solution. However, he found that the cells so isolated do not grow 
well in culture, demonstrating a heavy serum requirement and large losses at subculture. It is now 
recognised this method yields predominantly Type A synoviocytes,
59,242 as demonstrated by their 
failure to produce hyaluronan.
166 Type A cells do not persist in prolonged culture or serial 
passage.
1,176,242 Using this method, it has been shown that the number of Type A cells declines with 
time in culture (falling after about 4 days), and drops sharply after subculture procedures (<4% after 
1
st passage, <1% after 2
nd passage).
242 
 
Other researchers have used synovial organ culture methods involving biopsy specimens,
715 
weighed dissected synovial portions,
133,394,627, intact synovial villi,
565,570 or minced synovium.
223,714 
Such techniques have the advantage that they contain a representative mixture of type A and B 
synoviocytes, together with cells normally present in the subsynovial layer. However, one problem 
with organ culture methods is that weight-for-weight comparisons are invalid due to the variably 
increased cellularity of the synovial lining layer in inflammatory states.
337 If synovial organ cultures 
are cultured for long periods in such a manner that they are not disturbed, marginal cells adhere to 
the floor of the culture vessel and proliferate as a cell monolayer. This monolayer initially contains    71. 
both cell types, but synovial fibroblasts quickly overgrow Type A cells.
438 This explant outgrowth 
method has been widely used to isolate synoviocytes.
27,302 
 
The majority of recent synovial studies have employed a method whereby minced synovial tissue is 
subjected to sequential enzymatic digestion to yield a cellular suspension. Most utilise a sequential 
trypsin/collagenase digestion similar to that described by Smith and Ghosh (1987).
173,193,250,263,539,770 
While most studies use subcultured cells, McInnes et al. (1996)
532 used this method to derive a 
primary single cell suspension that was assayed directly. Several authors suggest that Type A cells 
adhere more rapidly than fibroblasts, and it is possible to select for them on this basis.
730 Without 
selection procedures, Type A cells are rapidly eliminated from synoviocyte monolayers.
128,377 Even 
synovial fibroblasts will eventually become senescent after 10-12 passages in monolayer culture.
231 
Georgescu et al. (1988)
250 studied the effect of continued passage on lapine synovial fibroblasts, and 
showed that the growth rate slowed after the 4
th passage, and was minimal after 8-12 population 
doublings.  
 
Recent advances in synoviocyte culture technique have included the use of three-dimensional 
culture systems, such as collagen gels.
810 Other studies have utilised co-cultures of synovial 
fibroblasts and macrophages, in attempts to simulate the in vivo interactions of Type A and B 
synoviocytes.
334,382,617,705,740 Such co-culture techniques certainly cause more rapid and more 
extensive release of catabolic factors in vitro.
617 
 
1.1.6.2   Culture  Requirements  of  Synoviocytes 
 
Synoviocytes are undemanding in their culture requirements. Addition of serum is not essential, but 
has a stimulatory effect on the biosynthesis of collagen, total protein, and glycosaminoglycans.
503,654  
Similarly, refreshing serum-containing culture medium has been shown to stimulate HA 
synthesis.
706 However, cells derived from inflamed synovium may be less sensitive to serum    72. 
depletion.
27 Moderate variations in media pH have no effect on cell growth, but may affect HA 
production.
145 Early investigations of rheumatoid synovial tissue showed a preference for relatively 
alkaline (pH 7.8) culture conditions.
27,648 Trypsinization of cellular monolayers transiently induces 
collagenase and plasminogen activator secretion, but this effect is reduced by presence of serum.
892 
Authors examining the effect of trypsin have shown that little cell damage occurs, and that recovery 
is rapid on the addition of serum-containing media.
59,503 
 
1.1.6.3    Differences Between Normal and Arthritic Synovium in Culture 
 
Smith and Hamerman (1969)
767 were among the first authors to note persistent differences between 
rheumatoid and normal synoviocytes in culture, showing altered morphology, growth, and cartilage 
catabolic activity.
766 Other studies have noted greater glucose consumption, lactate formation, and 
HA synthesis,
119 lower serum requirement in culture,
503, and altered responses to drugs
347 in cells 
derived from arthritic joints. Some authors have shown that such metabolic differences in inflamed 
synovia persist many generations in culture.
276,377,908 However, others have suggested that while the 
production of mediators such as PGE2 is increased in cultures derived from inflamed synovia 
relative to healthy tissues, this difference has disappeared after repeated media changes (i.e. with 
the loss of the non-adherent cell population).
530,531,689,705 This process parallels a change in cellular 
morphology - cells in primary culture are large (sometimes multinucleate), stellate, and granular in 
appearance, gaining a more fibroblastic appearance as culture progresses.
435,767 Castor et al. 
(1971)
119 first suggested that soluble “activating factors" were capable of inducing these changes in 
normal synovial fibroblasts, and that increased autocrine production of such factors may account for 
most of the in vitro changes observed. The typical stellate (or ‘dendritic’) morphology of activated 
cells is probably related to a prostaglandin–induced increase in intracellular cAMP.
55,334,435 PGE2 
production is massive in primary synovial fibroblast cultures, especially those of rheumatoid  origin 
(e.g. 1 g/10
6 cells/day),
172 and declines with time in culture.
176,276,689 
    73. 
It currently seems  unlikely that rheumatoid synoviocytes are inherently different from normal 
cells.
530 There are no ultrastructural features characteristic of rheumatoid cells.
431,917 One study 
showed no difference in glucose uptake or glycosaminoglycan synthesis.
26 Others have concluded 
quantitative rather than qualitative differences.
764 For example, production of IL-1-like activity is 
increased in RA synoviocytes, but is similar to cells derived from other arthritic conditions per unit 
of DNA.
97 However, rheumatoid synoviocytes do exhibit growth characteristics distinct from those 
of OA-derived cells; for example, only the former are capable of monoclonal expansion on soft 
agarose gels.
266,369 
 
A cell type intermediate of Type A and B cells has been described in early synovial 
cultures.
531,613,753 These intermediate / ’dendritic’ / ‘transformed-appearing’ cells are nominally 
associated with the cartilage and bone destruction which occurs in RA, and are major producers of 
degradative products such as collagenase in culture.
915 These cells, commonest in rheumatoid 
cultures, are characterised by dense rough endoplasmic reticulum, large irregular pale nuclei with 
prominent nucleoli, and abundant cytoplasm. There is some confusion in the literature over the 
origins of this cell type, and whether it represents a distinct cell type or an overstimulated Type A or 
B cell. Goto et al. (1987)
277 established clonal colonies of all three cell types and found that all 
retained distinct morphologies in long-term culture. However, Hendler et al. (1985)
342 observed 
direct transition of dendritic cells to fibroblasts and vice versa. It is interesting to note that in the 
former study, ‘dendritic cell’ clones maintained higher spontaneous IL-1 production – suggesting 
that autocrine cytokine stimulation may be responsible for their characteristic morphology.
277 
    74. 
The following metabolic changes are characteristic of ‘activated’ or chronically cytokine-stimulated 
synoviocytes: 
 
i)      strong expression of oncogene products such as c-fos and c-jun.
420,693 
ii)  reduced growth rate and shortened life span.
654,767 However, Myers and Brandt (1987)
567 noted 
that synovial cultures from arthritic dogs (8-12wks post ACLT) proliferated more rapidly than 
control specimens. It has been shown that IL-1 is mitogenic to synovial fibroblasts, but only 
when induction of PGE2 is blocked (e.g. by indomethacin).
172,304 
iii)  increased synthesis of glycosaminoglycan, particularly hyaluronic acid.
504 MCM,
117,168,654 
purified IL-1,
375,410,921,922 TNF-,
922 PGE2,
763 and bacterial lipopolysaccharide
99 all increase 
synovial glycosaminoglycan synthesis, possibly via an increase in the key enzyme hyaluronic 
acid synthetase.
654 However, HA produced by inflamed synoviocytes is of abnormally low 
molecular weight and reduced viscosity.
116,654 Expression of CD44 (the principal receptor for 
HA) is reduced in rheumatoid synovia.
341 
iv)  decreased synthesis of type I, III, and VI collagen.
62,168,683 This response marks another 
distinction between synoviocytes and tissue fibroblasts, in which these cytokines would 
normally stimulate fibrosis. 
v)      increased synthesis of other connective tissue proteins such as fibronectin 
453 
vi)     increased synthesis of prostaglandins, predominantly PGE2.
172,276 
vii)  increased synthesis of matrix metalloproteases.
138 Synovial fibroblast production of MMPs 
(92kD gelatinase, collagenase, stromelysin) wanes with time and passage in culture,
415,825,847 
but remains very sensitive to re-induction by IL-1 and TNF-.
173,174,176,480,595,847 In dermal 
fibroblasts, collagenase production has been shown to be reliant on mechanical stress within 
the supporting collagen framework, partially explaining the low resting expression in cells 
cultured on rigid substrates, and its induction by trypsinization.
447 
viii) increased spontaneous autocrine IL-1 production.
276 IL-1 receptors are also up-regulated in 
OA synoviocytes but this difference does not persist in culture.
709    75. 
ix)  dramatically increased IL-6 production.
296 Studies of clonal rheumatoid synovial fibroblast 
populations have shown that some clones are high IL-6 producers while others low producers, 
with production independent of the presence of other cell types or autocrine IL-1ß / TNF- 
stimulation.
64 However, another study showed no difference in IL-6 production between 
clones of fibroblastic, dendritic, or macrophage-like synoviocytes.
547  
x)  increased nitric oxide production.
532 However Stefanovic-Racic et al. (1994)
795 showed 
obvious differences between individual rabbit synovial fibroblast cultures with respect to NO 
production , with up to 10% showing no detectable production. 
 
1.1.7    PHARMACEUTICAL MANAGEMENT OF OSTEOARTHRITIS 
 
1.1.7.1    Non-steroidal anti-inflammatory drugs (NSAIDs) 
 
Non-steroidal anti-inflammatory drugs remain the mainstay for the pharmacological management of 
osteoarthritis symptoms. This is despite evidence that many common NSAIDs do not reduce joint 
degeneration in OA, and may even hasten it.
259 NSAIDs have traditionally been considered 
analgesic and anti-inflammatory drugs, without involvement in the predominantly cytokine-driven 
pathways of cartilage degradation in OA. Given recent revelations that COX-2 is superinduced in 
cartilage,
22 and that prostaglandins do indeed interact directly with cytokine actions and matrix 
metabolism,
24 NSAID usage is being re-examined in a new critical light. It is increasingly being 
recognised that despite their functional grouping, there is considerable variation in the mode of 
action of different NSAIDs. While long thought to act peripherally in inflamed tissues, there is also 
evidence that some of their analgesic action may be mediated centrally.
181  
 
The recent discovery of the inducible COX-2 isoform of cyclooxygenase has been of particular 
importance to NSAID pharmacology. The two COX isoforms share only 60% homology, though 
much of the difference in at the carboxy and amino termini, while the central portion is highly    76. 
conserved.
861 Thus the proteins are structurally very similar, though key amino acid differences 
allow selective pharmaceutical targeting of the induced isoform. This discovery lead to 
development and promotion of a new generation of NSAIDs which are reported to more selectively 
inhibit COX-2, and subsequently possess reduced gastrointestinal toxicity.
861 The COX selectivity 
of various NSAIDs has been investigated in dogs; meloxicam was found to have a COX-2:COX-1 
ratio of approximately 12:1, while for carpofen the ratio was approximately 1.75:1.
413 However, 
recent evidence also suggests an important role for COX-2 in the kidney, where it may be involved 
in renin release in salt-depleted and volume-depleted states.
575 Hence evidence is emerging that 
COX-2 selective inhibitors are not entirely free of renal toxicity in human or veterinary clinical 
practice.
91,489,690 
 
As their main mode of action is thought to be the inhibition of cyclooxygenase, the action of 
NSAIDs in the OA joint is dependent on the net role of prostaglandins, especially PGE2, in joint 
tissues. Past evidence suggests that PGE2 is largely supportive of cartilage matrix synthesis, and 
opposes some of the actions of IL-1ß in synovial tissue. This has lead to the proposal that NSAIDs 
may accelerate the progression of osteoarthritis. Certainly this is the case with many of the previous 
generation of NSAIDs. Indomethacin, aspirin, naproxen, and phenylbutazone have all been shown 
to suppress proteoglycan biosynthesis in cartilage, in a variety of species.
198,259,343,661 
Phenylbutazone is especially interesting in this regard as it is not a COX-inhibitor but specifically 
inhibits formation of PGE2. Similarly, indomethacin and ketoprofen have been shown to suppress 
chondrocyte collagen synthesis.
274 Moreover, aspirin and indomethacin have been shown to 
accelerate cartilage degeneration in animal models.
610,641 However, newer NSAIDs have been 
shown not to have deleterious effects on matrix synthesis. Rather, aceclofenac and tenidap actually 
increase glycosaminoglycan synthesis in human cartilage.
81,198 Carprofen also increases synthesis 
and reduces release of proteoglycan from equine and canine cartilage,
37,734 though inhibition of 
synthesis was seen at higher doses in the canine study. Numerous studies have shown meloxicam to 
have no detrimental effect on proteoglycan synthesis in human, porcine, or canine cartilage,
81,662,663    77. 
and no effect on DNA or type II collagen synthesis by human chondrocytes.
61 Similarly, piroxicam 
has no demonstrated effect on cartilage synthetic activity.
198,661 The effect of etodolac on 
glycosaminoglycan synthesis is less clear; while it has been shown to decrease synthesis in rabbit 
chondrocytes,
674 it had no effect on human chondrocytes in a three-dimensional culture system.
343 
These newer NSAIDs have also been attributed chondroprotective properties unrelated to their 
effects on proteoglycan synthesis. For example, etodolac prevents IL-1ß-induced suppression of 
chondrocyte collagen synthesis.
274,519 The chondroprotective label has also been applied to 
piroxicam
228,347,348 and tiaprofenic acid.
259,262,626  
 
The specific influence of NSAIDs on MMP activity requires further clarification. Sadowski and 
Steinmeyer (2001)
710 recently showed that a range of NSAIDs inhibited IL-1ß-induced collagenase 
activity in bovine articular chondrocyte cultures, while indomethacin and meloxicam additionally 
inhibited proteoglycan degradation. However, clear differences in their modes of action suggested 
that these effects were independent of cyclooxygenase inhibition. Arner et al. (1998)
43 found a 
range of NSAIDs to have no effect on aggrecanase activity in cartilage explant cultures. 
 
While the cartilage effects of COX inhibitors are well studied, their effects on synovial metabolism 
are surprisingly poorly known. Meloxicam was found to have no effect on IL-1ß release, but 
increased IL-6 production by human synovial explants.
663 In other studies, tenidap was shown to 
reduce synovial expression of IL-1 receptors and collagenase,
513 while nimesulide and naproxen 
reduce urokinase and IL-6 synthesis, and increase PAI-1 production in human OA synovial 
fibroblasts.
636 Meloxicam was found to attenuate the acute inflammatory synovial fluid changes 
provoked by intra-articular injection of contrast agent in dogs.
853 However in a separate but similar 
study, meloxicam prevented the pain but not the synovial fluid responses induced by intra-articular 
injection of calcium pyrophosphate crystals.
662 Etodolac reduces the arthritic changes associated 
with adjuvant arthritis
514 and type-II collagen-induced arthritis
373 in mice. These observations are    78. 
interesting in the light of revelations that homozygous COX-2-deficient mice display essentially 
normal inflammatory responses to antigen-induced arthritis.
371 
 
As the in vivo effects of the modern generation of NSAIDs do not fit those predicted from the 
known, mainly protective effects of PGE2 in joint tissues, COX-2 selectivity alone cannot explain 
the improved safety profile of these agents in cartilage. Evidence of a chondroneutral or even 
chondroprotective status for these drugs increasingly refutes the existence of a functional inhibitory 
feedback loop between PGE2 and IL-1ß. The observation that the stimulatory effect of aceclofenac 
on cartilage proteoglycan synthesis is dependant on the presence of serum, and that serum can be 
replaced in this role by IGF-1 alone,
198 seems to specifically contradict the positive interactions of 
PGE2 and the IGF-1 axis proposed by Pelletier and co-workers.
186,187,190 It seems increasingly likely 
that the interaction between PGE2 and NO is important in the actions of modern NSAIDs, and 
PGE2-mediated augmentation of chondrocyte NO production as observed by Onga et al. (2000)
599 
provides a possible link between prostaglandin production and cartilage degradation. Such 
discussion is seriously hampered by our incomplete understanding of the mode(s) of action of 
modern NSAIDs such as carprofen and meloxicam. L-NAME has been shown to block the anti-
nociceptive effects of meloxicam, nimesulide, ketorolac, and dipyrone in pain models in rats, 
suggesting involvement of a NO-cyclic GMP-mediated pathway in peripheral pain 
transmission.
6,283,374 Similarly, NO-releasing NSAIDs are being developed by the addition of 
nitroxybutyl moieties to existing NSAIDs such as aspirin, with the aim of reduced gastrointestinal 
toxicity.
818 These have also been found to possess increased anti-inflammatory activities.
137,230,883  
 
Given the strong evidence of a role for PGE2 in bone metabolism, COX inhibitors may also actively 
modify bony tissues. To date, studies suggest this effect is certainly possible but inconsistent. 
Meloxicam prevents alveolar bone loss in experimental periodontitis,
75 yet phenylbutazone 
decreases the rate of mineral apposition and healing of cortical defects in horses.
692 Pelletier et al. 
(1999)
633 found that carprofen, while preventing cartilage erosion following canine ACLT, also    79. 
reduced subchondral bone loss and normalised subchondral osteoblast metabolism. On this basis, 
the authors proposed that the protective actions of the drug might partly relate to its stabilising 
effect on subchondral bone. However, reduced bone loss might alternatively be explained by 
increased weight-bearing in this unilateral model, and bone morphology was not examined at other 
sites in this study. 
 
1.1.7.2   Corticosteroids 
 
Corticosteroids inhibit phospholipase A2, thereby reducing production of both cyclooxygenase and 
lipoxygenase end-products. As well as their potent anti-inflammatory action, corticosteroids are 
capable of decreasing cartilage degradation, and importantly are potent inhibitors of MMP 
activity.
710 However, they also suppress chondrocyte proteoglycan and collagen synthesis, by a 
mechanism that is poorly understood.
255 In synovial fibroblasts, hydrocortisone similarly reduces 
anabolic activity, particularly hyaluronic acid synthesis,
365,566,706-708,922 but also suppresses release of 
catabolic mediators such as plasminogen activator.
303 In vivo, both beneficial and deleterious effects 
have been demonstrated, a discrepancy possibly related to differences in dosage.
497,555,623 Current 
evidence suggests that occasional use of corticosteroids to manage acute episodes of joint pain may 
be beneficial, but prolonged use and high doses should be avoided.
389  
 
1.1.7.3   Sulphated  Heparinoids 
 
Pentosan Polysulphate 
Pentosan polysulphate (PPS) is produced by sulphation of xylanopyranose chains isolated from 
beech tree hemicellulose. The chondroprotective properties of PPS have been extensively reviewed 
by Ghosh (1999).
257 PPS has been shown both in vitro and in vivo to promote chondrocyte anabolic 
activity, and to limit cartilage catabolic events, particularly by inhibiting MMP activity. Its mode of 
action is not fully known, though many of its actions are mediated at the level of gene expression.    80. 
PPS increases synovial fibroblast hyaluronan synthesis, and increases the mean size of hyaluronan 
molecules synthesized,
365 thereby improving the viscoelastic and lubricating properties of synovial 
fluid. It has also been shown to up-regulate synovial release of TIMP-3,
819 and modulate release of 
nitric oxide and cytokines (IL-6) in rabbit synovial fibroblasts.
772,774 Due to anti-thrombotic and 
fibrinolytic activity presumably related to its heparinoid structure, PPS may improve capillary 
microcirculation in inflamed synovium and subchondral bone.
239,863 Numerous trials of PPS in 
rabbit, canine, and ovine models of OA have demonstrated a chondroprotective and anti-
inflammatory effect.
18,239,257,670,772,774  
 
Polysulphated-glycosaminoglycan 
Polysulphated glycosaminoglycan (PS-GAG), like PPS, contains highly sulphated 
glycosaminoglycan repeats (mainly chondroitin sulphate) but is sourced from animal rather than 
plant sources. It has been shown to have similar anabolic and anti-catabolic effects to PPS,
151 
though experimentally its effects in cartilage are somewhat inconsistent.
101 It has been shown to be 
protective in various arthritis models including rabbit immobilization,
271 intra-articular injection of 
iodoacetate in horses,
929,930 and canine meniscectomy
313 and ACLT models.
19 As with PPS, PS-
GAG increases both the rate of synthesis and molecular weight of hyaluronan produced by synovial 
fibroblasts.
238,584 It has been shown to increase the level and polymerisation state of synovial fluid 
HA after intra-articular injection in humans.
866 
 
1.1.7.4   Hyaluronan  Preparations 
 
Various purified preparations of hyaluronic acid (HA) are available for intra-articular use. Its mode 
of action is poorly understood; though its immediate effect is viscosupplementation of HA-depleted 
joint fluid, it is rapidly cleared from the joint cavity hence any lasting effects cannot be due to a 
simple replacement function. Its primary action may via an anti-inflammatory and anti-catabolic 
effect on synovial fibroblasts. Smith and Ghosh (1987)
770 showed that synovial fibroblast HA    81. 
synthesis is markedly influenced by the nature (especially molecular weight) of HA in the 
extracellular environment. HA has been shown to reduce the release of catabolic mediators such as 
IL-1ß by synovial fibroblasts in vitro.
816 Animal models suggest HA is most protective where 
cartilage degradation is linked to synovial inflammation, and is less effective where overloading is 
the primary cause.
256,259 Some studies have found that the protective effect of HA is influenced by 
the molecular weight of the preparation.
39 However, others have found this is not important.
751 
 
1.1.7.5   Oral  Supplements 
 
The majority of oral nutritional supplements or "nutraceuticals" promoted for the treatment of 
osteoarthritis contain glucosamine or chondroitin sulphate, either as a crude extract or in some 
purified form. Traditional extracts such as shark cartilage
235 and green-lipped mussel extract
863 
contain similar active ingredients. The widespread use of such compounds has been based on the 
premise that nutritional supply of glycosaminoglycan precursors in supraphysiological quantities 
will promote cartilage repair processes. Glucosamine has been shown to increase proteoglycan 
synthesis in IL-1ß-stimulated rat chondrocytes.
278 It has also been shown to suppress in vitro release 
of phospholipase A2, PGE2, collagenase, stromelysin, and NO by chondrocytes.
278,643 Other authors 
have suggested that the primary action of glucosamine may be via promotion of synovial HA 
production, thus providing a mechanism for the rapid clinical improvement often observed.
527 
Though evidence for in vivo efficacy has been largely anecdotal, increasing evidence of a beneficial 
effect is emerging from controlled clinical trials.
357,829  
 
Ginger extracts
787 and essential fatty acid supplements
544 are other oral preparations reported to be 
beneficial in osteoarthritis. One problem with evaluating such compounds is the magnitude of the 
placebo effect in human patients. For example, even patient interaction as slight as monthly 
telephone calls have been shown to have a significant effect on functional indices of OA.
679 
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1.1.7.6   Potential  Future  Therapies 
 
Anti-cytokine Therapies 
 
Increased understanding of the importance of cytokines in OA has lead to the development of 
therapies that target their induction or activity. Inhibitors of TNF--converting enzyme (TACE) and 
IL-1ß-converting enzyme (ICE) are promising agents currently in development.
621 Diacerein (4,5-
diacetoxy-9,10-anthroquinone-2-carboxylic acid) and its metabolite rhein also show promise as 
anti-IL-1 therapies. In both OA cartilage and synovium in vitro, diacerein reduces IL-1 synthesis, 
IL-1 receptor levels, ICE activity, and MMP expression.
511,622 Diacerein may also modify 
subchondral bone responses in OA.
368,622 Diacerein has been shown to effectively reduce OA 
symptoms in human
638 and ovine
368 trials; however, gastrointestinal side-effects were observed 
which may limit its usefulness. More specific molecular targeting of cytokines may be possible in 
the near future. Gene transfer of IL-1Ra was successful in suppressing both joint inflammation and 
cartilage erosion in an animal model.
492 However, approaches targeting TNF-R55 have proved 
disappointing.
557 
 
MMP Inhibitors 
 
Agents inhibiting MMP activity have been the focus of intensive research over the last decade. 
Given the predominant role of MMPs in cartilage degradation, it is likely that such agents would be 
of significant benefit in OA. However, the low cartilage permeability of MMP inhibitors so far 
developed has limited their efficacy.
639,871 Tetracycline and its synthetic derivatives possess potent 
MMP inhibitory activity independent of their antimicrobial activities.
23,871 Doxycycline inhibits 
activity and synthesis of MMP-1, -8, and -13 in cell culture,
311,754,755 and has been shown to reduce 
the progression of OA in the canine ACLT model.
931 However, no disease-modifying effect was 
found in a clinical trial of doxycycline in RA patients.
790    83. 
 
Nitric Oxide Synthase Inhibitors (NOSI) 
 
As both physiological and pathological roles have been identified for NO, the in vivo effects of 
NOS inhibitors (NOSI) on the degradative and inflammatory changes of arthritis are difficult to 
predict.
381 To date, experimental studies in animal models of arthritis have consistently shown 
NOSI to confer a beneficial effect. NOSI suppress the progression of arthritis, particularly synovial 
inflammation, in acute inflammatory models such as rat adjuvant arthritis,
792 streptococcal cell wall 
arthritis,
525 and rabbit antigen-induced arthritis.
608 As NO is a principal effector of immune-
mediated vascular injury and modulator of leucocyte function,
215 these findings are to be expected. 
However in the zymosan-induced arthritis model, cartilage from iNOS knockout mice showed 
reduced pathology, markedly less inhibition of proteoglycan synthesis, and normal IGF-1 
responsiveness, while joint inflammation was similar to that of wild-type mice.
854,856 NOSI were 
also effective in restoring proteoglycan synthesis after intra-articular administration of IL-1ß in 
rats.
649 This suggests that NOSI might possess chondroprotective capabilities separate from any 
anti-inflammatory effects.  
 
Convincing evidence that NOSI might possess disease-modifying properties in the less 
inflammatory, more slowly progressive disorder of osteoarthritis is still lacking, though suppression 
of NO production has been implicated in the chondroprotective effect of many existing OA 
therapies, such as tetracyclines.
23,53,235 Using the canine ACLT model, Pelletier and coworkers have 
shown that the selective iNOS inhibitor L-N-iminoethyl-L-lysine (L-NIL) reduces development of 
cartilage and synovial pathology, synovial fluid IL-1ß, and chondrocyte immunostaining for iNOS, 
nitrotyrosine, MMP-1 and -3, and caspase 3, a marker of apoptosis. No evidence of toxic effects 
was recorded.
630,631,633,634 However, these studies were short (10-12 weeks of treatment), and grading 
of joint pathology was somewhat subjective. In addition, ACLT was performed by a blind stab 
incision, a technique criticised for creating significant intra-articular haemorrhage and subsequent    84. 
synovial inflammation.
569 Nevertheless, this data is encouraging and further trials of NOSI in other 
OA models should ensue. Issues of potential toxicity (in processes as varied as cardiovascular 
regulation, wound repair, and immune response) need to be better addressed before clinical trials 
are attempted.
359 Such toxic effects will be lessened, but not completely eliminated, by using 
selective inhibitors of iNOS. Other interactions might be predicted from known actions of nitric 
oxide. For example, NOS inhibition may reduce PGE2 production within the OA joint. Preliminary 
evidence from the canine ACLT model suggests this is indeed the case, as L-NIL treatment reduced 
canine synovial fluid PGE2 content and cartilage COX-2 expression.
630 However, NOSI may 
accentuate local bone resorptive processes in arthritis, as well as potentially influencing peripheral 
bone density.
199,405,906 
 
 
1.2      STUDY BACKGROUND 
 
Osteoporosis is the most common metabolic bone disease in the developed world, and represents a 
substantial and escalating burden to healthcare services.
615 The disorder is characterised by reduced 
bone mineral density, associated with bone fragility and an increased risk of fractures. Whilst 
hormone replacement therapy of oestrogen supplementation is an effective treatment, compliance is 
often poor due to concern over potential hormonal side-effects such as withdrawal bleeding, weight 
gain, breast tenderness, and increased risk of uterine and breast cancer.
204,615,720 Despite the potential 
of newer therapies such as bisphosphonates and selective oestrogen receptor modulators 
(SERMs),
466,720 an acceptable but inexpensive therapy for osteoporosis (one which restores bone 
density and trabecular connectivity with minimal side-effects) remains a major goal in 
pharmacological research.
615 
 
As recent research has suggested that the skeletal and cardiovascular protective effects of oestrogen 
are largely mediated by nitric oxide, nitric oxide donors might therefore be novel and effective    85. 
therapies for osteoporosis, eliminating the concomitant side-effects associated with the use of 
oestrogen replacement therapy. Wimalawansa and co-workers have demonstrated that glyceryl 
trinitrate prevents both ovariectomy- and corticosteroid-induced bone loss in rats,
904,906 and have 
begun trials in human patients.
902 Early results of clinical trials have shown a significant protective 
effect against bone loss following surgical menopause, equivalent to that of oestrogen 
supplementation.
902 Similarly, intermittent use of nitrates by elderly women has been 
epidemiologically associated with increased bone mineral density in the hip and heel.
380 
 
However, NO is suspected to be a key mediator involved in the inflammatory and catabolic changes 
in cartilage in arthritic disorders such as RA and OA.
381,789 NO production is elevated within OA 
joints,
25,49,538,609,637,676,791 and NO has been shown to have multiple effects on joint tissues in vitro, 
including reduction in articular cartilage proteoglycan synthesis,
349,393,801,822 increased MMP 
synthesis,
561 and extensive interactions with other inflammatory mediators.
346,532,637 Experiments 
using iNOS inhibitors in two rodent models of inflammatory arthritis
525,792 and a canine OA 
model
619 have shown that such compounds reduce the progression of arthritic changes. However, 
knowledge of the net effects of NO-donors on cartilage metabolism in vivo is presently unknown 
and requires urgent clarification given not only their proposed therapeutic use in preventing 
osteoporosis, but also their current routine use in the treatment of angina and other cardiac disorders 
in elderly patients, who may also be osteoarthritic. 
 
The in vivo effects of NO-donors also need to be considered in relation to subchondral bone, given 
the hypothesis by some authors that subchondral changes may be central to the early pathogenesis 
of OA.
184,618,659 It might be proposed that NO may influence the progression of arthritis by 
promoting subchondral bone sclerosis, increasing subchondral bone stiffness and the resultant 
stresses transmitted to chondrocytes. Furthermore, by promoting angiogenesis,
937 NO may play a 
role in the neovascularization of the calcified cartilage zone that accompanies subchondral 
remodelling as a histological hallmark of OA.
346,791    86. 
Any evaluation of the effects of nitric oxide needs to encompass study of its interactions with 
oestrogen status. Oestrogen levels and NO synthesis are closely linked in many 
tissues,
36,406,666,676,884,890 and plasma levels of NO and oestrogen are closely correlated.
703 Oestrogen 
is itself suspected to play an important role in joint tissue homeostasis.
36,666,676,884,890 There is 
abundant but conflicting epidemiological evidence that oestrogen plays a role in OA, most 
consistent of which is the rise in OA incidence at the time of menopause,
577,578,782 and the protective 
effect of oestrogen replacement therapy.
577,719,783,934 Experimental evidence is conflicting: while 
administration of oestrogen has been shown to cause cartilage degeneration in animal 
studies,
699,701,834,837 ovariectomy of ewes induces biomechanical deterioration of articular cartilage 
preventable by oestrogen replacement.
841 
 
The importance of oestrogen in OA may be primarily due to its effects on bone.
226 The role of 
oestrogen in maintaining bone mass is well known. Therefore its relative role in the OA process 
depends on whether subchondral bone attrition or sclerosis is relatively more important in the 
pathogenesis of OA, a factor which is currently unknown. It has been suggested that the protective 
effect of oestrogen replacement therapy in OA is related to a reduction of bone turnover and 
stabilisation of subchondral bone remodelling.
578 Oestrogen withdrawal (or menopause) might 
therefore be expected to worsen concurrent osteoarthritis by increasing subchondral bone loss. 
However, osteoporosis and OA are negatively correlated epidemiologically.
312,779  
 
In order to investigate the subtle structural changes in joint tissues induced by pharmacological 
interventions, a method of objectively quantifying these changes is required. Recent improvements 
in the processing power of personal computers, and the availability of sophisticated image analysis 
software, has lead to the application of computerised image analysis methodologies to structural 
assessments in arthritis.
126,299,384,455,750 However published methods vary widely, and no consensus 
yet exists regarding the best ways to apply this technology. 
    87. 
1.3     AIMS AND HYPOTHESES 
 
The broad aims of this project were to: 
 
i)  to develop and apply novel and published computerised image analysis methods for 
histomorphometric analysis of structural changes in cartilage and subchondral bone in the 
ovine meniscectomy model of osteoarthritis. 
ii)  to further develop understanding of the OA process in this well-established surgical model, 
particularly with respect to the role of synovial membrane and subchondral bone changes 
within the overall pathogenesis. 
iii)  to extend earlier studies
367,611,769 demonstrating significant structural and biochemical 
alterations in joint tissues following ovariectomy in sheep. 
iv)  to assess the influence of prior ovariectomy on the development of cartilage, synovial, and 
subchondral bone lesions following ovine meniscectomy. 
v)  to investigate the effects of an exogenous nitric oxide donor, glyceryl trinitrate, on the 
structural and metabolic integrity of joint tissues in normal, ovariectomised, and 
osteoarthritic (meniscectomised) sheep.   
 
The specific hypotheses to be tested were: 
 
i)  computerised image analysis methodologies would be more sensitive to structural 
alterations in joint tissues in the ovine meniscectomy model of OA, compared to traditional 
semi-quantitative scoring methods. 
ii)  the gross synovitis thought to occur in this OA model
474 would be accompanied by 
demonstrable microscopic pathology, and persistent metabolic alterations in synoviocytes 
in vitro.    88. 
iii)  ovariectomy of aged ewes would induce structural and metabolic alterations in femoro-
tibial articular cartilage, as well as synovial and subchondral bone tissue.  
iv)  prior ovariectomy of ewes would worsen and/or accelerate the progression of joint changes 
following meniscectomy. 
v)  the topical use of an exogenous nitric oxide donor, glyceryl trinitrate (GTN), would reduce 
the loss of bone mineral density following ovariectomy in aged ewes, as has been shown in 
other species.
902,904,906 
vi)  the same dose of GTN which produces the above skeletal effects would adversely affect the 
structural and metabolic integrity of normal articular cartilage, in keeping with the known 
degradative effects of NO on chondrocytes.
78,140,322,802,803,822 
vii)  given the net effect of NO varies in physiological and pathological conditions
381,552 and NO 
is a key mediator of oestrogen activity,
36,329,330,406,666,676,884,890,906 that the response of joint 
tissues to GTN treatment would vary between normal animals, ovariectomised animals, and 
animals with surgically-induced OA.  
viii)  given nitric oxide synthase inhibitors reduce the progression of experimental 
arthritis,
525,619,792 that GTN treatment would worsen and/or accelerate the progression of 
joint changes in the ovine meniscectomy model of OA.    89. 
CHAPTER 2: 
 
DEVELOPMENT OF NOVEL METHODS OF HISTOLOGIC 
ASSESSMENT OF CARTILAGE AND SYNOVIUM, IN A TRIAL OF 
ORAL AVOCADO-SOYA UNSAPONIFIABLES 
 
2.1   INTRODUCTION 
 
Traditionally, histological analysis of cartilage pathology has been qualitative. Whilst histological 
grading systems have been used, such as that developed by Mankin,
498 these are at best semi-
quantitative, subjective, and prone to inter-user variability. Recent applications of image analysis 
systems to quantitative analysis of cartilage changes in arthritis demonstrate the potential and 
acceptance of this technology.
126,299,384,750,927 Shimizu et al. (1997)
750 demonstrated that 
determination of cartilage area and safranin-O staining intensity by computerised image analysis 
allowed reliable and precise evaluation of cartilage deterioration in a rabbit model of osteoarthritis.
 
 
In the past, management of OA has primarily focussed on the relief of symptoms, using agents such 
as analgesics and NSAIDs. Such an approach has been criticised for failing to prevent continued 
articular cartilage degeneration, and in the case of certain NSAIDs, exacerbating the process by 
inhibiting proteoglycan synthesis.
197 Identifying agents which are capable of preventing, slowing, or 
reversing the structural and pathological alterations which occur in OA joints is an important 
research objective. Such agents, termed disease-modifying osteoarthritis drugs (DMOADs), are 
difficult to evaluate in clinical trials, due to the slow progression of OA in humans and the 
challenge of assessing joint changes by non-invasive methods.
259,463 The use of animal models    90. 
permits the timing of onset to be known, producing a homogeneous, reliable model of the OA 
process for the evaluation of disease-modifying therapies.
258,260 
 
Avocado-soya unsaponifiables (ASU) is a novel anti-arthritic agent derived from unsaponifiable 
residues of avocado and soya oils, mixed in the ratio of 1:2 respectively. ASU have been shown in 
various  in vitro systems to partially reverse the effects of IL-1ß on cultured chondrocytes, 
stimulating collagen synthesis and inhibiting the production of matrix metalloproteases, IL-6, IL-8 
and PGE2.
317,345,517,518 A similar effect has also been demonstrated in rheumatoid synoviocytes.
517,518 
Boumediene et al. (1999)
86 recently reported that ASU enhanced the expression of transforming 
growth factor-ß (TGF-ß) in cultured articular chondrocytes, providing the first clues as to its 
possible mode of action. The active ingredients of the plant extract are unknown, but synergism 
between the avocado and soya components, and their relative ratios, appears to be important.
345,491 
The only published animal study found oral ASU significantly prevented the occurrence of cartilage 
lesions in a rabbit post-contusive model.
522 While its symptomatic efficacy was recently 
demonstrated in double blind, placebo-controlled prospective clinical trials in patients with 
osteoarthritis,
82,491 including evidence of reduced joint space narrowing,
464 its ability to also protect 
the articular cartilage of osteoarthritic joints in vivo remains to be established.  
 
Many clinical studies have used qualitative or semi-quantitative scoring systems to grade 
synovitis.
434,468,471,569,613,697 While these studies have mostly examined rheumatoid synovia, several 
have examined the synovial changes accompanying OA.
470,568,682,768 Smith et al. (1997)
768 found that 
in patients with early OA, a significant increase in synovial thickness, vascularity, inflammatory 
cell infiltration, and cytokine production was consistently detected even in early stages of the 
disease. While synovitis is known to occur in the ovine meniscectomy model of OA,
474 
histopathological changes have not been systematically examined. 
    91. 
The purpose of this trial was to: (1) examine the effect of ASU on the histological progression of 
joint changes in the ovine lateral meniscectomy model of OA; (2) compare traditional qualitative 
methods of assessing cartilage histological changes, with a novel computerised histomorphometric 
method; and (3) assess the level of microscopic synovitis developed in this model, using a 
qualitative scoring system.  
 
2.2   MATERIALS  AND  METHODS 
 
2.2.1   TRIAL  PROTOCOL 
 
2.2.1.1   Source  of  Animals 
 
All animal procedures were approved by the Murdoch University Animal Ethics Committee. Forty-
eight mature (three year old) Merino wethers were obtained from a single source. Animals were 
selected for uniformity of size, conformation, soundness of health, and for absence of lameness. On 
introduction to the Murdoch University farm, the sheep were ear-tagged and vaccinated against 
clostridial diseases and Corynebacterium pseudotuberculosis [Glanvac 6, CSL, Australia]. All 
sheep were treated prophylactically for endo- and ectoparasites [Ivomec Liquid for Sheep 
(ivermectin), MSD Agvet, Australia; Vanquish, (alphamethrin 50 g/L), SmithKline Beecham, 
Australia] and to prevent footrot [Footrite (zinc sulphate 224 g/L), Hardman, Australia].  
 
2.2.1.2   Meniscectomy 
 
Animals were assigned randomly to one of six treatments groups. In four of the groups of 8 sheep 
(n=32), bilateral lateral meniscectomy was performed. Surgery on both left and right joints was 
performed within a single anaesthetic procedure. The day before surgery, three 50g/hr fentanyl 
patches [Durogesic, Janssen-Cilag, Belgium] were applied to a clipped area of skin in the mid-   92. 
thoracic area, and held in place with a canvas band. These patches remained in place for 3 days and 
have been shown to provide effective analgesia in sheep.
203 After deprivation of food and water 
overnight, the sheep were anaesthetised with intravenous thiopentone sodium (50mg/ml) [Thiobarb, 
Pitman-Moore, Australia]. Anaesthesia was maintained with inhaled halothane [Rhône Mérieux, 
Australia] using a Fluotec 3 vaporiser [Cyprane Keighley, UK] and a circle anaesthetic circuit. Both 
hindlimbs were clipped and aseptically prepared, and 1g of cephazolin sodium [David Bull 
Laboratories, Australia] was injected intravenously immediately prior to surgery. A 10cm 
parapatellar incision was made on the lateral aspect of the femoro-tibial joint, and dissection 
continued through incision of the fascia lata, crural retinaculum, and joint capsule to expose the 
lateral meniscus. Bleeding was controlled throughout surgery using electrocoagulation. All 
peripheral capsular attachments of the meniscus were stripped using a meniscotome, before 
severing the cranial tibio-meniscal ligaments using a number 15 scalpel blade. The cranial pole of 
the meniscus was grasped and pushed caudally under the collateral ligament and popliteus tendon. 
With caudal retraction of the skin and fascia lata, a second fascial incision was made caudal to the 
collateral ligament to expose the translocated cranial pole of the meniscus. This was grasped with a 
Backhaus towel clip and retracted caudolaterally. With tension applied to the meniscus, a 
meniscotome was used to locate and sever the femoro-meniscal ligament and any remaining caudal 
tibial attachments, allowing removal of the meniscus. The joint was then lavaged with sterile saline 
before closure of the the retinacular and fascial incisions using 3 metric polydioxanone sutures 
[PDS II, Ethicon, USA] in a continuous pattern. Subcuticular tissues were apposed in two layers 
using 3 metric poliglecaprone 25 sutures [Monocryl, Ethicon, USA], and the skin closed using 2 
metric braided polyglactin 910 [Vicryl, Ethicon, USA] in a buried intradermal pattern. Following 
surgery, all animals received 100mg of flunixin meglumine by intramuscular injection [Ilium 
Flunixin, Ilium, Australia]. The sheep were maintained under close observation for 3-5 days in pens 
within a covered barn area, before return to pasture. Complications were infrequent, and were 
mostly limited to transient lameness or seroma formation at the surgical site.  
    93. 
2.2.1.3   Trial  Protocol 
 
Following a brief recovery period, sheep were maintained on irrigated pasture and supplemented 
with lupin grain daily. From approximately one month postoperatively, meniscectomised groups 
were given orally administered capsules of ASU  (900mg/weekday) [Piascledine 300
®] or placebo 
(paraffin oil) both provided by Pharmascience [Laboratoires Pharmascience, Courbevoie, France]. 
Dosing was not performed at weekends. This dose, higher than the usual daily human dose, was 
used to compensate for the weekday-only administration protocol and the possibility of partial 
degradation of the compound in the rumen. Body weights were recorded at approximately monthly 
intervals. Treatment groups were therefore: meniscectomy plus ASU (MX+ASU), meniscectomy 
plus placebo (MX), or non-operated control (NOC). Eight sheep of each treatment type were 
euthanased at approximately three months and six months postoperatively (except the six-month 
MX group, which contained only seven animals, due to the death of one animal from neurological 
symptoms of unknown origin). 
 
2.2.1.4   Sacrifice  and  Tissue  Processing 
 
At sacrifice, the sheep were killed by intravenous injection of 20ml of pentobarbitone sodium (300 
mg/ml) [Valabarb, Pitman-Moore, Australia]. Joints were immediately dissected and the soft tissues 
removed. Histological slides were prepared from each of the following regions: medial femoral 
condyle (MFC), lateral femoral condyle (LFC), medial tibial plateau (MTP), lateral tibial plateau 
(LTP), and trochlear groove (TG) (six months post-op only). Osteochondral slices (approximately 
3mm thick) were taken from each region by bandsaw cuts in the medio-lateral plane, perpendicular 
to the articular surface. Cuts were positioned in the femoral condyles at the point of tibial contact in 
normal stance, and in the tibial plateaux at the level of the intercondylar eminences. Bone slices 
were fixed in 10% neutral buffered formalin for 48 hours, then decalcified in 10% formic acid / 5% 
formaldehyde for 7 days. The specimens were then washed, dehydrated in increasing alcohol    94. 
concentrations (70-100%), and double-embedded in methyl benzoate/celloidin and paraffin wax. 
4m sections were cut on a rotary microtome and adhered to treated glass slides [Superfrost Plus, 
Menzel Gläser, USA].  
 
Toluidine blue staining was performed in batches under constant conditions. Sections were 
deparaffinised in 70% alcohol for 15 minutes, stained in 0.04% toluidine blue / 0.1M sodium 
acetate buffer (10 minutes) then 0.1% fast green (2 minutes), dehydrated in isopropanol then 
xylene, and coverslipped.  
 
2.2.2   GROSS  PATHOLOGY 
 
At six months, colour slide photographs were taken of the opened joints. Four joint regions (MFC, 
LFC, MTP and LTP) were later scored for cartilage damage and osteophyte formation, by a single 
blinded operator, according to the following scale:
39 
 
 
Cartilage:     Osteophytes: 
0 = normal        0 = none 
1 = roughened        1 = slight osteophyte development 
2 = fibrillated / fissured     2 = moderate osteophyte development 
3 = small erosion (<5mm)    3 = marked osteophyte development 
4 = large erosion (>5mm) 
 
 
 
 
Gross synovial pathology was noted at the time of joint dissection, according to the following scale: 
 
 
 
Synovium (all regions): 
0 = normal 
1 = slight abnormality (e.g. redness or fibrosis) 
2 = synovitis 
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2.2.3     CARTILAGE HISTOPATHOLOGICAL SCORING  
 
Semi-quantitative histopathological scoring was performed on 4m toluidine blue-stained sections 
according to a published modification
474,926 of Mankin’s grading system.
498 In one section from each 
of the four joint regions, four zones were scored: (1) outer (abaxial) margin; (2) outer perilesional 
zone; (3) lesional zone (or spatially equivalent zone in controls); and (4) inner perilesional zone. 
Scoring was done by a single observer, according to a five point scale (Figure 2.1), and a mean 
aggregate score determined as the average of these four zonal values (maximum possible score = 
26). 
 
2.2.4     HISTOMORPHOMETRIC IMAGE ANALYSIS 
 
Computer-assisted histomorphometric image analysis was conducted in a manner similar to that 
described by Shimizu et al.
 (1997).
750 Sections were mounted in a slide cartridge customised to hold 
glass slides, scanned directly using a slide scanner [Microtek Slidescanner 35t plus (Model PTS-
1950), Microtek Lab Inc., USA] and acquired at 400 dpi  resolution using standard graphics 
software [ScanWizard v3.0.7, Microtek Lab Inc., USA; Adobe Photoshop v3.0, Adobe Systems, 
USA]. Stored image files were analysed using image analysis software [Image Pro Plus v3.0.1, 
Media Cybernetics, USA] on a personal computer [Power Macintosh 7600/200, Apple Computer 
Inc., USA]. Spatial calibration was performed by scanning a 10x10mm high precision graticule, and 
the intensity scale was calibrated to give a positive linear response to increasing optical density 
(white=0, black=255).     96. 
 
Figure 2.1:   The cartilage histopathological scoring system used in this study (after Little et al. 
(1997)
474) 
 
 
I   Structure    
0 normal 
1 slight  surface irregularities 
2  moderate surface irregularities 
3 severe  surface  irregularities 
4  clefts / fissures into transitional zone (1/3
rd depth) 
5  clefts / fissures into radial zone (2/3
rds depth) 
6  clefts / fissures into calcified zone (full depth) 
7  fibrillation and/or erosion to transitional zone (1/3
rd depth) 
8  fibrillation and/or erosion to radial zone (2/3
rds depth) 
9  fibrillation and/or erosion to calcified zone (full depth) 
10  fibrillation and/or erosion to subchondral bone 
 
II Cellularity    
0 normal 
1  increase or slight decrease 
2 moderate  decrease 
3 severe  decrease 
4  no cells present 
 
III Chondrocyte  Cloning 
0 normal 
1 several  doublets 
2 many  doublets 
3  doublets and triplets 
4 multiple  cell  nests 
 
IV  Territorial Toluidine Blue Staining 
0 normal 
1  increase or slight decrease 
2 moderate  decrease 
3 severe  decrease 
4 no  staining 
 
V  Interterritorial Toluidine Blue Staining 
0 normal 
1  loss of staining to tangential zone (1/3
rd depth) 
2  loss of staining to transitional zone (2/3
rds depth) 
3  loss of staining to radial zone (full depth) 
4 no  staining 
 
Maximum aggregate score = 26    97. 
Using the image analysis software, markers were applied such that the cartilage length was divided 
into three zones each comprising approximately 1/3
rd of the total arc length, termed the inner, 
middle, and outer zones (Figure 2.2). The middle zone included the usual point of erosion in the 
lateral compartment of meniscectomised animals. In each of the three zones, the intensity of 
toluidine blue staining, an index of proteoglycan content,
253 was determined as the mean pixel 
optical density after conversion from colour to greyscale (Figure 2.4). Uncalcified cartilage and 
subchondral bone plate thickness (mm) were determined from Masson’s Trichrome-stained sections 
with similarly defined zones, using a radial thickness algorithm within the software to generate 
mean  thickness  measurements between lines delimiting the cartilage surface, most advanced 
tidemark, and limit of cortical subchondral bone (intertrabecular spaces < 500m). Areas of obvious 
osteophyte growth were excluded from analyses. 
 
Figure 2.2:   Schematic representation of the femoro-tibial joint in cross-section, showing division 
of the articular cartilage and subchondral bone plate of each condyle into inner (I), middle (M), and 
outer (O) zones, for the purposes of histomorphometric analysis. LFC, lateral femoral condyle; LTP, 
lateral tibial plateau. 
    98. 
 
Reproducibility of this method was assessed by repeat scanning and analysis of ten sections (data 
not shown), and was found to be high. Mean variation of repeated thickness analyses was ±5%, and 
that of mean staining intensity measurements was ±2%. 
 
2.2.5    SYNOVIAL HISTOPATHOLOGICAL SCORING 
 
Specimens of synovium were obtained from the suprapatellar fold at the time of sacrifice and fixed 
in 10% neutral buffered formalin. Histopathological scoring was performed on 4m haematoxylin 
and eosin-stained sections by a single blinded observer, according to the following scale (modified 
from Smith et al. (1997)
768) (Figure 2.3): 
 
 
Figure 2.3:   The synovial histopathological scoring system used in this study 
 
A:  Intimal hyperplasia  0  normal  (1-2  layers) 
1  mild-moderate, focal thickening  (3-4 layers) 
2  mild-moderate, diffuse thickening  
3  moderate-marked, diffuse thickening (>5 layers) 
 
B:  Lymphocytic / plasmacytic   0  none 
     infiltration     1  mild-moderate,  focal  infiltrate 
2 mild-moderate,  diffuse  infiltrate 
3  moderate-marked, diffuse infiltrate 
 
C:  Subintimal / perivascular fibrosis  0 none 
1   slight fibrosis 
2 moderate  fibrosis 
3   marked fibrosis 
 
D:  Vascularity    0  normal   
1  slight increase in vascular elements 
2  moderate increase in vascular elements  
3  marked increase in vascular elements  
 
    99. 
2.2.6   STATISTICAL  ANALYSIS     
 
Statistical comparisons were generated using specialist software [Statview 5.0, SAS Institute Inc., 
USA], performing one-way analysis of variance (ANOVA) to analyse variance across treatment 
groups, and Fisher’s analysis of least significant difference (Fisher’s PLSD) to compare treatment 
group means, except where indicated. A significance level of p=0.05 was used throughout this 
study. The medial compartment of the joint was found to be significantly affected by lateral 
meniscectomy, preventing the use of the medial compartment as an internal control.  
    100. 
2.3   RESULTS   
 
2.3.1   BODY  WEIGHT 
 
There was no significant difference in body weights between the three groups before the trial 
commenced (Figure 2.7). Animals were in moderately lean body condition. After surgery, mean 
body weights of meniscectomised animals were significantly below those of non-operated control 
animals. Mean body weights of animals receiving placebo capsules were consistently lower than 
those of animals receiving ASU, significantly so at 5-6 months post-operatively.  
 
2.3.2    GROSS PATHOLOGY   
 
Meniscectomised joints showed gross pathological changes comparable with early human OA, with 
articular cartilage erosion in the lateral compartment (milder changes in the medial compartment), 
and moderate-marked osteophyte development (Figure 2.5). In control animals, gross changes were 
restricted to occasional cartilage roughening, and/or slight osteophyte formation, in the medial 
compartment. Joints of animals treated with ASU tended to have lower cartilage scores than non-
treated (Table 2.1) though this difference was not statistically significant. Osteophyte values were 
similarly high in both groups. MX+ASU sheep showed a tendency for a greater degree of gross 
synovitis than MX, which approached statistical significance (p=0.066). 
 
2.3.3    CARTILAGE HISTOPATHOLOGICAL SCORING 
 
Articular cartilage sections from meniscectomised animals showed central areas of fibrillation and 
erosion, with loss of chondrocytes and toluidine blue staining. Adjacent regions showed 
chondrocyte cloning and increased toluidine blue staining intensity (Figure 2.6). Mean 
histopathological scores were higher in meniscectomised animals compared to those of NOC. This    101. 
difference was significant only in the lateral compartment at three months (data not shown), but in 
all regions at six months post-op (Table 2.2). There were no significant differences between 
aggregate scores of ASU-treated animals and those of the placebo group, at three or six months. 
MX+ASU animals showed a tendency for lower scores than MX in the LFC at six months which 
approached statistical significance (p=0.0504).  
 
2.3.4   HISTOMORPHOMETRIC  IMAGE  ANALYSIS 
 
Intensity of Toluidine Blue Staining   
At three months post-op (Figure 2.8), the mean intensity of cartilage toluidine blue staining tended 
to increase in the medial compartment, but decrease in the lateral compartment, primarily due to 
loss of stain in the area of central erosion. At six months post-op (Figure 2.9), loss of toluidine blue 
stain predominated, except in the trochlear groove. MX+ASU animals showed either a greater 
increase or decreased loss of stain relative to MX in all regions, statistically significant in the MTP 
(90±9  vs 78±11, p=0.015), LTP (81±4 vs 67±9, p=0.001), and TG (104±9 vs 93±7, p=0.023; 
NOC=89±6, p=0.011) at six months post-op. 
 
Uncalcified Cartilage Thickness     
Mean uncalcified cartilage thickness tended to increase following meniscectomy. At three months 
post-op (Figure 2.8, left) increased cartilage thickness was prominent in the MFC, and outer zones 
of the LFC and LTP. At six months post-op (Figures 2.10 and 2.11, above), cartilage thicknesses 
tended to be higher in MX+ASU than MX, especially in the middle (lesion) zone. In the middle 
zone of the LFC, MX+ASU cartilage was significantly thicker than MX (p=0.0181) or NOC. In the 
middle zone of the LTP, MX cartilage tended to be thinner than both NOC and MX+ASU 
(p=0.0506) values.  
 
    102. 
Subchondral Bone Plate Thickness 
Subchondral bone plate (SCP) thickness (Figures 2.10 and 2.11, below) tended to increase in the 
lateral compartment following meniscectomy. This increase was greatest in the outer zone, but was 
significant in all zones. In the inner zone of the LTP, significantly lower SCP thickness was found 
in MX+ASU compared with MX animals (p=0.049).  
 
2.2.5    SYNOVIAL HISTOPATHOLOGICAL SCORING 
 
Meniscectomised sheep showed a significant increase in lymphoplasmocytic infiltrate, subintimal 
fibrosis, and subintimal vascularity relative to control sheep (Table 2.3). MX+ASU sheep showed a 
significantly greater degree of fibrosis (p=0.010) and sum of scores (p=0.042) relative to MX 
animals.    103. 
    104. 
 
Figure 2.5:   Gross appearance of the femoral condyles (left) and tibial plateaux (right)
of non-operated control (above) and meniscectomised (below) joints. Note cartilage
erosion and extensive osteophyte formation six months after meniscectomy.  MED,
medial; LAT, lateral.
MED
MED MED
MED LAT
LAT LAT
LAT
Figure 2.6:   Histological  appearance of toluidine blue-stained articular cartilage in the
tibial plateaux of non-operated control  (left) and meniscectomised (right) sheep. Note
surface fibrillation and fissure formation, with regions of  proteoglycan depletion and
chondrocyte death adjacent to regions of attempted hypertrophic repair.   105. 
Figure 2.7:   Body weights (mean ± SE) of non-operated control (NOC), meniscectomised (MX), 
and ASU-treated meniscectomised (MX+ASU) animals, by date (approximately monthly intervals).  
* MX+ASU differs significantly from MX, p<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2.1:  Gross pathology scores (mean ± SD) at six months in control (NOC), meniscectomised 
(MX), and ASU-treated meniscectomised (MX+ASU) animals. 
* differs significantly from NOC (p<0.05)
 ;  a: p=0.066 (MX vs MX+ASU) 
 
Treatment Group  Cartilage 
fibrillation 
(max = 16) 
Osteophyte 
formation 
(max = 12) 
Gross 
Synovitis 
(max = 2) 
NOC  0.56±0.73 0.37±0.62 0.06±0.25 
MX  6.86±2.11* 6.43±1.91* 0.71±0.91* 
MX+ASU  6.19±0.36* 6.37±1.54* 1.19±0.75*
a 
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Table 2.2:  Mean aggregate histopathology scores (mean ± SD) at six months, in the lateral and 
medial femoral condyles (LFC, MFC) and tibial plateaux (LTP, MTP) of control (NOC), 
meniscectomised (MX), and ASU-treated meniscectomised (MX+ASU) animals.  
* differs significantly from NOC (p<0.05), b: p=0.0504 (MX vs MX+ASU); maximum score = 26 
 
Treatment Group  LFC MFC  LTP MTP 
NOC  3.12±1.00 2.53±0.94 4.43±1.81 3.91±1.57 
MX  9.07±0.45 4.32±1.46*  9.04±1.81 5.36±1.48 
MX+ASU  8.03±1.22*
b  4.00±0.94* 9.00±1.37* 5.97±1.77* 
  
 
 
 
 
Table 2.3:     Synovial membrane histopathology scores (six months post-meniscectomy) of control 
(NOC), meniscectomised (MX), and ASU-treated meniscectomised (MX+ASU) animals. 
* differs significantly from NOC (p<0.05), † MX+ASU differs from MX (p<0.05); maximum score = 3; 
maximum sum = 12 
 
Treatment 
Group 
Intimal 
hyperplasia 
Cellular 
infiltrate 
Subintimal 
fibrosis 
Vascularity SUM 
NOC  1.50±0.53 0.50±0.76  0.87±0.64  0.75±0.71  3.62±2.07 
MX  1.00±0.82 1.43±0.53*  1.00±0.58  1.14±1.21  4.57±2.76 
MX+ASU  1.50±0.92 2.00±0.76*  2.12±0.83*†  1.87±0.64  7.50±2.39*† 
    107. 
              
 
 
Figure 2.8:   Uncalcified cartilage thickness (left) and proteoglycan content (right) (mean 
greyscale pixel intensity; white=0, black=255) of toluidine blue-stained 4µm histological 
sections from normal sheep (NOC), meniscectomised sheep (MX), and meniscectomised 
sheep treated with avocado-soya unsaponifiables (MX+ASU), in the inner, middle and 
outer zones of the lateral and medial femoral condyles (LFC, MFC) and lateral and medial 
tibial plateaux (LTP, MTP) three months post-operatively.  
* differs significantly from NOC (p<0.05); error bars represent one standard error.    108. 
          
Figure 2.9:   Cartilage proteoglycan content, measured as mean greyscale pixel intensity 
(white=0, black=255) of toluidine blue-stained 4µm histological sections from normal 
sheep (NOC), meniscectomised sheep (MX), and meniscectomised sheep treated with 
avocado-soya unsaponifiables (MX+ASU), in the inner, middle and outer zones of the 
lateral and medial femoral condyles (LFC, MFC) and lateral and medial tibial plateaux 
(LTP, MTP), and medial, middle, and lateral zones of the trochlear groove (TG) six months 
post-operatively.  
* differs significantly from NOC (p<0.05), † MX+ASU differs significantly from MX 
(p<0.05); error bars represent one standard error.     109. 
 
 
Figure 2.10:   Thickness (mm) of uncalcified cartilage (above) and the subchondral bone 
plate (below) in normal sheep (NOC), meniscectomised sheep (MX), and meniscectomised 
sheep treated with avocado-soya unsaponifiables (MX+ASU), in the inner, middle and 
outer zones of the lateral femoral condyle (LFC) (left) and the medial femoral condyle 
(MFC) (right) six months post-operatively.  
* differs significantly from NOC (p<0.05), † MX+ASU differs significantly from MX 
(p<0.05); error bars represent one standard error. 
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Figure 2.11:   Thickness (mm) of uncalcified cartilage (above) and the subchondral bone 
plate (below) in normal sheep (NOC), meniscectomised sheep (MX), and meniscectomised 
sheep treated with avocado-soya unsaponifiables (MX+ASU), in the inner, middle and 
outer zones of the lateral tibial plateau (LTP) (left) and the medial tibial plateau 
(MTP)(right) six months post-operatively. 
* differs significantly from NOC (p<0.05), † MX+ASU differs significantly from MX 
(p<0.05)   
a  : p=0.0506 (MX vs MX+ASU); error bars represent one standard error.     111. 
2.4   DISCUSSION   
 
  Hypothesis: that computerised image analysis methodologies would be more 
sensitive to structural alterations in joint tissues in the ovine meniscectomy model 
of OA, compared to traditional semi-quantitative scoring methods. 
 
As shown in previous studies using this model, lateral meniscectomy induced thinning, fibrillation, 
and erosion of articular cartilage secondary to altered joint congruity and load distribution in the 
meniscus-deficient lateral compartment.
258,260,264,474 In cartilage adjacent to these lesions, an increase 
in cartilage thickness was evident, due to a combination of over-hydration of disrupted cartilage and 
hypertrophic repair responses. In the early hypertrophic stages of experimental OA, increased 
chondrocyte biosynthetic activity usually precedes the inhibition of synthesis or degradation of 
proteoglycans, resulting in a period of increased proteoglycan concentration in the matrix.
499,554,869 
This early response is generally coupled with damage to the collagen network, particularly in the 
superficial region, allowing over-hydration of aggrecan and volume expansion of articular cartilage. 
The increase in cartilage thickness seen here following meniscectomy may be the result of cartilage 
swelling, marginal osteochondral remodelling, and/or hypertrophic matrix production 
accompanying attempted cartilage repair.
635,869 However, focal cartilage erosion occurred 
simultaneously, partially reversing this increase and giving meniscectomised animals mean 
uncalcified thickness values in eroded zones similar to those of controls. The tendency for greater 
cartilage thickness observed in the middle cartilage zone of ASU-treated animals, statistically 
significant in the LFC (Figure 2.10), is therefore difficult to interpret but may be the result of 
reduced cartilage erosion, and/or increased matrix production, in the presence of a disrupted 
collagen network.  
 
Quantitation of toluidine blue staining provides further evidence of partial preservation of articular 
cartilage integrity by ASU following cartilage insult. Loss of toluidine blue staining was 
significantly reduced by ASU treatment in both tibial plateaux at 6 months post-op (Figure 2.9). In    112. 
the trochlear groove at six months post-op, toluidine blue staining of MX+ASU animals was 
significantly greater than either MX or NOC animals. Again, the tendency for increased (or reduced 
loss of) cartilage proteoglycan content in ASU-treated animals may be the result of decreased 
catabolism and/or increased anabolism. The exaggerated compensatory increase in proteoglycan 
production in areas distant to the insult, such as the trochlear groove, is suggestive of a pro-anabolic 
effect. These findings are consistent with published in vitro studies showing ASU are capable of 
stimulating matrix production and reducing the deleterious effects of IL-1ß on articular chondrocyte 
metabolism.
317,345,517,518 It was recently suggested that many of the actions of ASU may be mediated 
by an increase in expression of TGF-ß,
86 a potent stimulator of chondrocyte matrix production and 
antagonist of the deleterious effects of IL-1.
653,672,673,754,852 The results of this trial appear consistent 
with such a mechanism of action.  
 
Subchondral bone plate changes reflected altered joint mechanics resulting from meniscectomy, in 
that SCP thickness decreased in the outer zone of the medial compartment (reduced load-bearing), 
and increased in the lateral compartment, especially in zones previously protected by the meniscus. 
Significantly reduced subchondral sclerosis in the inner zone of the LTP in ASU-treated animals 
suggests modification of OA-stimulated subchondral events by this drug. However, as SCP 
thickness changes were more pronounced in other zones, in which the drug showed no effect, the 
importance of this effect is unknown. 
 
The use of a synovial histopathological scoring system was found to be useful in demonstrating the 
effects of ASU. While the synovial changes observed were modest, ASU-treated animals were 
found to have a significantly greater degree of synovial fibrosis relative to placebo-treated animals. 
This effect may again be consistent with its reported influence on TGF-ß expression. Experimental 
studies indicate an important role for TGF-ß in promoting the fibrosis, lining cell hyperplasia, and 
inflammatory cell infiltration that accompanies synovitis.
16,446,563,687,877,878 When experimentally 
injected directly into joints, TGF-ß causes fibrosis and increased synovial cellularity, due to    113. 
fibroblast proliferation and monocyte recruitment.
16 TGF-ß is thought to act synergistically with IL-
1 in inducing fibroblast proliferation.
878 While it is immunosuppressive, suppressing T-cell and 
macrophage function,
446,805,806,878 TGF-ß is also markedly chemotactic, stimulating recruitment of 
leucocytes.
16,852,857 Intra-articular administration of anti-TGF-ß antibodies greatly reduces 
inflammatory cell accumulation and tissue pathology in rat streptococcal cell wall-induced 
arthritis.
877 It is therefore conceivable that ASU may accentuate synovial fibrosis, if acting through a 
TGF-ß-related mechanism as proposed by Boumediene et al. (1999).
86 However, synovial 
hyperplasia was found not to be a significant sequelae of meniscectomy in this trial.  
 
Little clinical data was collected in this trial. However, body weight changes provide possible 
clinical evidence for an improvement of animal well-being with ASU treatment. Decreased weight 
gain of meniscectomised animals is likely to be a result of post-surgical stress and subclinical 
lameness (affecting grazing behaviour, therefore lowering food intake). This effect appears to be 
lessened in animals treated with ASU, though a direct effect of the drug on weight gain cannot be 
ruled out from the data. It is also possible that ASU may confer analgesic properties independent of 
any chondroprotective effects.  Patient non-steroidal anti-inflammatory drug usage was evaluated as 
the primary efficacy criteria in one placebo-controlled clinical trial,
82 and was found to be 
significantly reduced by ASU treatment. However, an increase in exercise has been shown to 
exacerbate the cartilage degeneration seen in the similar ovine medial meniscectomy model.
40,265 
Any analgesic effect attributable to ASU in this trial would therefore be expected to have lessened 
the beneficial effects seen on the progression of osteoarthritic lesions. 
 
The results obtained confirmed the advantages of computerised, quantitative methodologies for 
assessment of joint changes in arthritis. Scores obtained by gross visual assessment and a published 
histopathological scoring method
474,926 failed to demonstrate any significant effect of ASU 
treatment. However, results obtained by computerised image analysis revealed subtle but 
statistically significant effects of the drug, in maintaining articular cartilage proteoglycan content    114. 
and thickness, and modifying subchondral sclerosis. Most studies of potential DMOADs in animal 
models have used qualitative or semi-quantitative outcome measures, such as the size of cartilage 
erosions or osteophytes.
632 Such measures are unreliable and difficult to reproduce due to inter-
operator error. There are relatively few published reports applying computerised digital imaging 
techniques to the quantification of cartilage damage. Chang et al. (1997)
126 used video image 
analysis to quantify Indian ink staining of lapine articular surfaces. Hacker et al. (1997)
299 applied 
an image analysis method to measure surface roughness and various dimensional parameters 
associated with repair of osteochondral defects. Intra- and inter-observer precision was assessed and 
was found to be high. Image analysis has also been used to determine loss of cartilage area and 
surface roughness following ACLT in rabbits.
750,927 Shimizu et al. (1997)
750 assessed proteoglycan 
content following safranin-O staining, as both the percentage area stained (using a density-slice 
function) and the mean greyscale intensity of stained areas.  
 
The method used here showed several advantages to those of previous reports. Firstly, the use of a 
slide scanner provided a simple, low-cost alternative to complex digital imaging systems. By 
adapting a slide cartridge to hold glass slides, a standard slide scanner is converted into a useful 
densitometer, with a simple constant light source, and a charge-coupled device (CCD) detector free 
of interposed apertures, lenses, or automatic gain controls. Secondly, toluidine blue staining was 
quantified rather than safranin-O. A comparison of the two staining methods has shown toluidine 
blue to be preferable for demonstrating loss of cartilage metachromasia.
253 However, as the degree 
of staining might be expected to be influenced by variables such as staining time, all sections need 
to cut and stained using stringent protocols, to minimise this source of variability. Thirdly, mean 
greyscale pixel intensity was used rather than a thresholding approach defining “stained area”.
750 
Greyscale intensity of stained regions (defined by density slice) as measured by Shimizu et al. 
(1997)
750 was found to be a less useful parameter, due to the non-parametric nature of the data 
obtained (results not shown). Le Roux et al. (2000)
455 similarly used a whole-area mean greyscale 
approach to quantify safranin-O staining following canine ACLT. Fourthly, the use of more    115. 
sophisticated image analysis software allowed easy determination of mean radial thickness 
measures, which were found to be more sensitive subtle cartilage changes than cruder cross-
sectional area measures (data not shown). The use of thickness rather than area determinations also 
removes the need to first measure and define a region of cartilage for analysis. 
 
One complication in interpreting thickness and proteoglycan-staining parameters in this model is 
the presence of simultaneous catabolic and anabolic responses in articular cartilage. Areas of 
fibrillation and proteoglycan loss are bounded by regions of hypertrophic repair and increased 
proteoglycan content. Similarly, cartilage thickness is increased (by over-hydration and swelling) at 
the same time as focal areas are eroded. Previously reported image analysis methods have mostly 
utilised the rabbit ACLT model.
126,299,750 In this rapidly progressive model, severe cartilage erosion 
and disruption predominate. In the present ovine meniscectomy model, the histopathological 
changes induced are comparatively mild, and cartilage erosion is relatively focal. Therefore, 
histomorphometric methods which quantify changes over the entire articular cartilage area may be 
more sensitive to the surrounding compensatory and hypertrophic events, thus complicating 
interpretation of results. The division of the cartilage area into inner, middle, and outer zones aided 
assessment of focal events such as cartilage erosion.    116. 
CHAPTER 3 
 
EFFECTS OF GLYCERYL TRINITRATE, OVARIECTOMY, AND 
MENISCECTOMY ON FEMORO-TIBIAL JOINT TISSUES OF AGED 
EWES 
 
3.1   INTRODUCTION 
 
Glyceryl trinitrate (propane-1,2,3-triol trinitrate) (Figure 3.1) is a lipophilic organic nitrate which is 
rapidly cleaved in vivo to inorganic nitrite, then to nitric oxide. As an efficient nitric oxide donor, it 
has been used for many years as a vasodilator and symptomatic treatment for angina pectoris, 
hypertension, and congestive heart failure. A variety of delivery systems are available, including 
buccal tablets, oral sprays, topical ointments, slow-release discs, and intravenous preparations.
2 The 
pharmacokinetics of organic nitrates are complex as they are highly lipophilic and widely 
distributed throughout the body. Extensive metabolism occurs within erythrocytes, vascular 
endothelium and liver cells.
2  
 
Wimalawansa and co-workers have used GTN extensively to study the effects of nitric oxide donors 
on bone metabolism in rats
903,904,906,907 and humans.
902 Preliminary studies compared various nitric 
oxide donors (GTN, molsidomine, sodium nitrite, L-arginine) and found GTN to be the most 
effective.
901 The GTN dosage used in the following trial was extrapolated directly from these rat 
studies, to give equivalent dosage on a mg per week basis. However, the frequency of 
administration was lower, due to labour constraints. The pharmacokinetics of GTN in sheep have 
not been studied. Plasma levels are very low (sub-nanogram) and difficult to assay due to the rapid 
decomposition in plasma.
60,160,725,920 Determination of plasma GTN levels following topical    117. 
administration in sheep was therefore outside the scope of this study. However, a pilot study was 
performed in four sheep, which showed a distinct peak in plasma nitrite levels 1-2 hours after 
administration in three of the four sheep (data not shown), as has been shown after human usage.
60 
No side effects or behavioral changes were observed and the absence of methaemoglobinaemia was 
confirmed by potassium ferricyanide assay
213 (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1:   Structure of glyceryl trinitrate. 
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3.2   MATERIALS  AND  METHODS 
 
3.2.1   TRIAL  PROTOCOL 
 
3.2.1.1   Source  Of  Animals 
 
Aged Merino ewes (Peppin strain) were obtained from a farm near Cataby, Western Australia. 
These animals were born in 1993 making them six and a half years old at the start of the trial. All 
animals were bred on the property and subsequently managed together, and therefore represented 
stock of genetically and environmentally homogenous background. Experimental subjects were 
selected from a larger group by size, weight, and body condition criteria (50-60 kg, body score 1+ 
or above) and to exclude those animals which were obviously lame, unthrifty, or appeared never to 
have lambed.  
 
On introduction to the Murdoch University farm, the sheep were ear-tagged and vaccinated against 
clostridial diseases and Corynebacterium pseudotuberculosis [Glanvac 6, CSL, Australia]. All 
sheep were treated with an internal parasiticide [Cydectin Oral Drench for Sheep, Fort Dodge, 
Australia; moxidectin 1 g/L], an external parasiticide [Vanquish Long Wool, Coopers Animal 
Health, Australia; alpha-cypermethrin 50 g/L], and a preventive footrot preparation [Footrite, 
Merial Australia, Australia; zinc sulphate 224 g/L]. In each sheep, both stifles joints were palpated 
and medio-lateral radiographs obtained, to rule out pre-existing arthropathy. To ensure that they 
were non-pregnant and actively cycling, all non-ovariectomised ewes received 125g of 
cloprostenol [Juramate, Jurox, Australia] by intramuscular injection. A vasectomised (teaser) ram 
with a raddle harness was used to detect ewes coming into oestrus; the few which did not were 
excluded from the trial.  
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3.2.1.2   Surgery 
 
3.2.1.2.1 Ovariectomy 
 
Twenty-four sheep were ovariectomised by midline laparotomy. After deprivation of food and 
water overnight, the sheep were anaesthetised with intravenous thiopentone sodium (50mg/ml) 
[Jurox, Australia]. Anaesthesia was maintained with inhaled halothane [Rhône Mérieux, Australia] 
using a Fluotec 3 vaporiser [Cyprane Keighley, UK] and a circle anaesthetic circuit. Ovariectomy 
was performed, under full sterile conditions, via a 5cm midline laparotomy incision placed 
approximately 5cm forward of the cranial border of the mammary gland. The ovaries were 
exteriorised from the body cavity, the ovarian pedicle was clamped and ligated, and all ovarian 
tissue was removed. The excised tissue was visually inspected to confirm the entire ovary had been 
removed. All sheep showed signs of recent ovarian activity (enlarging follicles or corpora lutea). 
One sheep was found to be in early pregnancy; in this ewe, full ovariohysterectomy was performed 
via an enlarged midline incision. The linea alba incision was closed using 3 metric polydioxanone 
suture [PDS II, Ethicon, USA], the subcutaneous tissues were apposed using 3 metric 
poliglecaprone 25 suture [Monocryl, Ethicon, USA], and the skin sutured with 3 metric 
polypropylene [Prolene, Ethicon, USA] in a simple interupted pattern. To provide analgesia, all 
ewes received 100mg of flunixin meglumine [Ilium Flunixin, Ilium, Australia] by intramuscular 
injection postoperatively. Cutaneous sutures were removed 9 days after surgery. 
 
3.2.1.2.2 Meniscectomy 
 
Bilateral lateral meniscectomy was performed on 24 sheep. Twelve of these sheep had been 
ovariectomised 5 weeks previously, as described in Chapter 2. As in the previous trial, 
complications and visible lameness were minimal. One ewe showed extensor weakness suggestive 
of peroneal nerve damage, which resolved spontaneously within one week.    120. 
 
3.2.1.3      Glyceryl Trinitrate Treatment  
 
Animals assigned to GTN-treated groups were identified by coloured ear tags. Treatment was 
performed twice per week (i.e. 3-4 day intervals). Calculated doses (0.7 mg/kg) of 2% glyceryl 
trinitrate ointment [Nitro-Bid®, Hoechst Marion Roussel, Australia] (Figure 3.2) were individually 
dispensed by weight onto waxed paper squares immediately prior to treatment. At scheduled 
treatment times, the entire mob was brought into a sheep shed and animals to be treated were 
drafted into a race. With the sheep standing in the race, the ointment was applied with gloved hands 
to the hairless region of skin on the medial aspect of the upper thigh, an area of approximately 250 
cm
2 (Figure 3.4), and gently rubbed until the ointment was absorbed. No behavioural abnormalities 
or other signs were observed to indicate any side-effects associated with GTN treatment. 
 
3.2.1.4      Animal Maintenance And Sampling  
 
The sheep were maintained as a single mob, and rotated between 1-2 hectare paddocks on the 
University farm. Pastures were irrigated and consisted mainly of kikuyu, perennial white and 
strawberry clover (minimally oestrogenic varieties), and perennial ryegrass. Sheep were weighed at 
approximately monthly intervals. Maintenance was limited to regular foot trimming and 
endoparasiticidal treatment [Closantel (closantel 37.5 g/L), West Stock Distributors, Australia; 
Ivomec Liquid for Sheep (ivermectin 0.8 g/L), Merial, Australia]. Toe or sole abscesses were an 
occasional problem and were treated by corrective trimming, intramuscular injection of procaine 
penicillin / streptomycin [Ilium, Australia], and short-term confinement in a dry shed if necessary. 
Faecal eggs counts were tested periodically to monitor endoparasite burdens. 
 
Urine was collected at various time points, either during anaesthesia, by free catch following 
induction of urination by nasal occlusion, or at the time of sacrifice. Animals were sacrificed in a    121. 
staggered, blocking design over a period of four months. Two GTN-treated animals were sacrified 
simultaneously with two sheep from the relevant control group. Periods of post-meniscectomy, 
post-menisctomy, and of GTN treatment are indicated in Table 3.1. 
 
Table 3.1:   Treatment intervals (weeks) at time of sacrifice, by treatment group. 
Group  Weeks post-ovariectomy  Weeks post-meniscectomy  Duration of GTN treatment 
NOC  - -  26-28 
OVX  28-30 -  26-28 
MX  - 27-29  25-27 
OVX+MX  32-34 27-29  23-25 
 
 
 
To label mineralizing bone, all animals received  intravenous injections of calcein (15 mg/kg) 
thirteen days before sacrifice, and xylenol orange (15 mg/kg) three days before sacrifice.
729 Calcein 
[Sigma, USA] was prepared as a 40 mg/ml solution in water for injection. The solution was 
adjusted to pH 7.4 with sodium hydroxide, filtered through a 0.2m syringe filter, and injected 
slowly intravenously via a 19 gauge butterfly catheter in the lateral cephalic vein. Xylenol orange 
[ICN Biomedicals, USA] was prepared as a 40 mg/ml solution, adjusted to pH 7.4 with 
hydrochloric acid, and administered similarly. 
 
3.2.1.5    Sacrifice And Tissue Processing 
 
At time of sacrifice, jugular blood samples were collected from each sheep before euthanasia by  
intravenous injection of 20ml of pentobarbitone sodium (300 mg/ml) [Valabarb, Pitman-Moore, 
Australia]. Serum for osteocalcin assay was separated within 2 hours, and frozen immmediately at -
80°C. Urine was collected and both hindlimbs were skinned and removed intact. The first lumbar 
vertebrae was identified and removed for storage in 70% ethanol. One randomly selected leg (left or 
right) was sealed in plastic bags, stored in crushed ice, and transported overnight by air to the 
Raymond Purves Bone and Joint Laboratory (Institute of Bone and Joint Research, University of    122. 
Sydney at the Royal North Shore Hospital, St. Leonards, NSW). This limb was used for 
biomechanical testing, intact bone densitometry, and tibial plateau decalcified histology. The 
contralateral limb remained at Murdoch University for tissue culture procedures. After tissue had 
been harvested for culture, a band-saw was used to remove osteochondral slabs for histologic and 
biochemical assessment. Two 2-3 mm thick, mid-transverse sections were taken : (i) one across the 
femoral condyles, to include the point of tibial contact in usual stance, placed into formalin (for 
decalcified histology); and (ii) one across the tibial plateau, at the level of the intercondylar 
eminences, placed into 70% ethanol (for cubic bone density assessment and undecalcified bone 
histology). 
 
3.2.2   GROSS  PATHOLOGY 
 
Gross pathological assessment was recorded as the joint was opened prior to tissue culture, using 
the scale detailed previously (see 2.2.2). 
 
3.2.3   DYNAMIC  BIOMECHANICAL  TESTING 
 
The biomechanical properties of tibial articular cartilage were assessed by Dr. Richard Appleyard 
(Orthopaedic Research Institute, University of New South Wales at the St. George Hospital, NSW), 
using a recently developed hand-held indentation device.
35 Briefly, the device incorporated a handle 
and a 150mm long stainless steel tube (5mm external diameter) (Figure 3.5). Located at one end of 
the tube was a vibration unit consisting of a flexing beam, held in a cantilevered configuration, with 
strain gauges attached. A small cylindrical probe (0.5mm diameter) was attached to the free end of 
the beam and extended out the side of the side of the tube through a narrow slot. A long shielded 
wire connected the indenter to a strain gauge amplifier unit that was connected to a computer, via an 
A-to-D card. A single frequency waveform (20Hz), applied to the instrument, caused the probe to 
vibrate in an up-and-down motion with respect to the tube opening. The amplitude of oscillation    123. 
was set at ±0.03mm. Both the supply and response (strain gauge) signals were monitored 
simultaneously, and these time domain signals converted into the frequency domain using Fast 
Fourier Transform (FFT) techniques.  
 
Biomechanical testing was performed on intact tibial plateaux, which had been frozen at –20°C 
awaiting analysis. Freeze-thawing of cartilage has been shown to have no effect on biomechanical 
properties.
47 On the day of testing, the samples were immersed in fresh phosphate-buffered saline 
(PBS) and equilibrated to 20°C for 45 minutes. Using a grid projected onto the articular surface by 
a modified slide projector, a 3 x 3 array was marked on the cartilage surface of the lateral and 
medial tibial plateaux with Picro Sirius red stain (Figure 3.6). At each of these locations (n=18), the 
indentation probe was pressed against the surface with moderate pressure. Dynamic stiffness and 
phase lag were continuously displayed on a computer monitor. Pressing a button on the handle of 
the indentation device instructed collection of data. On completion of biomechanical testing, 
articular cartilage thickness was determined at each location using a needle penetration method.
807 
Accuracy and precision trials using the indenter on standard rubbers and normal ovine tibial 
plateaux have demonstrated excellent correlations.
35 
 
The dynamic shear modulus, G
*, was calculated using the theory published by Hayes et al. 
(1972),
331 where: 
 
G* =   P 
*
  (1- ) 
H 
*  4a  
 
and a is the indenter radius, P*/H* is the dynamic force divided by the dynamic displacement 
(dynamic stiffness), s the Poisson’s ratio and  is the theoretical correction function. Hayes et al. 
(1972) tabulated the variation in  with alteration in Poisson’s ratio and aspect ratio, a/h, where h is 
the thickness of articular cartilage beneath the indenter.
331    124. 
 
3.2.4   HISTOLOGICAL  ASSESSMENTs 
 
3.2.4.1   Cartilage  Histology 
 
Specimens were processed for decalcified histology as described in Chapter 2. Computerised image 
analysis was completed as described previously, with the following exceptions: (i) femoral condylar 
sections were cut at 5m instead of 4m, (ii) quantification of toluidine blue staining (mean 
greyscale pixel intensity) was performed only in the femoral condyles, as freezing may have caused 
artifactual loss of proteoglycan in the tibial plateaux; and (iii) greyscale pixel intensity was 
measured by the image analysis software NIH Image v.1.62 [National Institutes of Health, USA] 
instead of Image Pro. In addition, cross-sectional osteophyte area (mm
2) was determined in each 
region in meniscectomised sheep. Calcified cartilage pathology was evaluated according on a scale 
of 0-4 (below), at each of the four zones scored for histopathology. Calcified cartilage vascularity 
was measured as the number of blood vessels invading the length of the calcified cartilage layer 
(Figure 3.9), excluding marginal regions of osteophytic remodelling.
367 Chondrocyte number was 
also quantified in the middle zone of each femoral condyle, by counting the number of distinct 
nuclei in a 250x250m grid using an eyepiece graticule positioned midway between the surface and 
tidemark layers, at three adjacent locations.  
 
CALCIFIED CARTILAGE SCORE 
 
0:  Intact subchondral bone plate and single tidemark 
1:  Intact subchondral bone plate with multilayered tidemark 
2:  Blood vessels penetrating into calcified cartilage layer 
3:  Blood vessels penetrating through calcified cartilage layer to tidemark 
4:  Tidemark penetrated by blood vessels 
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3.2.4.2      Collagen Birefringence 
 
Quantitative analysis of collagen birefringence was performed in 4m sections from the tibial 
plateaux (intact osteochondral sections) and the LFC (full-thickness cartilage plug) of non-
meniscectomised sheep only. Sections were treated with bovine testicular hyaluronidase [ICN 
Biomedicals, Australia] to remove proteoglycans, then stained with Picro Sirius red using a 
modification of the published method of Junqueira et al. (1979).
396 Birefringence intensity was 
determined using methods similar to those of Király et al. (1997)
421 and Arokoski et al. (1996).
45 
Stained sections were viewed through a Leica DMLB polarisation microscope [Leica, Germany] 
under monochromatic ( 550nm) light supplied by an interference filter [OG 550nm, Schott, 
Germany]. With the cartilage surface oriented at 45° to the lower polarisation filter, greyscale 
digital images were collected using a digital camera. A full-thickness birefringence intensity profile 
was generated using image analysis software [Image Pro Plus v3.0.1, Media Cybernetics, USA]. 
The profile plot was then normalised by depth (0= cartilage surface, 1= calcified cartilage) to allow 
comparative analysis of cartilage of different thickness (Figure 3.7). 
 
3.2.4.3   Synovial  Histopathology 
 
Synovial pathology was scored subjectively, as detailed in Chapter 2 (see 2.2.5). In addition, 
cellularity was assessed. Using an eyepiece graticule [Olympus, Japan] defining a 250m-square 
grid (50m divisions) at x200 magnification, positioned over relatively flat segments of synovia, 
the number of cell nuclei in a 250m long strip of intima (to a depth of 50m) was counted at five 
randomly selected points of each specimen. 
    126. 
 
 
3.2.4.4    Undecalcified Bone Sections 
 
Lateral tibial plateau bone slabs (stored in 70% ethanol) were dehydrated by sequential exposure to 
90% and 100% ethanol. Slabs were then exposed to two changes of methyl methacrylate (MMA) 
monomer [Fluka Chemike, Switzerland] prior to embedding. Monomer was washed prior to use to 
remove hydroquinone inhibitors of spontaneous polymerisation, by washing three times with an 
equal volume of 5% w/v NaOH and three times with ultrapure water. Monomer was then dewatered 
by overnight addition of granular anhydrous CaCl2 followed by filtration. Bone specimens were 
then embedded in MMA monomer activated by the addition of 30g/L benzoyl peroxide [Sigma, 
USA], in small capped gass jars. The jars were placed in an evacuated dessicator within a 37°C 
oven for 4-5 days. When polymerisation was complete, the jars were broken and the blocks were 
trimmed to a small field (approximately 10x10mm, in the central zone of LTP) using a hacksaw and 
a low-speed diamond saw [Buehler Isomet, USA]. 
 
Undecalcified sections (5m) were cut on a Model 1140 Reichert-Jung Autocut microtome using a 
“D”-profile tungsten carbide microtome knife [Austral Scientific, Australia]. Sections were floated 
onto an 80°C water bath and collected onto silanized glass slides, which were then clamped 
between sheets of plastic and baked at 60°C overnight. Sections were stained with solochrome 
cyanin to differentiate osteoid (Figure 3.11).
607 Briefly, slides were stained with solochrome cyanin 
(1% w/v solochrome cyanin [BDH Chemicals, UK], 2% v/v glacial acetic acid, 0.4% ammonium 
ferric sulphate, in ultrapure water) for 20 minutes, rinsed in warm water for 2-4 minutes until bone 
appeared blue, dehydrated through increasing alcohol concentrations, cleared in xylene and 
mounted with DPX.  
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Surface parameters were calculated in cancellous bone by manual point-counting, using a Weibel II 
eyepiece graticule with 21 parallel bars [Graticules Ltd, UK]. Where a bar crossed from marrow 
space to bone, the surface was recorded as quiescent surface, osteoid surface (stained red-pink), or 
eroded surface (Howship’s lacunae present). Three to five hundred surfaces were counted in each 
section. Surface parameters were calculated as a percentage using total surface as the referent in all 
cases. Trabecular volume was calculated by image analysis of scanned sections [NIH Image v.1.62; 
National Institutes of Health, USA], and calculated as a percentage using total volume as the 
referent. 
 
Unstained undecalcified sections were examined using a fluorescent microscope [Olympus Vanox; 
Olympus Optical Co., Japan] with blue filters (BG-12 exciter filter, DM-500 and O-515 dichroic 
mirror, O-515 barrier filter). Using the above point-counting technique, surfaces were counted as 
either labelled or unlabelled according to the presence of a distinct line of calcein fluorescence 
(Figure 3.12). Xylenol orange labelling was faint and indistinct, so was excluded from analyses. 
The reasons for this are unknown, though xylenol orange has been shown to fade with prolonged 
storage or exposure to solvents.
660 Labelled surface was calculated as a percentage of total surface. 
The small sample and density of the cortical bone prevented accurate calculation of surface-
labelling parameters in the subchondral bone plate. Instead, calcein labelling was scored 
qualitatively according to the following scale: 
 
SUBCHONDRAL BONE PLATE CALCEIN SCORE 
0: No  calcein-labelled  osteons 
1:  Few calcein-labelled osteons (<25%) 
2:  Multiple calcein-labelled osteons (25-50%) 
3:  Many calcein-labelled osteons (50-75%) 
4:  Most osteons calcein-labelled (>75%) 
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3.2.5   BONE  DENSITOMETRY 
 
Bone mineral density of the dissected first lumbar vertebra was determined by dual-energy X-ray 
absorptiometry (DEXA) using a Hologic QDR 1000-W densitometer [Hologic Inc., USA]. 
Vertebrae were anatomically positioned on a perspex support and immersed in a 10cm water bath. 
The region of interest (ROI) was defined manually to include only the vertebral body itself.  
 
BMD was determined in the LTP, MTP, LFC, MFC, femoral head and neck, and femoral and tibial 
diaphyses using a Hologic QDR 4500-W absorptiometer [Hologic Inc., USA]. A bed of rice of 
constant thickness (5cm) was used to both position the specimen and to simulate soft-tissue density. 
Scanning of subchondral sites was conducted such that the weight-bearing articular surface was 
parallel to the beam. Bone density (gm/cm
2) was determined as the mean of three 5x3 mm ROI, in 
the inner, middle and outer subchondral zones of the tibial plateau, and three 3x3 mm ROI in the 
corresponding zones of the femoral condyles.
368 The dissected femoral head and tibial and femoral 
shafts were scanned in normal anatomical position (anteroposterior). Five ROI were analysed in the 
proximal femur: femoral neck (23x32 mm), Ward's triangle (10x10mm), two 5x5mm ROI in the 
subchondral weight-bearing region, and the fovea capitus (5x5cm). In the tibia and femur, ROI 
included approximately 3cm of the entire shaft excised from the mid-diaphyseal region. 
 
 
BMD was also determined in tibial bone slabs prior to undecalcified histology, using a Hologic 
QDR 4500-W absorptiometer [Hologic Inc., USA] (Figure 3.3). The slabs were placed flat on a 
perspex plate overlaying a bed of rice (5cm). ROI were identifed as for the intact condyles. The 
thickness of the slab was determined using a digital caliper, and the bone density reported in 
gm/cm
3 as described by Armstrong (1993).
39 
 
 
    129. 
3.2.6    BLOOD AND URINE ASSAYS 
 
3.2.6.1    Plasma 17ß-Oestradiol 
 
Plasma 17ß-oestradiol concentrations were measured using the method of Webb et al. (1985),
887 
involving an affinity chromatography extraction procedure followed by double-antibody 
radioimmunoassay (RIA). All antibodies used were those described by Webb et al. (1985),
887 kindly 
provided by Prof. Graeme Martin (Dept. of Animal Science, University of Western Australia). A 
known volume of serum (2-5 ml) was diluted to 10 ml with ultrapure water and gently mixed for 2 
hours at room temperature with antibody-sepharose 4B beads (sheep anti-oestradiol-17ß-6-
carboxymethil-oxime serum). Beads were recovered by passing mixture through baked glass 
columns containing sintered glass filters (porosity 1) and rinsing twice with water. Bound steroid 
was eluted with 3ml of 90% methanol and evaporated to dryness. A standard preparation of 2,4,6,7-
3H-17ß-oestradiol [Amersham Pharmacia Biotech, UK] in sheep plasma was included in each batch 
to evaluate extraction efficiency. Samples were then resuspended in gelatin-phosphate buffer (0.1% 
gelatine in PBS) and dispensed in duplicate into 12 x 75mm glass tubes. Aliquots of radioiodinated 
steroid (17ß-oestradiol-11-tyrosinemethyester) and first antibody (rabbit anti-17ß-oestradiol-11ß-
succinyl-BSA serum, 1:240,000 dilution) were added prior to incubation for 4 hours at room 
temperature. 100l normal rabbit serum, diluted in gelatin-phosphate buffer  containing 0.1M 
ethylenediaminetetraacetic acid (EDTA), and 100l of second antibody (donkey anti-rabbit serum) 
were then added as precipitating agents. Following a 36 hour incubation at 4°C,  1.5ml of ice-cold 
polyethylene glycol (2% in PBS) was added and the tubes centrifuged at 3000 rpm for 25 minutes. 
The supernatant was immediately aspirated and the radioactivity in the precipitates counted by 
routine gamma counting. Concentrations of oestradiol were computed by ‘AssayZap Universal 
Assay Calculator’ [Elsevier-Biosoft, Cambridge, UK] against a standard curve (0-100 pg/ml) 
assayed simultaneously, and corrected for extraction efficiency (65.4 ± 3.2 %) and original plasma 
volume.     130. 
 
3.2.6.2    Serum Osteocalcin 
 
Osteocalcin was assayed by Graeme Worth at Sir Charles Gairdner Hospital, Perth, Australia using 
a competitive radioimmunoassay. Briefly, 
125I-bovine osteocalcin tracer, rabbit anti-bovine 
osteocalcin serum, and normal rabbit serum were combined with the test sample or bovine 
osteocalcin standard and incubated for 48 hours at 4°C. Antibody complexes were precipitated by 
addition of an anti-rabbit gamma globulin precipitating sera and centrifugation. Precipitates were 
washed once, and counted by routine gamma counting. Antisera raised against bovine osteocalcin 
have been shown to cross-react with both human and ovine osteocalcin.
157  
 
3.2.6.4    Urine Collagen Crosslinks 
 
Pyridinoline and deoxypyridinoline assays were kindly performed by Nick Avery (Collagen 
Research Group, University of Bristol) on air-freighted frozen urine samples. Collagen crosslinks 
have been shown to be extremely stable in frozen and freeze-thawed samples.
251 Collagen crosslinks 
were detected using a published high-performance liquid chromatography (HPLC) method.
761 
Briefly, urine was mixed with 6N hydrochloric acid and to 115°C for 24 hours. Hydrolysates were 
then freeze-dried and pre-chromatographed on a Whatman CF-1 cellulose powder column. 
Following vacuum concentration and resuspension in 1% trifluoroacetic acid, HPLC was performed 
using a 4.6 x 100mmm Shandon Hypercarb-S graphitic carbon column. With a flow rate of 
1ml/minute and 0.25%/ml, crosslink peaks were resolved using a linear gradient from 0-15% 
tetrahydrofuran in water, both containing 0.5% trifluoroacetic acid. Resulting peaks were quantified 
by comparison to known standards prepared in the laboratory.  
 
Urine collagen crosslink content was corrected for urine creatinine concentration. Creatinine was 
assayed in urine diluted 1:100 in ultrapure water, using a modified Jaffe reaction.
333 50l of dilute    131. 
urine, 0.5ml 0.04M picrate, 0.5ml 0.75M NaOH, and 950l H20 were combined in a disposable 
cuvette. The absorbance at  500nm was determined on a spectrophotometer [Beckamn DU-650; 
Beckman, USA] and compared to standard solutions (0-20g/ml) of creatinine. 
 
3.2.7    CELL CULTURE PROCEDURES AND ASSAYS ON CELL CULTURE 
CONDITIONED MEDIA (CM) 
 
After skinning and removal of the hindlimb, the distal crus and excess muscle tissue were removed 
and the joint sprayed with 70% ethanol. The joint was then transferred to a laminar flow cabinet, 
after which point it was handled only with full sterile procedure. After further trimming of all tissue 
overlying the joint capsule, the joint was carefully dissarticulated and synovial, cartilage, and bone 
tissue removed to labelled petri dishes containing sterile PBS [Trace Scientific, Australia] for 
subsequent tissue culture. 
 
All cell culture and bioassay procedures used tissue culture-treated plastic multiwells manufactured 
by TPP [Techno Plastic Products, Switzerland], unless otherwise specified. Water for all assay and 
culture procedures was purified by ultrafiltration [MilliQ Ultrapure Water System, Millipore 
Australia]. All cell culture incubation was conducted in a 37°C humidified 5% CO2 incubator 
[Forma Scientific, USA]. Foetal calf serum (FCS) was obtained from Trace [Trace Scientific, 
Australia].  Ovine recombinant IL-1ß
743 was kindly supplied by the Centre for Animal 
Biotechnology, University of Melbourne, Australia. [5'-
3H] thymidine (1mCi/ml) was obtained 
from Amersham Pharmacia Biotech, UK. All ß-counting was conducted using a Beckman LS 3801 
Liquid Scintillation counter [Beckman, USA] after addition of 3ml of scintillation fluid [EcoLite 
(+), ICN Biomedicals, USA] per scintillation tube. 
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3.2.7.1    Patellar Cartilage Explant Culture 
 
Four cartilage explant discs were removed from the proximal articular surface of the patella using a 
disposable 3mm biopsy punch [Stiefel, Germany]. After rinsing in sterile PBS, the explants were 
transferred to individual wells of 24-well multiwell culture plates. Explants were cultured in 500l 
of Hams F12 medium [Sigma, USA] supplemented with 1mM L-glutamine [Sigma, USA], 50g/ml 
gentamicin [David Bull Laboratories, Australia], and 10% v/v foetal calf serum, pH 7.2. After 24 
hours of culture, media was replaced by 500l of fresh Hams F12/10% FCS supplemented with 
4Ci/ml Na
35SO4 [Amersham Pharmacia Biotech, UK]. 100pg/ml ovine recombinant IL-1ß was 
added to two of the wells. After a further 48 hours of incubation, the explants (patted dry) and 
aliquots of conditioned media were immediately frozen at -20°C. Media for PGE2 assay (NOC and 
MX sheep only) was stored at -80°C.  
 
3.2.7.2    Subchondral  Bone  Explant  Culture 
 
Explant culture of subchondral bone was performed using the method of Hilal et al. (1998).
350 Two 
subchondral bone explants were removed from the anteromedial portion of the lateral tibial plateau 
using a 5mm Michele bone biopsy trephine. After excision of attached cartilage and cancellous 
bone using a No. 11 scalpel blade, the explants were rinsed thoroughly in PBS and transferred to 
individual wells of a 24-well culture plate. 1ml of serum-free BGJb medium (Fitton-Jackson 
modification) [Sigma, USA] supplemented with 50g/ml gentamicin was added to each well. After 
incubation for 95 hours, aliquots of conditioned media were frozen at -20°C. The explants were 
patted dry with tissue and weighed on a 0.00001g balance [Sartorius, Germany]; subsequent assay 
results are expressed as activity per mg wet weight of tissue. 
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3.2.7.3    Synovial Fibroblast Culture 
 
Synovial lining was harvested by sharp dissection with a No. 11 scalpel blade, from all regions of 
the joint. Care was taken to exclude excessive subsynovial or fibrous tissue. The synovium was 
placed into PBS, diced finely using two No. 11 scalpel blades in a scissoring action, and transferred 
to a sterile plastic centrifuge tube. The tissue was washed by two cycles involving the addition of 
excess PBS, centrifugation (10 mins, 2000 rpm, 20° C), and careful removal of excess PBS between 
the floating and sediment layers using a plastic transfer pipette. An equal volume of 0.2% trypsin 
solution [Gibco BRL, USA] in 0.1% EDTA was added to the tubes, which were then stored at 4°C 
overnight. Leaving synovium at 4°C in normal saline overnight has been shown to have no apparent 
effect on subsequent culture or viability.
530 After incubation for 1 hour at 36°C, 1ml of FCS was 
added, and the tubes centrifuged as before. Excess trypsin solution was removed to leave a volume 
of 10ml, before addition of 40ml of Dulbecco's Modified Eagles Medium [Trace Scientific, 
Australia] supplemented with 44mM NaHCO3, 15mM N-[2-hydroxyethyl]piperazine-N'-[2-
ethanesulfonic acid] (HEPES) [Sigma, USA], and 10% FCS, pH 7.2 (DMEM/10% FCS). After 
centrifuging as before, excess solution was removed and an equal volume of 2 mg/ml collagenase 
solution [Clostridial Type IA; Sigma, USA] in DMEM/10% FCS was added before incubation for 3 
hours at 36°C. After centrifuging as before, the supernatant (including digested fat layer) was 
removed to waste. The sediment was washed twice by gentle resuspension in fresh media, 
centrifugation as before, and removal of supernatant. The sedimented cells were thoroughly 
resuspended in 15ml of media, and filtered through a single layer of autoclaved sheer polyester 
voile (mesh size 25 x 25 m) before mixing an aliquot with an equal volume of 0.4% trypan blue 
[Sigma, USA] and counting cell yield and viability with an improved Neubauer haemocytometer 
[Weber Scientific International Ltd., England]. Viability was always >95%. After removing aliquots 
for primary cell culture, the remaining cell suspension was transferred to two 75cm
2 canted neck 
cell culture flasks [Corning Inc., USA] and cultured in DMEM/10% FCS containing 10 ml/L of an    134. 
antibiotic / antimycotic mixture (10 000U penicillin, 10mg streptomycin, 25g amphotericin B per 
ml) [Sigma, USA].  
 
Primary isolates were cultured for 8 days, with changes of media at days 3 and 6. During this 
period, cultures proliferated to confluence, and changed from a sparse pavement-like appearance to 
dense whorls of fibroblastic spindle-shaped cells (Figure 3.10). To subculture, media was removed 
and the monolayer rinsed twice with sterile PBS. 1-2 ml of 0.2% trypsin in 0.1% EDTA was added 
to each flask before incubation for 3-5 minutes. The loosened cell sheet was transferred to 15ml 
centrifuge tubes and washed twice by suspension in excess DMEM/10% FCS, centrifugation (10 
min, 2000rpm, 20°C), and removal of the supernatant to waste. After thorough resuspension in fresh 
media, cell concentration was counted using a haemocytometer as before. Cells not needed for 
further subculture were sedimented by centrifugation and resuspended in 200l TEDG buffer 
(10mM Tris HCl, 1.5mM EDTA, 2mM dithiothreitol, 10% v/v glycerol, pH 7.5) and frozen at -
20°C awaiting oestrogen receptor assay. 
 
Cells from each sheep were plated into four wells of two tissue culture-treated 24-well culture 
plates at an initial cell density of 2x10
5 cells/well. After 4 hours, media and any unattached cells 
were removed and replaced with 500l fresh DMEM/10% FCS. Two of the wells were 
supplemented with 100 pg/ml ovine recombinant IL-1ß. After incubation for 48 hours, aliquots of 
conditioned media were immediately frozen at -20°C pending biochemical assays (-80°C for PGE2 
determinations). The remaining cell monolayer was drained and frozen at -20°C awaiting assay of 
DNA content.  
 
Passaged cells from each sheep were also seeded into pentiplicate wells of tissue culture-treated 96-
well culture plates [Falcon, USA] at a density of 1x10
4 cells/well (200l/well) for separate 
proliferation assay. Media was replaced after 4 hours to remove any unattached cells. After 44 
hours of incubation, 50l of 
3H-thymidine solution (5Ci/ml in DMEM/10%FCS) was added to    135. 
each well. After a further 4 hour incubation, media was removed, and the cell monolayers were 
rinsed twice with PBS. 100l of 0.2% trypsin/0.1% EDTA was added before incubation at 37°C for 
20 minutes. Using a cell harvester [PHD Cell Harvester, Cambridge Technology, USA], cells were 
harvested onto glass filter paper discs [Whatman GF/C glass microfibre filters, Whatman 
International, England] which were placed in scintillation vials and counted by routine ß-counting. 
 
Primary isolates were also cultured for cytokine determinations. After filtering the digestate and 
counting the resulting single cell suspension, cells were plated in quadruplicate into 24-well 
multiwell culture plates at 5x10
5 cells/well. The media was carefully changed after 24 hours and 
replaced with 500l fresh DMEM/10% FCS with the addition of 1g/ml lipopolysaccharide 
[Escherichia coli  Serotype O55:B5; Sigma, USA] to two of the wells. After a further 48 hours of 
incubation, aliquots of conditioned media and the drained culture plates were immediately frozen at 
-20°C. Careful removal of media was found not to disturb the cell layer, as the cells rapidly secreted 
and became embedded in a loose glycosaminoglycan matrix. 
 
3.2.7.4    DNA Assay 
 
DNA was assayed using the fluorescent DNA binding agent Hoescht 33258 (bis-benzimide).
417,442 
Synovial culture wells were carefully emptied of all conditioned media. 500l of papain solution 
was added to each well (approximately 0.8 U/ml papain [Sigma, USA; from papaya latex] in PBS 
with 0.005M EDTA and 0.01M cysteine added, pH 6.0) before incubation for 2 hours at 60°C. 
Cartilage explants were papain digested in 650l papain solution for 4 hours at 60°C. 200l of the 
digestate was combined with 300l dye solution in a 10mm borex test tube (2g/ml Hoescht 33258 
[Sigma, USA] in 2M NaCl, 0.05M Na3PO4, pH 7.4) and mixed well. After standing for 5 minutes, 
1ml of buffer was added and the fluorescence read on a Perkin Elmer LS-50 luminescence 
spectrometer (ex 350nm, em 450nm). DNA content (g/well) was calculated versus a standard 
curve of calf thymus DNA [Sigma, USA] assayed in parallel. As all synovial fibroblast monolayers    136. 
were visibly confluent at the end of the culture period, the DNA content of each well is proportional 
to confluent cell density (g per 24-well microplate well). 
 
3.2.7.5    Nitric Oxide 
 
Nitric oxide release was assayed colorimetrically as the nitrite content of conditioned media using 
the Greiss reaction.
286,297 100l of CM was combined in a disposable cuvette with 500l of 1% 
sulfanilamide [ICN Biomedicals, USA] in 5% H3PO4, and 500l of 0.1% N-(1-
naphthyl)ethylenediamine dihydrochloride [ICN Biomedicals, USA]. After 5 minutes, the 
absorbance at  540nm was measured on a spectrophotometer [Beckamn DU-650; Beckman, USA]. 
The appropriate media blank value (determined using 5% H3PO4 without sulfanilamide) was 
subtracted from all absorbances. The nitrite content was detemined against a standard curve of 0-
50M NaNO3 [Sigma, USA] assayed in parallel. 
 
3.2.7.6    MMP Activity 
 
MMP activity was assayed in CM from serum-free cultures. Both auto-activated and total (p-
aminophenylmercuric acetate (APMA)-activated) activities were determined using the fluorogenic 
substrate [(7-methoxycoumarin-4-yl)acetyl](Mca)-Pro-Leu-Gly-Leu-[N-3-(2,4-dinitrophenyl)-L-
2,3-diaminopropionyl-](Dpa)-Ala-Arg-NH2 [Novabiochem, Switzerland, #03-32-5032].
425 This 
extremely sensitive substrate is cleaved primarily by gelatinases but also by (amongst others) 
MMP-1, -3, and -7 and is suitable for assay of total MMP activity in crude preparations.
66,425 
 
The fluorescent substrate was stored frozen in dimethyl sulfoxide (DMSO) (1mg/ml) and further 
diluted to 40 M in TC buffer (50mM Tris-HCl, 5mM CaCl2, pH 7.5) before use. 20l of diluted 
substrate was combined with an equal volume of CM and incubated for 2 hours (cartilage explant 
CM) or 4 hours (synovial fibroblast CM) in a 37°C water bath. The reaction was terminated with    137. 
1ml of cold 40mM EDTA and the fluorescence determined on a Perkin Elmer LS-50 luminescence 
spectrometer (ex 328nm, em 393nm). A blank consisting of substrate only was subtracted from all 
results and the activity reported as F/min/g DNA where F equals the change in fluorescence 
units over the incubation period. 
 
Total (APMA-activated) activity was determined after incubation (3hr, 37°C) of 50l CM with 10l 
2.5mM APMA. APMA solution was prepared by 1:4 dilution of 10mM stock (3.5mg/ml in 0.1M 
NaOH) in TTC buffer (50mM Tris-HCl, 5mM CaCl2, 0.05% (v/v) Triton X-100) and readjusted to 
pH 7.5. 20l of activated CM was assayed as above after 1 hr incubation.  
 
3.2.7.7  
35SO4-Labelled Proteoglycan Synthesis 
 
35SO4-labelled proteoglycans were isolated by precipitation of free 
35SO4 as insoluble BaS04.
151 
400l of cartilage explant digestate was combined in a 12 x 75 mm borosilicate test tube with 200l 
of a solution containing equal volumes of 0.2M Na2SO4 and 50mg/ml chondroitin sulphate A (CSA) 
[Sigma, USA; from bovine trachea], then vortexed. 100l of 0.4M BaCl2 was added before 
vortexing again. Tubes were then centrifuged in a Beckman J-6B refrigerated centrifuge at 1000 g 
for 10 minutes. 400l of the supernatant was transferred to a clean test tube without disturbing the 
precipitate. 100l of a 2:5 mixture of 50mg/ml CSA and 0.4M BaCl2 was added and the tubes 
vortexed, before addition of 100l 0.2M Na2SO4, vortexing, and centrifuging as before. 200l 
aliquots of the supernatant were carefully transferred to scintillation vials and the radioactivity 
counted on a Beckman LS 3801 Liquid Scintillation counter [Beckman, USA]. Results are 
expressed as DPM per g DNA in the explant. 
 
35SO4-proteoglycan content was also determined in cartilage explant conditioned medium. 100l of 
CM was added to 400l papain solution and digested as before (2 hours, 60°C). 400l of the 
digestate was assayed as above. Total 
35SO4-proteoglycan synthesis was calculated as the total DPM    138. 
of the explant plus the total DPM of the CM. Percentage release of newly synthesised proteoglycan 
was determined as the DPM of CM x 100 / total DPM of CM + explant.  
 
3.2.7.8   PGE2 
 
Conditioned media samples for PGE2 assay were stored at -80°C for a maximum of six months 
prior to assay. Assay was performed using a commercially available enzyme immunoassay (EIA) 
[Cayman Chemical Company, USA] according to the manufacturers instructions. The 2B5 
monoclonal antibody in this kit is highly specific for PGE2, though some cross-reactivity with PGE1 
and PGE3 is documented in the product specifications. Briefly, CM samples were diluted 1:10 in 
EIA buffer (1:100 dilution for IL-1ß-stimulated cartilage CM). 50l of the diluted samples were 
added to individual wells of a 96-well plate pre-coated with goat anti-mouse antibody. 50l  of 
PGE2-acetylcholinesterase tracer and 50l of murine PGE2 monoclonal antibody were added prior 
to incubation for 18 hrs at 4°C. The plate was then rinsed five times with the supplied wash buffer 
before addition of Ellman's reagent. After incubation for a further 150 minutes, the absorbance at 
 405nm was determined on a microplate spectrophotometer [Biorad Model 450 Microplate reader; 
Biorad, USA]. After subtraction of non-specific binding values, the %B/B0 (% bound/maximum 
binding) was determined for each sample and compared to a standard curve of 7.8 - 1000 pg/ml 
PGE2 assayed in parallel. 
 
3.2.7.9    Urokinase-Type Plasminogen Activator (uPA) Activity 
 
uPA activity was measured in conditioned cell culture media using the chromogenic plasmin 
substrate H-D-valyl-leucyl-lysine-p-nitroaniline dihydrochloride [S-2251™, Chromogenix, Italy] in 
a modification of the Leprince et al. (1989)
462 adaptation of the two-step assay of Coleman and 
Green (1981).
149 20l of serum-free CM was combined in 96-well microwells with 20l of 
plasminogen solution (0.1g/L bovine plasminogen [Sigma, USA] in 100mM glycine, 100mM Tris-   139. 
HCl, 0.5mg/ml bovine serum albumin, pH 8.5) and mixed well. Plasminogen-independent activity 
was assessed by adding equivalent buffer only. After incubation (2 hrs, 37°C), 160l of substrate 
mixture was added (0.1mM H-D-Val-Leu-Lys-pNA in 200mM Na3PO4, 200mM NaCl, 0.25mM 
DTNB [5,5'-dithio-bis(2-nitrobenzoic acid); Sigma, USA], 0.1% Triton X-100, pH 7.5). The 
combination of dilution, pH reduction, and addition of NaCl and Triton X-100 effectively 
terminates further plasminogen activation and maximises plasmin activity.
149 After a further 15 
minutes of incubation, absorbance at  405nm was read on microplate spectrophotometer [Biorad 
Model 450 Microplate reader; Biorad, USA]. Plasminogen-independent activity was subtracted 
from plasminogen-dependant wells, and the results compared to a range of human urokinase 
standards (0-0.01 g/ml) [Sigma, USA] included in each microplate. 
 
Alternative assay was conducted using the fluorogenic urokinase substrate benzyloxycarbonyl(Bzl)-
Gly-Gly-Arg-[7-amino-4-methylcoumarin](AMC) [Novabiochem, Switzerland].
938 Briefly, 
substrate was dissolved in DMSO and diluted to a 0.2mM working solution in 20mM Tris-HCl, pH 
7.5. 20l of CM (or uPA standard) and 20l of substrate solution were combined in a glass test tube 
and incubated for 24 hours at 37°C. Reaction was terminated with 1ml of 0.1M -amino-n-caproic 
acid (EACA) [Sigma, USA] in 20mM Tris, pH 7.5, and the fluorescence read on a Perkin Elmer 
LS-50 luminescence spectrometer (ex 383nm, em 455nm).  
 
3.2.7.10   IL-6  Bioassay 
 
IL-6 content of CM from primary synovial cultures was assayed using a bioassay of IL-6-dependant 
7TD1 hybridoma cells [supplied by the Walter and Elisa Hall Institute, Melbourne, Australia].
358 
7TD1 cells were grown in RPMI-1640 media [Sigma, USA], 10M ß-mercaptoethanol, 10% v/v 
FCS (RPMI-1640/10%FCS), supplemented with 100 ng/L IL-6 [human recombinant IL-6; 
Boehringer Mannheim Biochemica, Germany]. For the bioassay, 25l of primary CM was added to 
duplicate wells of a 96-well culture plate [Techno Plastic Products, Switzerland] and diluted with    140. 
75l of RPMI-1640/10% FCS. Dilutions of recombinant human IL-6 served as a standard for 
quantification. 7TD1 cells were harvested by centrifugation, washed twice in RPMI/10% FCS 
(without IL-6), and added to the assay plates at a density of 10,000 cells/well (in 100l). After 
incubation for 72 hours at 37°C, 0.5Ci of 
3H-thymidine was added to each well before incubation 
for a further 6 hours. Cells were harvested as described above (see 3.2.7.3). Radioactivity of the 
discs was counted by routine liquid scintillation counting. Half-maximal stimulation was produced 
by 10 pg/ml IL-6, similar to that reported in other studies
358,583,875 and the product data sheet (ICN 
Biomedicals, USA). 
 
3.2.7.11    IL-1 Bioactivity (Lymphocyte Proliferation Assay) 
 
IL-1 bioactivity of primary synoviocyte CM was assayed using an ovine lymphocyte proliferation 
assay.
743 The thymus of a 4-week old lamb was collected aseptically and minced coarsely before 
being pushed through a stainless steel sieve (mesh size 150m). The resulting material was diluted 
in DMEM/10% FCS and filtered through a single layer of sheer polyester voile (mesh size 25 x 25 
m) to yield a single cell suspension. After three wash cycles of centrifugation and resuspension in 
fresh media, the cells were counted and added to 96-well tissue culture plates at 7x10
5 cells/well in 
DMEM/10%FCS containing 4g phytohaemagglutinin [from Phaseolus vulgaris; Sigma, USA]. An 
equal volume of CM sample (diluted 1:5 in DMEM/10% FCS) or diluted ovine recombinant IL-1ß 
was added before incubation for 48 hours. 
3H-thymidine was added to each well (0.5Ci/well) 
before incubation for a further 16 hours. Cells were harvested onto glass filter paper using a cell 
harvester, and the incorporated radioactivity counted by routine liquid scintillation counting. The 
IL-1ß standard curve showed a linear proliferative response between 2 and 1000 pg/ml; limit of 
detection was approximately 1 pg/ml.  
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3.2.8   Oestrogen  Receptor  Assay 
 
The presence of oestrogen receptors in ovine synovial fibroblasts was demonstrated by Scatchard 
saturation analysis using hydroxyapatite precipitation.
65 A single saturating dose (SSD) assay was 
then used to compare receptor levels between treatment groups.
776 For the saturation analysis, four 
75cm
2 flasks of synovial fibroblasts (second passage) were cultured to confluence and harvested by 
brief trypsinization and centrifugation. Cells were resuspended in 1000l TEDG buffer (10mM Tris 
HCl, 1.5mM EDTA, 2mM dithiothreitol, 10% v/v glycerol, pH 7.5). Cells were disrupted by a 
single freeze-thaw cycle followed by sonication (Braunsonic 1510 [Braun, Germany] sonicator, 
50W, 2 bursts of 20 seconds). An aliquot of the homogenate was removed for DNA determination. 
The homogenate was then centrifuged for 12 minutes at 29 psi (approximately 250,000 g) in an 
airfuge [Beckman Air-driven Ultracentrifuge, Beckman, USA]. 100l of cytosol was combined in a 
glass test tube with 25l of [2,4,6,7-
3H]oestradiol [Amersham Pharmacia Biotech, UK] and 25l of 
either buffer (non-specific bonding) or unlabelled oestradiol solution (specific binding). A range of 
3H-oestradiol concentrations (8,6,4,2, and 1nM) were used with or without a corresponding 100-
fold excess of 17ß-oestradiol [ICN Biomedicals, USA]. After mixing, the test tubes were covered 
and incubated for 4 hours at 4°C. During incubation, a 10l sample was taken from each tube to 
determine the total radioactivity. 
 
After incubation, 300l of 10% washed hydroxyapatite slurry (0.1g/ml in TEDG buffer) [Biorad 
DNA-grade HTTP; Biogel, Australia] was added. After incubation for a further 45 minutes at 4°C, 
2ml of buffer was added before sedimenting the hydroxyapatite by centrifugation (1000g, 5 mins, 
4°C), and complete removal of the supernatant (containing non-protein-bound steroid) to waste. 
This washing step was repeated twice more, before transfer of the hydroxyapatite sediment to 
scintillation vials for routine ß-counting. Specific binding was determined by subtracting non-
specific binding (determined by regression plot of non-specific binding versus total radioactivity 
added) from total binding. For Scatchard analysis, results were plotted as bound/free (nM/nM)    142. 
versus bound steroid (nM). For SSD assays, results are expressed as pmol bound per mg DNA in 
the crude homogenate. 
 
3.2.9   Statistical  Methods 
 
Statistical comparisons were generated using specialist software [Statview 5.0, SAS Institute Inc., 
USA], performing one-way analysis of variance (ANOVA) to analyse variance across treatment 
groups, and Fisher’s protected least significant difference (Fisher’s PLSD) test to compare means of 
all treatment groups. Only the following statistical comparisons were reported: all treated groups vs 
NOC; OVX+GTN vs OVX; MX+GTN,  OVX+MX, and OVX+MX+GTN vs MX; and 
OVX+MX+GTN vs OVX+MX. When multiple zones or points were compared simultaneously, 
zone (inner, middle, or outer) or point identifier was included as a second independent variable. In 
comparing histopathological scores in multiple zones for each region, mean scores (for single 
criteria) or mean aggregate scores (for sum of means) were tested statistically. Unless otherwise 
described, correlations were tested using the Pearson correlation test. A significance level of p=0.05 
was used throughout.  
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3.3     RESULTS 
 
3.3.1     BODY WEIGHTS 
 
The mean body weight of all sheep (Figure 3.14) at the start of the trial was 56.1±5.2 kg, with no 
significant differences between sheep later allocated to treatment groups. After meniscectomy, 
sheep lost an average of 5.6 kg by the time of next weighing. Unoperated sheep gained weight 
rapidly early in the trial period (corresponding to spring pasture growth), with lower weight gains in 
the latter half of the trial. An average of 3.4 kg was lost by all sheep due to shearing of wool in the 
middle of the trial period. GTN treatment had no significant effect on body weight. 
OVX+MX+GTN sheep has consistently lower body weights than the OVX+MX sheep after 
initiating treatment, but this difference was not statistically significant by repeated measures 
analysis of variance (p=0.187). 
 
3.3.2   GROSS PATHOLOGY 
 
The joints of non-meniscectomised sheep showed minimal gross pathology, though some degree of 
roughening or fissuring of cartilage was seen in the MTP in 83% of specimens, usually in the region 
not covered by the meniscus. Mild cartilage lesions were less commonly observed in the LTP and 
MFC, while no cartilage abnormalities were observed in the LFC. Four non-meniscectomised joints 
showed minor osteophyte formation. The joints of all meniscectomised groups showed significantly 
greater cartilage erosion and osteophyte formation (p<0.0001) (Figure 3.15). Gross erosion of 
cartilage and marked osteophyte formation was mostly limited to the meniscectomised lateral 
compartment, with the medial compartment showing minor changes. The cartilage of the MFC was 
often grossly normal despite severe lateral pathology (54% of specimens). Complete erosion of LFC 
and/or LTP cartilage exposing the subchondral bone was seen in a few animals. Ovariectomy and    144. 
GTN treatment had no significant effect on the development of gross cartilage pathology or 
osteophyte formation. 
 
In non-meniscectomised animals, cartilage scores were higher in left knees when compared to right 
knees (2.67±2.34 vs 1.25±0.75), though this difference was not statistically significant (p=0.059). 
Osteophytic changes were observed only in left knees (p=0.004). However, there was no difference 
in the gross pathology observed between left and right knees of meniscectomised sheep. 
 
Nineteen of 24 of meniscectomised sheep (79%) showed some degree of synovial change (synovial 
hyperaemia, fibrosis, or synovitis). Nine of 24 specimens (37%) were found to have overt synovitis. 
The degree of gross synovitis was significantly correlated to both gross cartilage pathology 
(p=0.021) and osteophyte formation (p=0.009) (Figure 3.16). Four non-meniscectomised sheep 
(17%) showed slight synovial abnormalities and none demonstrated synovitis. 
 
3.3.3   BIOMECHANICAL  TESTING 
 
Dynamic biomechanical testing of non-meniscectomised animals (Figure 3.17) revealed an overall 
reduction in phase angle () in tibial cartilage of both NOC+GTN (11.0±1.9°; p=0.0003) and OVX 
(10.9±2.2°; p<0.0001) sheep relative to NOC (12.1±2.3°). Phase angle of OVX+GTN (12.6±2.7°) 
was significantly greater than OVX (p<0.0001) and did not differ significantly from NOC. 
Similarly, tibial cartilage thickness was reduced overall relative to NOC in NOC+GTN (p<0.0001) 
and OVX (p=0.0002), but did not differ in OVX+GTN sheep. Thinning of cartilage was most 
prominent in the LTP. Dynamic stiffness was found to be significantly increased overall in 
NOC+GTN (6.31±4.76 N/mm; p=0.015) and OVX (6.20±5.52 N/mm; p=0.039) relative to NOC 
(5.59±5.06 N/mm). However, when stiffness was corrected for cartilage thickness as the dynamic 
shear modulus (G*) according to the theory of Hayes et al. (1972),
331 no overall differences were 
apparent, though regional differences were noted particularly in the inner regions of the LTP    145. 
(Figure 3.17). Results for G* and  were comparable with previous reports of the shear properties of 
articular cartilage.
745,746,935 
 
After meniscectomy, cartilage thickness decreased in the inner regions of the tibial plateaux and 
increased in the outer regions (Figure 3.18). MX+GTN had significantly thinner cartilage in the 
eroded middle regions of the LTP relative to MX. OVX+MX sheep had significantly thicker 
cartilage overall relative to MX (p=0.001); this greater thickness was evident in both inner (eroded) 
and outer (intact) regions. However, cartilage thickness of OVX+MX+GTN sheep differed from 
MX in the inner MTP only, and did not differ overall. Dynamic shear modulus (G*) was 
significantly lower in all meniscectomised groups, primarily due to changes in the lateral tibial 
cartilage; this reduction was significantly greater in OVX+MX and OVX+MX+GTN groups 
relative to that of MX (p<0.0001). Phase changes in meniscectomised groups were variable; phase 
was significantly lower overall relative to NOC in OVX+MX animals (p=0.029) but significantly 
greater in OVX+MX+GTN sheep (p=0.024).  
 
3.3.4   HISTOLOGICAL  ASSESSMENTS 
 
3.3.4.1   Cartilage  Histology 
 
3.3.4.1.1 Cartilage  Histopathological  Scores 
 
OVX animals showed significantly greater aggregate histopathology scores (Table 3.2) in the MFC, 
relative to NOC (p=0.009). Specifically, scores for abnormalities of structure (p=0.045) and 
interterritorial staining (p=0.048) were significantly increased relative to NOC. OVX+GTN sheep 
did not differ from NOC in the MFC, and showed significantly lower scores for structure and 
interterritorial staining relative to OVX (p=0.043 and p=0.03 respectively). Both OVX and 
OVX+GTN animals showed significant loss of territorial staining in the LTP (p=0.035 and    146. 
p=0.024) relative to NOC.  
 
Histopathology scores were increased in all regions in meniscectomised groups, though these 
differences were not significant in the MTP. MX+GTN animals were found to have significantly 
greater structural damage (p=0.033) and loss of interterritorial staining (p=0.003) in the MFC, and 
greater scores for chondrocyte cloning in the LFC (p=0.015), relative to MX. OVX+MX and 
OVX+MX+GTN animals had significantly lower aggregate scores in the LFC, relative to MX 
(p=0.018 and p=0.034 respectively). In the LFC, OVX+MX showed lower scores for structure 
(p=0.030), territorial staining (p=0.003) and interterritorial staining (p=0.002) relative to MX. 
OVX+MX and OVX+MX+GTN animals also showed reduced loss of interterritorial staining 
relative to MX in the MFC (p=0.007 and p=0.007 respectively).  
 
Ovariectomy resulted in increased neovascularisation of the calcified cartilage layer in both 
qualitative and quantitative indices. Scores for calcified cartilage pathology (Table 3.3) were 
significantly increased in both OVX and OVX+GTN sheep when the whole joint was considered 
(p=0.038 and p=0.007 respectively). Calcified cartilage vascularity (number of invading 
vessels/tidemark length) (Figure 3.19) was also increased overall in OVX (p=0.0003), OVX+GTN 
(p=0.002), and NOC+GTN (p=0.03) relative to NOC. Femoral condyle chondrocyte density did not 
differ between non-meniscectomised groups (Table 3.4) 
 
After meniscectomy, scores for both calcified cartilage pathology (Table 3.3) and vessel number 
(Figure 3.19) were increased in all regions (p<0.0001), especially the lateral compartment. 
MX+GTN sheep had a greater number of vessels invading calcified cartilage in the LFC relative to 
MX (p=0.031). However, scores for pathology and vessel number were lower than MX sheep in the 
MTP (p=0.023 and p=0.010 respectively). Vessel number was higher overall in OVX+MX and 
OVX+MX+GTN groups overall relative to MX sheep (p=0.019 and p=0.034 respectively), though 
scores for calcified cartilage pathology did not differ. Chondrocyte density was increased in the    147. 
LFC in MX (p=0.013) and MX+GTN (p=0.010), but not OVX+MX or OVX+MX+GTN animals 
(Table 3.4). 
 
3.3.4.1.2 Computerised  Histomorphometry 
 
Uncalcified Cartilage Thickness 
Mean uncalcified cartilage (UCC) thickness measures determined by image analysis (Figures 3.20 – 
3.23,  above) were comparable to results using the needle probe. Overall, NOC+GTN had 
significantly thinner UCC in the MFC (p=0.035) and LTP (p<0.0001), with a similar trend in the 
LFC. OVX sheep also had thinner UCC in the LTP (p=0.006) with a similar trend in the LFC 
(p=0.07).  
 
After meniscectomy, MX sheep showed thinner cartilage in the LFC and thicker cartilage in the 
MFC, though these changes were not significant. Cartilage was significantly thinner in the eroded 
middle (p<0.0001) and inner zones (p<0.0001) of the LTP and inner zone of the MTP (p=0.0003), 
while cartilage thickness was significantly increased in the outer zone of the LTP (p=0.011). 
OVX+MX animals showed significantly thicker UCC relative to MX in all locations, except the 
inner and middle zones of the MFC. OVX+MX+GTN similarly showed thicker cartilage relative to 
MX, except in the LTP, where UCC was significantly thinner than that of OVX+MX animals 
(p=0.0008). 
 
Subchondral Bone Plate Thickness 
Subchondral bone plate (SCP) thickness [Figures 3.20 – 3.23, below] was increased in NOC+GTN 
in the MTP (p=0.002), with a similar trend in the MFC (p=0.156). OVX sheep had significantly 
thinner SCP in the LFC (p<0.01) and LTP (p=0.001), while OVX+GTN had significantly thicker 
SCP relative to OVX in the MFC (p=0.04), LFC (p<0.0001) and LTP (p=0.002) and did not differ 
significantly from NOC.    148. 
 
After meniscectomy, the SCP of MX animals was significantly thicker in the LFC (p=0.035) and 
the outer region of the LTP (p=0.008), while thinning of the SCP was found in the outer zone of the 
MFC (p=0.034). MX+GTN animals showed significantly greater increase in SCP thickness relative 
to MX in the middle zone of the LFC (p=0.024), and reduced loss of bone thickness in the outer 
zone of the MFC (p=0.049). OVX+MX and OVX+MX+GTN groups did not differ significantly 
from MX, though OVX+MX showed no increase in SCP thickness relative to NOC in the outer 
zone of the LFC, as was seen in MX sheep. 
 
Intensity Of Toluidine Blue Staining 
The mean greyscale pixel intensity of toluidine blue-stained histological sections, an index of 
proteoglycan content (Figure 3.24), was significantly lower in the MFC of NOC+GTN sheep 
(p=0.011). Similarly, staining intensity was also significantly lower in the LFC and MFC of both 
OVX (p=0.0005 and p=0.002 respectively) and OVX+GTN animals (p=0.040 and p<0.0001 
respectively). 
 
After meniscectomy, toluidine blue staining was significantly lower in all zones except the inner 
zone of the LFC. Loss of staining was significantly greater in OVX+MX sheep relative to MX in 
the LFC (p=0.021), with a similar trend in the MFC. Similarly, loss of staining in OVX+MX+GTN 
sheep was greater than that of MX in both the LFC (p=0.021) and the MFC (p=0.005). 
 
Toluidine blue staining intensity of patellar plugs (Figure 3.25) was significantly reduced in OVX 
animals only (p=0.023). MX+GTN, OVX+MX and OVX+MX+GTN animals all showed lower 
intensity of toluidine blue staining though this was not statistically significant. 
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Osteophyte Size 
Osteophyte size, measured as the cross-sectional area (mm
2) (Figure 3.26), was greatest in the LFC 
and to lesser extent the LTP. While no statistically significant differences were evident in each 
region, pooling of the regional values showed that both MX+GTN (p=0.049) and OVX+MX 
(p=0.022) sheep showed greater osteophyte growth relative to MX ewes. 
 
3.3.4.2   Collagen  Birefringence 
 
Collagen birefringence profile plots revealed a distinct superficial peak in greyscale intensity in all 
regions tested (Figures 3.27 – 3.29). Superficial collagen birefringence was significantly increased 
in both NOC+GTN and OVX sheep (relative to NOC) in the LFC and middle zone of the LTP, with 
a similar trend in other regions. NOC+GTN sheep showed significantly greater intermediate zone 
birefringence in the outer zone of the LTP, and middle zone of the MTP, relative to NOC. 
 
3.3.4.3    Synovial Histopathological Scores 
 
Differences between treatment groups were modest. As GTN-treated animals did not differ 
significantly from untreated animals in any criteria, results were pooled within each surgical group 
(Table 3.5). MX±GTN animals showed greater scores for intimal hyperplasia (p<0.0001), 
inflammatory infiltrate (p=0.012), vascularity (p=0.017), and greater sum of scores (p=0.005), 
relative to NOC±GTN synovia. Similarly, OVX+MX±GTN sheep showed greater scores for intimal 
hyperplasia (p=0.018), inflammatory infiltrate (p=0.031), fibrosis (p=0.008), vascularity (p=0.032), 
and greater sum of scores (p=0.036), relative to NOC±GTN synovia. OVX+MX±GTN synovia 
showed less intimal hyperplasia relative to MX±GTN sheep (p=0.037). Cellularity of the synovial 
initima did not differ significantly between treatment groups (Figure 3.30). 
 
    150. 
3.2.4.4    Undecalcified Bone Histomorphometry 
 
Histomorphometry of undecalcified bone sections from the middle zone of the LTP revealed few 
statistically significant differences between treatment groups. NOC+GTN sections showed less 
eroded trabecular surface relative to NOC (p=0.0072) (Figure 3.31). Osteoid surface, trabecular 
bone volume (Figure 3.32), and calcein-labelled surface did not differ significantly between groups. 
SCP calcein score (see 3.2.4.4) was significantly increased in OVX+MX relative to NOC animals 
(p=0.387), and reduced in OVX+GTN relative to OVX (p=0.0313) (Table 3.6). 
 
 3.3.5    BONE MINERAL DENSITY 
 
Ovariectomised sheep had lower bone mineral density (BMD) than NOC sheep at all extra-articular 
sites tested (Figure 3.34), though this difference was statistically significant only in the first lumbar 
vertebra (p=0.045). Meniscectomised sheep also showed loss of BMD relative to NOC animals, 
which was statistically significant in the first lumbar vertebra (p=0.045) and the femoral head and 
neck sites (p=0.047).  
 
Subchondral BMD (Figure 3.35) was significantly greater in the LFC of NOC+GTN (p=0.004) and 
lower in both OVX and OVX+GTN sheep in the LTP (p=0.004, p=0.015 respectively) and MTP 
(p=0.0002, p<0.0001 respectively), relative to NOC. After meniscectomy, subchondral BMD was 
increased in the LFC (p=0.002) and LTP (p=0.018), and decreased in the MFC (p=0.0003) and 
MTP (p<0.0001). MX+GTN sheep showed a greater increase in subchondral BMD in the LFC 
(p=0.019) and LTP (p=0.011), and reduced loss of BMD in the MTP (p=0.023), relative to MX. 
Subchondral BMD changes in OVX+MX sheep were similar to those in MX animals, though 
OVX+MX+GTN sheep had lower subchondral BMD in the LFC (p=0.018) and MFC (p=0.021).  
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Determinations of the 'cubic' BMD (gm/cm
3) of tibial bone slabs (Figure 3.36) more clearly showed 
the effect of ovariectomy on subchondral BMD. OVX sheep had lower BMD in the LTP (p=0.022) 
and MTP (p=0.026), relative to NOC. Similarly, OVX+MX sheep had lower BMD in the LTP 
(p=0.003) and MTP (p=0.013) relative to MX. Results were strongly correlated with subchondral 
bone plate thickness as measured in the contralateral limb (p<0.0001, r
2=0.141) (Figure 3.37). 
 
Across all groups, bone mineral density was greater in the left stifle relative to the right, in both the 
tibial plateaux (0.85±0.14 vs 0.82±0.16; p=0.032) and femoral condyles (1.01±0.17 vs 0.96±0.16; 
p=0.0014). This difference was most pronounced in the medial compartment.  
 
3.3.6    BLOOD AND URINE MARKERS 
 
3.3.6.1   Plasma  17ß-Oestradiol 
 
Plasma oestradiol levels (Figure 3.38) were relatively low in all sheep. Levels were significantly 
reduced at 5 weeks and subsequent time points post-ovariectomy. In MX±GTN sheep, plasma 
oestradiol levels were significantly increased at the time of sacrifice, relative to NOC animals 
(p=0.004). 
 
3.3.6.2   Serum  Osteocalcin 
 
At the time of sacrifice, serum osteocalcin levels (Figure 3.39) were increased in OVX+GTN 
(p=0.047), MX (p=0.020), OVX+MX (p=0.040) and OVX+MX+GTN (p=0.005) sheep relative to 
NOC animals. Levels in MX+GTN animals were significantly lower relative to MX (p=0.004), and 
did not differ from those of NOC sheep.  
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3.3.6.3   Urine  Collagen  Crosslinks 
 
Urinary levels of collagen pyridinium crosslinks (Figure 3.40) did not differ significantly between 
treatment groups. MX+GTN sheep showed a tendency towards lower levels of Pyr and Dpyr 
relative to MX animals. 
  
3.3.7    ASSAYS ON TISSUE-CULTURE CONDITIONED MEDIA 
 
3.3.7.1    Patellar Cartilage Explants 
 
Nitric Oxide 
Interleukin-1ß-stimulated cultures produced approximately twice the amount of nitric oxide 
(measured as nitrite / g DNA) (Figure 3.41) compared to unstimulated cultures (p<0.0001). Nitric 
oxide production by OVX cultures was increased in both unstimulated (p=0.005) and IL-1ß-
stimulated (p<0.0001) wells relative to NOC. However, OVX+GTN cultures produced less NO 
relative to OVX in both unstimulated (p=0.044) and IL-1ß-stimulated (p=0.010) wells, and did not 
differ significantly from NOC cultures. In IL-1ß-stimulated wells, MX/MX+GTN cultures 
produced less NO relative to NOC/NOC+GTN cultures (p=0.046) 
 
35SO4-labelled Proteoglycan Synthesis 
IL-1ß-stimulation caused a slight  reduction (average -23%) in de novo (
35SO4-labelled) 
proteoglycan synthesis (Figure 3.42). Approximately 25% of the total 
35SO4-labelled proteoglycan 
was present in conditioned media., with no significant difference between groups in the proportion 
released. Explants from OVX sheep produced more 
35SO4-labelled proteoglycan relative to NOC in 
unstimulated cultures (p=0.031). Similarly, OVX/OVX+GTN explants produced more 
35SO4-
labelled proteoglycan relative to NOC/NOC+GTN under IL-1ß-stimulated conditions (p=0.010). 
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MMP Activity 
Auto-activated MMP levels (not shown) represented on average 30% of total MMP activity. Auto-
activated MMP activity was increased in unstimulated OVX cultures relative to NOC cartilage 
(14.9±5.6  vs 10.6±2.6, p=0.019). IL-1ß-stimulation had no significant effect on auto-activated 
levels but produced an approximately four-fold increase in total (APMA-activated) MMP activity 
(p<0.0001) (Figure 3.43). In unstimulated cultures, there were no significant difference between 
groups in total MMP activity. However, under IL-1ß-stimulated conditions, total MMP activity was 
increased relative to NOC in both OVX (p<0.0001) and OVX+GTN (p=0.0002) cultures. 
 
3.3.7.2   Subchondral  Bone  Explants 
 
Nitric Oxide 
There were few significant differences between groups (Figure 3.44). OVX+MX+GTN cultures 
produced less NO per mg wet weight relative to OVX+MX (p=0.016).  
 
PGE2 
Prostaglandin E2 release (pg per mg wet weight) was increased in OVX+MX (p=0.001) and 
OVX+MX+GTN (p=0.002) explants relative to NOC (Figure 3.45). OVX+MX/OVX+MX+GTN 
sheep also produced greater levels of PGE2 relative to MX/MX+GTN explants (p=0.002), which 
did not differ from NOC. 
 
Urokinase-type Plasminogen Activator Activity 
Urokinase-type plasminogen activator (uPA) activity was increased in conditioned media from 
OVX (p=0.023), OVX+MX (p=0.0002), and OVX+MX+GTN (p<0.0001) explants relative to NOC 
(Figure 3.46). Activity in media from MX explants did not differ from NOC cultures. Activity was 
increased relative to MX in conditioned media from both OVX+MX (p=0.0002) and 
OVX+MX+GTN (p<0.0001) cultures.     154. 
 
3.3.7.3   Synovial  Cultures 
 
3.3.7.3.1  Passaged Synovial Fibroblast Cultures 
 
Nitric Oxide 
Addition of IL-1ß to synovial fibroblast cultures caused a slight but statistically significant 
reduction in nitric oxide production (measured as nmol nitrite / g DNA) (p=0.005). NO release 
was greater in MX cultures (Figure 3.47) relative to NOC, in both unstimulated (p=0.004) and IL-
1ß-stimulated (p=0.002) wells. However, OVX+MX cultures produced less NO relative to MX, in 
both unstimulated (p=0.042) and IL-1ß-stimulated (p=0.036) wells. 
 
PGE2 
A wide variation between individual cultures with respect to PGE2 release. IL-1ß-stimulation 
induced a 3-4 fold increase in PGE2 release (p<0.0001) (Figure 3.48). No statistically significant 
differences were observed between treatment groups. 
 
MMP Activity 
IL-1ß-stimulated cultures demonstrated an increase in total MMP activity (mean increase 145% of 
unstimulated cultures, p<0.0001), but showed no significant effect on auto-activated levels. Auto-
activated levels averaged 9% of total (APMA-activated) levels in unstimulated cultures and 6.6% of 
IL-1ß-stimulated totals. No significant differences in auto-activated MMP activity were observed. 
MX and OVX groups had higher total activity than NOC, though this difference was not significant. 
OVX+MX and OVX+MX+GTN sheep possessed greater total MMP activity relative to NOC, 
under both unstimulated (p=0.023 and p=0.003 respectively) and IL-1ß-stimulated (p=0.002 and 
p=0.0004 respectively) conditions (Figure 3.49). Total IL-1ß-stimulated MMP activity of 
OVX+MX sheep was greater than that of MX cultures (p=0.038). Similarly, total MMP activity of    155. 
OVX+MX+GTN cultures were also elevated relative to MX, under both unstimulated (p=0.020) 
and IL-1ß-stimulated conditions (p=0.009).  
 
Urokinase-type Plasminogen Activator Activity 
Urokinase-type plasminogen activator activity did not differ between IL-1ß-stimulated and 
unstimulated synovial fibroblast cultures (Figure 3.50). uPA activity was increased in MX cultures 
relative to NOC, in unstimulated wells (p=0.026) but not IL-1ß-stimulated wells. OVX+MX 
cultures released significantly greater levels of uPA activity relative to NOC under both resting  
(p=0.011) and IL-1ß-stimulated (p=0.005) conditions. Under IL-1ß-stimulated conditions, uPA was 
increased relative to MX in both OVX+MX (p=0.004) and OVX+MX+GTN (p=0.048) cultures.  
 
Assay using the fluorogenic substrate (results not shown) proved more time-consuming and less 
sensitive than the former method, but uPA activities obtained in preliminary tests closely matched 
those from the chromogenic substrate assay, confirming urokinase as the principal plasminogen 
activator in these CM. 
 
 Proliferation Rate and Confluent Density 
There were no significant differences in proliferation rate (
3H-thymidine incorporation, DPM) 
between treatment groups (Figure 3.51). Confluent cell density was approximated as DNA content 
(g) per well in 24-well microplate cultures (Figure 3.52). Confluent cell density was on average 
90% greater in wells containing 10% FCS compared to those with unsupplemented media (results 
not shown). In FCS-supplemented cultures, confluent density was lower in meniscectomised groups 
relative to non-meniscectomised animals in both unstimulated (3.05±0.13 vs 3.60±0.14 g 
DNA/well;  p=0.0076) and IL-1ß-stimulated wells (3.05±0.13 vs 3.63±0.15 g DNA/well; 
p=0.0048).  
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3.3.7.3.2 Primary  Synovial  Cultures 
 
Interleukin-6 Bioactivity 
Production of IL-6 bioactivity by primary synovial isolates was much lower than that reported by 
previous authors (Figure 3.53).
296,539,698 Addition of LPS (1g/ml) caused an average 8-fold increase 
in IL-6 bioactivity (p<0.0001). IL-6 bioactivity was greater in conditioned media from 
OVX/OVX+GTN cultures relative to NOC/NOC+GTN wells (p=0.036). 
 
Interleukin-1 Bioactivity 
Spontaneous release of IL-1 bioactivity by primary synovial isolates was lower in OVX / 
OVX+GTN cultures relative to NOC / NOC+GTN (p=0.022) (Figure 3.54). Similarly, OVX+MX / 
OVX+MX+GTN cultures produced less IL-1 bioactivity relative to both NOC / NOC+GTN 
(p=0.015) and MX / MX+GTN (p=0.041). 
 
3.2.8   OESTROGEN  RECEPTORS 
 
Scatchard analyses performed on several of the cell lines confirmed the presence of specific 
oestradiol receptors in ovine synovial fibroblast cultures, though only low levels were detected. A 
single class of receptor appeared to be present (Figure 3.55A). Receptor levels (as detemined by 
single point assay) were increased following ovariectomy and meniscectomy, though this difference 
was not statistically significant (Figure 3.55B). 
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Table 3.2:  Mean aggregate cartilage histopathology scores in the lateral and medial femoral 
condyles (LFC, MFC) and tibial plateau (LTP, MTP). 
* differs significantly from NOC (p<0.05), † differs significantly from MX (p<0.05), ‡ OVX+GTN 
differs significantly from OVX (p=0.023); maximum possible score = 26 (see 2.2.3) 
 
Treatment Group  LFC MFC  LTP MTP 
NOC  1.87±0.34 1.45±0.57 2.19±0.31 3.37±0.53 
NOC+GTN  2.21±1.05 2.25±1.16 2.67±1.09 2.33±2.10 
OVX  1.75±0.71 3.04±0.97*  2.00±0.64 1.83±0.95 
OVX+GTN  1.92±1.03 2.12±0.79‡  2.87±0.75 2.81±1.28 
MX  12.67±1.84* 5.21±1.52*  14.54±1.62* 6.92±2.27 
MX+GTN  12.92±4.10* 6.33±2.21*  14.12±2.87* 8.21±3.87 
OVX+MX  9.54±2.03*† 4.08±1.62*  14.79±1.28* 7.75±3.96 
OVX+MX+GTN  9.87±3.39*† 3.92±1.18*  15.37±4.20* 7.92±3.71 
 
 
 
 
 
Table 3.3:    Mean scores for calcified cartilage pathology in the lateral and medial femoral 
condyles (LFC, MFC) and tibial plateau (LTP, MTP). 
* differs significantly from NOC (p<0.05), † MX+GTN differs significantly from MX (p=0.023); 
maximum possible score = 4  
 
Treatment Group  LFC MFC  LTP MTP 
NOC  1.33±0.20 1.21±0.12 1.12±0.31 1.21±0.19 
NOC+GTN  1.08±0.30 1.25±0.55 0.92±0.30 1.21±0.43 
OVX  1.37±0.34 1.58±0.49 1.29±0.29 1.58±0.75 
OVX+GTN  1.58±0.26 1.62±0.26 1.12±0.52 1.79±0.37* 
MX  2.17±0.49* 1.75±0.45* 1.79±0.48* 1.96±0.56* 
MX+GTN  2.21±0.64* 1.67±0.58  2.12±0.47* 1.25±0.39† 
OVX+MX  2.21±0.43* 1.50±0.45  1.75±0.32* 1.58±0.46 
OVX+MX+GTN  2.04±0.46* 1.67±0.20  2.08±0.54* 1.87±0.75* 
 
 
 
 
 
Table 3.4:     Chondrocyte density (nuclei / 250 x 250 m) in the intermediate zone of the central 
weight-bearing regions of the lateral and medial femoral condyle (LFC, MFC). 
*  differs significantly from NOC (p<0.02) 
 
Treatment Group  LFC MFC 
NOC  54.7±6.2 46.2±5.8 
NOC+GTN  54.0±10.7 48.1±5.4 
OVX  52.8±14.1 42.3±4.9 
OVX+GTN  49.8±13.3 46.2±13.5 
MX  77.2±24.8* 49.7±13.9 
MX+GTN  79.1±22.3* 46.9±8.3 
OVX+MX  71.8±6.5 46.3±10.9 
OVX+MX+GTN  68.7±13.0 44.9±8.4 
    171.    172.    173.    174.    175.    176.    177.    178.    179. 
    180.    181. 
Table 3.5:     Synovial membrane histopathology scores (results for GTN-treated and untreated 
animals are pooled). 
* differs significantly from NOC±GTN (p<0.05), † OVX+MX±GTN differs from MX±GTN (p=0.037); 
maximum score = 3; maximum sum = 12 
 
 
Treatment Group  Intimal 
hyperplasia 
Cellular 
infiltrate 
Subintimal 
fibrosis 
Vascularity SUM 
NOC±GTN  0.92±0.63  1.00±0.60 1.58±0.56 1.17±0.72  6.21±3.09 
OVX±GTN  0.92±0.67  1.21±0.84 1.87±0.64 1.25±0.69  6.50±2.28 
MX±GTN  2.17±0.65* 1.83±0.98*  1.92±0.51 1.92±0.67* 9.29±2.50* 
OVX+MX±GTN  1.58±0.70*† 1.71±0.62* 2.25±0.62* 1.83±0.86*  8.46±2.24* 
 
 
 
 
 
Figure 3.30:     Cellularity of the synovial intimal layer (nuclei per 250mx50mx4m).  
No significant differences between treatment groups. Error bars represent one standard error. 
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3.4     DISCUSSION 
 
3.4.1    EFFECT OF LATERAL MENISCECTOMY ON FEMORO-TIBIAL JOINT 
TISSUES OF AGED EWES 
 
3.4.1.1    Cartilage Changes After Meniscectomy 
 
The cartilage damage in this trial was more severe than that seen in the younger wethers used in 
Chapter 2. In these aged ewes, cartilage erosions were larger and deeper, occasionally to eburnated 
subchondral bone. In contrast to the previous trial, an increase in cartilage thickness was observed 
only in the outer zone of the LTP. Loss of proteoglycan was also more severe, especially in 
uneroded areas such as the medial femoral condyle. This contrasts with the hypertrophic repair 
response seen in peripheral areas in the younger sheep of Chapter 2. The difference between the two 
trials in the severity of the lesions produced by an identical meniscectomy procedure may be related 
to genetic variation, gender, or the older age of the sheep used. Aged human cartilage has been 
shown to have reduced capacity for repair responses.
422,896 
 
Cartilage lesions were most severe in the tibial plateau, probably because the femoro-tibial 
articulation effectively involves a greater cartilage surface area in the femoral condyles, compared 
to the tibial surface. Lesions were less severe in the medial compartment, and due to the high 
frequency of mild fibrillation in the medial tibial plateau in control animals, few significant 
differences between groups were observed in this region. Mild cartilage fibrillation in the medial 
tibial plateau has been previously reported as a normal finding in other species.
126  
 
There were relatively few statistically significant differences in cartilage biomechanical properties 
between meniscectomised and unoperated sheep. This was mostly due to aberrant readings from 
severely damaged regions of cartilage, where erosion down to the level of calcified cartilage or    199. 
subchondral bone yielded extremely high stiffness values and hence a high standard error. Loss of 
dynamic stiffness (G*) was most dramatic in the outer portions of the LTP, i.e. the area previously 
protected by the meniscus. A similar loss of dynamic stiffness has been reported in other 
biomechanical studies of OA cartilage.
455,745,746 However, a consistent increase in phase lag () was 
not evident in this study as reported previously.
34 Reasons for this are unknown and require further 
clarification. Le Roux et al. (2000)
455 similarly found no phase change in tibial plateau cartilage 
following canine meniscectomy.  
 
The  in vitro responses of ovine cartilage to IL-1ß (i.e. increased nitric oxide and latent MMP 
synthesis, suppression of proteoglycan synthesis) were similar to those reported in other 
species.
106,125,130,349,684,712,791  However,  few differences were evident between patellar cartilage 
explants from normal and meniscectomised sheep. No significant difference in nitric oxide release, 
35SO4-proteoglycan synthesis, or MMP activity was observed. This finding was unexpected given 
numerous studies showing persistent metabolic alterations in OA cartilage.
49,538,625,864 The patella 
may not be a very representative site to sample, given that the proteoglycan content of patellar 
cartilage was similar between normal and menisectomised sheep (Figure 3.25). However, this is 
likely due to loss of previously increased (hypertrophic) levels, rather than being indicative of a 
normal metabolic state. Appleyard et al. (1999)
33 showed significant biomechanical and 
immunohistochemical changes in patellar cartilage six months following ovine meniscectomy. It 
appears that the metabolic changes associated with meniscectomy in this region are less consistent 
in vitro. 
 
3.4.1.1    Synovial Changes After Meniscectomy 
 
Hypothesis:  that the gross synovitis thought to occur in this OA model
474 
would be accompanied by demonstrable microscopic pathology, and persistent 
metabolic alterations in synoviocytes in vitro. 
    200. 
Results in this trial confirm that gross synovitis is a common feature of the ovine meniscectomy 
model of osteoarthritis. Many (79%) of meniscectomised joints showed some gross evidence of 
synovial change, and 37% showed overt synovitis. However, differences at the histological level 
were more modest. While meniscectomised sheep were generally found to have a greater degree of 
intimal hyperplasia, lymphoplasmocytic infiltration, and vascularisation, similar changes were 
observed in some normal sheep. While synovial histopathological scores were found to be 
significantly correlated with severity of degenerative joint changes, the predictive power of this 
relationship (i.e. r
2 values) was low. Intimal fibrosis was not found to be a significant sequelae of 
meniscectomy in this aged ewe trial, as it was in the younger wethers used in Chapter 2. These 
findings suggest firstly that the method used here to objectively score synovial histopathology lacks 
sufficient sensitivity to discriminate the more subtle changes seen in this OA model, compared to 
those seen in rheumatoid arthritis or long-standing human OA.
470,568,682,768  Sampling at more than 
one site may have improved evaluation of synovial changes. However, histological scoring of 
human synovial biopsies shows little variation between multiple sites, and good correlation with 
gross synovial pathology.
469,697 Secondly, it suggests that the synovial membrane of normal sheep 
rarely fits the classic description of healthy synovium, with a single layer of intimal cells and little 
fibrous tissue. Synovial changes seem to be more common in aged sheep, perhaps due to 
accumulated micro-injury over time. Pasquali-Ronchetti et al. (1992)
613 investigated age-related 
changes in human synovia, and similarly noted an increase in fibrosis and number of fibroblasts 
with increasing age. 
 
In vitro, synovial fibroblasts from meniscectomised sheep displayed greater release of nitric oxide 
and plasminogen activator, as has been reported in other arthritis models.
102,532,535,795  A modest 
increase in synovial MMP activity was seen, as has also been demonstrated previously.
138,323,366,536 
However, meniscectomy had no apparent effect on synovial PGE2 production, in contrast to 
numerous published studies, though these have principally examined rheumatoid 
synovia.
175,338,526,530,715 Synovial PGE2 production was much lower than that of patellar cartilage per    201. 
g of DNA, especially after IL-1ß stimulation (results not shown). This is consistent with Amin et 
al. (1997)
22 who identified cartilage as the major source of prostaglandins within the OA joint, 
following super-induction of COX-2 expression in chondrocytes. 
 
The in vitro responses of ovine synovial fibroblasts to IL-1ß stimulation were also not entirely 
consistent with those reported in other studies of arthritic synovia. While PGE2 production and 
latent MMP activity were significantly increased by the addition of IL-1ß, urokinase activity did not 
increase as has generally been reported.
308,459,529 Ito et al. (1992)
375 similarly found that recombinant 
human IL-1 had no effect on urokinase or PAI-1 production by human rheumatoid synovial 
fibroblasts. The growth characteristics of synovial fibroblasts in this model were consistent the 
report of Smith and Hamerman (1969),
767 which noted that rheumatoid synovial fibroblasts showed 
decreased cell density when confluent. 
 
The effect of IL-1ß on synovial fibroblast nitric oxide release was surprising, with a slight but 
statistically significant reduction in NO production observed. This contrasts with results obtained 
from cartilage explants, in which NO production was greater per g of DNA and was 
approximately doubled by IL-1ß stimulation. This suggests that chondrocytes may be the major 
source of IL-1 in the meniscectomised ovine joint. Other in vitro studies have found NO release by 
synovial tissue to be inconsistent.
539 Mentzel and Bräuer (1998)
539 found that TNF--induced nitric 
oxide production was greater in normal synoviocytes than in arthritis-derived cells. Sakurai et al. 
(1995)
714 found that whilst NO was produced by freshly isolated human synoviocytes, 
supplementation with IL-1ß alone produced minimal stimulation, and that passaged rheumatoid 
synovial fibroblast lines produced no detectable NO. Similarly, Rediske et al. (1994)
676 found 
negligible NO production in cultured human synoviocytes. Species differences seem likely, as rats 
and rabbits are the only species in which NO production by passaged synovial fibroblast lines has 
been reported.
539,795 Even in rabbit cultures, NO production is variable, with a small percentage of 
culture lines failing to produce NO under any conditions.
795 NO production could not be induced in    202. 
the immortalised HIG-82 rabbit synovial fibroblast line.
795 Immunohistochemical studies have also 
found synovial fibroblasts to be quite heterogenous with respect to iNOS expression.
454,532 It seems 
likely that a more complex cytokine stimulus is required for the induction of iNOS in ovine 
synovial fibroblasts.
676 IL-1ß alone does not induce iNOS in human cardiac fibroblasts,
752 human 
foetal fibroblasts,
717 or murine macrophages.
894 Interferon- may be an important co-stimulus, by 
increasing tetrahydrobiopterin synthesis (a cofactor of NO synthesis) as it does in murine dermal 
fibroblasts.
894  
 
Also contrary to published reports, meniscectomy had no significant effect on the release of IL-6 or 
IL-1 by primary synoviocyte isolates. IL-6 production was found to be several orders of magnitude 
lower than that shown by similar bioassay methods in other synovial studies.
296,539,698 This may have 
been due to species-specific effects on the bioassay system used, as the human recombinant IL-6 
used as a standard produced similar effects on hybridoma proliferation as in published reports.
583 
Elevated IL-6 production is a key defining feature of synovial fibroblast activation which was 
apparently absent in this study. IL-1 bioactivity was also low and did not differ in meniscectomised 
sheep. While IL-1 bioactivity has also been shown to be species-specific,
28,456,521 the assay used in 
this study utilised a published ovine lymphocyte assay and a recombinant ovine IL-1ß standard. 
Brennan et al. (1989)
92 found spontaneous IL-1 production by human OA synovia was very low, 
using a similar assay. 
 
3.4.1.3    Bone Responses After Meniscectomy  
 
As has been shown previously,
38,39 significant remodelling of subchondral bone was evident six 
months after meniscectomy. The subchondral bone plate was thickened in the LFC but thinner in 
the outer MFC, reflecting the altered pattern of loading in the meniscus-deficient joint. Changes in 
the tibial plateau were limited to the outer zone of the LTP, the region normally protected by the 
meniscus in the intact joint. As cartilage changes were most severe in the tibial plateau and mild in    203. 
the femoral condyles, there appears to be a poor regional correlation between cartilage and 
subchondral bone thickening. It has been proposed
350,506,618,658 that the local bone sclerosis 
accompanying OA results in a stiffer, less compliant subchondral plate, thereby increasing 
compressive forces on the overlying chondrocytes and accelerating cartilage degeneration. The lack 
of a clear regional correlation in this study suggests different stresses (mechanical or biochemical) 
are responsible for the changes observed in cartilage and subchondral bone. Similarly, the lack of 
subchondral bone sclerosis in the medial compartment, despite OA-like changes in the overlying 
cartilage, shows that subchondral bone changes are not necessary for the progression of cartilage 
lesions. A similar lack of correlation has been shown in the canine ACLT model.
90,179,180 
 
Changes in peri-articular bone mineral density were more consistent, and showed the same pattern 
of increased BMD in the lateral compartment and relative osteopenia in the medial side of the joint. 
This again reflects the changes in joint kinetics following meniscectomy, whereby external femoral 
rotation and slight valgus displacement of the stifle increased loading in the lateral compartment. 
Early loss of subchondral bone volume and density is common in surgical animal models of OA, 
due to decreased loading of the joint.
179,540,614 The use of a bilateral meniscectomy model 
theoretically prevents unloading due to shift of weight to the the contralateral limb. However, the 
loss of BMD from femoral head and neck sites (with a similar trend in the femoral and tibial 
diaphyses) suggests that some compensatory gait change does occur. The pattern of changes in this 
trial suggests that subchondral bone changes in this and other surgical models of OA are driven 
largely by changes in joint loading, rather than being directly related to cartilage pathology. 
However, the subchondral bone changes following meniscectomy may still be useful in the study of 
the bone changes accompanying OA, as demonstrated by the modified bone responses seen in trials 
of putative DMOADs.
104,368  
 
The observation that BMD changes were more prominent than altered SCP thickness  is interesting, 
as the classic concept of OA subchondral bone involves a sclerotic but hypomineralised matrix.
39,293    204. 
Karvonen  et al. (1998)
403 used a similar DEXA method to show a significant decrease in 
periarticular BMD in patients with early knee OA. Results in this model show that in some regions 
(e.g. LTP) a significant increase in subchondral BMD occurs, accompanied by only minor 
thickenening of the subchondral plate. Increased subchondral bone density is seen in other animal 
models of OA.
54,89,659 
 
Tidemark alterations and neovascularisation of the calcified cartilage layer were prominent 
following meniscectomy in this trial. Possibly due to the advanced age of the subjects, multiple 
tidemarks were present in nearly all sheep, including control animals. However, blood vessels were 
seen to invade the calcified cartilage in greater number and to a greater depth in meniscectomised 
animals, especially in the lateral joint compartment. Armstrong (1993)
39 and Simpson (1994)
760 
found that calcified cartilage changes were not a distinct feature of the sheep meniscectomy model. 
This discrepancy may be due to differences in responses to medial and lateral meniscectomy, the 
age of the subjects, or (more likely) to differences between bilateral and unilateral surgery and the 
loading-driven subchondral bone remodelling subsequently induced. 
 
Femoro-tibial bone mineral density measurements revealed a distinct difference between the left 
and right stifles. Left joints showed significantly higher BMD, and this mirrored a greater 
prevalence of cartilage lesions and osteophytes in the left leg of unoperated sheep. The same trend 
was found in studies by Armstrong.
39,41 This suggests that the left hindleg bears greater forces 
during normal activity than the right. This might be due to the uneven abdominal distribution of the 
rumen, or due to preferential usage of a 'leading' leg. Normal dogs show as much as 4% difference 
in bone morphologic parameters between the left and right hind legs.
179 
 
Serum osteocalcin levels were significantly increased in meniscectomised sheep. This suggests an 
increase in bone formation (or bone turnover) in these animals, and was seen despite significant net 
loss of bone density at several extra-articular sites (L1, femoral head and neck). Stress is unlikely to    205. 
have caused this elevation, as it has been shown in sheep that while short-term stresses such as 
handling or transport are unlikely to influence osteocalcin levels, long-term corticosteroid 
administration  reduces plasma levels. Human studies have shown both elevated
240,350 and 
reduced
11,779,798 osteocalcin levels in OA patients. A trend towards increased urinary excretion of 
deoxypyridinoline (Figure 3.40) was also evident. Bone histomorphometric analysis failed to 
demonstrate a significant difference in bone turnover in the area examined (central LTP), though a 
trend towards increased calcein-labelled surface was apparent (Figure 3.33). Armstrong et al. 
(1994)
38 also failed to demonstrate any significant change in histomorphometric variables in peri-
articular trabecular bone following ovine meniscectomy, though an increase in osteoid volume and 
tetracycline labelling were demonstrated in the subchondral cortex. This suggests that even 
immediately adjacent to the joint, cancellous bone is shielded from altered focal forces following 
meniscectomy, by thickening of the overlying subchondral plate.  
 
The significant elevation in serum oestradiol levels seen in MX animals at the time of sacrifice is of 
great interest. While a link between circulating oestradiol levels and human OA has frequently been 
postulated, multiple studies have failed to conclusively establish a link.
226,578,778,784 However, Tsai et 
al. (1992)
838 found that synovial fluid oestradiol levels are elevated in OA patients when compared 
to normal postmenopausal women, to levels proportionate with OA severity. This finding suggests 
that local production of oestradiol within OA joints may represent a potential source of circulating 
hormone. Appreciable levels of 17ß-hydroxysteroid dehydrogenase activity have been shown in 
rabbit cartilage.
68 The results of this trial demonstrate that elevation in serum oestradiol can occur 
secondary to an induced OA-like process. Alternatively, stress may have influenced oestradiol 
synthesis. Acute stress raises serum oestradiol levels in intact female rats.
756 However in ewes, 
stress (such as that from transport) has generally been shown to suppress fertility and follicular 
oestradiol production, by interrupting LH secretion.
200 The observation of a similar rise (not 
statistically significant) in serum oestradiol of OVX+MX sheep suggests that if stress was a factor, 
extra-ovarian sources of oestradiol must be involved. In ewes, a considerable proportion of    206. 
circulating oestradiol is not of ovarian origin but comes from both adrenal secretion and peripheral 
aromatization of weak oestrogen precursors.
127 However, the ovine adrenal mainly produces weak 
oestrogen precursors, and this production is suppressed by glucocorticoids (N. Adams, personal 
communication). ACTH administration does not acutely raise serum oestradiol levels in 
ovariectomised pigs.
564 Other peripheral sources may therefore be more likely, and it is possible that 
the meniscectomised joint itself may be involved.  
 
3.4.2   EFFECT OF OVARIECTOMY ON FEMORO-TIBIAL JOINT TISSUES OF 
AGED EWES 
 
Hypothesis: that ovariectomy of aged ewes would induce structural and 
metabolic alterations in femoro-tibial articular cartilage, as well as synovial and 
subchondral bone tissue.  
 
3.4.2.1    Cartilage Changes After Ovariectomy 
 
The results of this study provide strong evidence that ovariectomy induces significant structural 
changes in ovine articular cartilage and subchondral bone, as recently suggested by other 
authors.
367,611,769,841 Ovariectomised sheep were found to have thinner cartilage in the lateral joint 
compartment, with a generalised reduction in tibial phase lag (), and increased shear modulus (G*) 
in the inner regions of the LTP (Figure 3.17). While no changes in gross appearance were evident, 
histological examination showed a deterioration of structure and loss of proteoglycan, as confirmed 
by the loss of toluidine blue staining intensity in the femoral condyles and patella. Patterns of 
collagen birefringence suggest that collagen structure was also altered, particularly in the superficial 
zone.  
 
Turner et al. (1997)
841 demonstrated that the biomechanical integrity of cartilage was adversely 
affected by ovariectomy in aged ewes, as evidenced by decreased aggregate modulus (compressive    207. 
stiffness) and shear modulus, but not cartilage thickness or permeability. Studies in young rabbits
667 
and rats
597,918,923 have shown an increase in cartilage thickness following ovariectomy, though due to 
species and age differences the latter findings may not be applicable to the current study. In this 
trial, femoro-tibial articular cartilage of ovariectomised animals was found to be thinner, especially 
in the lateral compartment. In the absence of gross or microscopic erosion, cartilage thinning may 
be due to two processes. Firstly, net reduction in matrix production (as suggested by the reduction 
in toluidine blue staining of femoral cartilage) may have produced an ‘atrophic’ cartilage state. 
Secondly, advancement of the tidemark may have lead to endochondral ossification of the lower 
layers of articular cartilage. The increase in calcified cartilage neovascularisation certainly suggests 
active remodelling of this layer, as shown by Hwa et al. (2001)
367 in a related trial. However, the 
simultaneous reduction in subchondral bone thickness shows that the net result of osteochondral 
remodelling processes is a thinner subchondral plate. While not measured separately, the calcified 
cartilage layer appeared to be of similar thickness to that of control sheep.  
 
While cartilage compressive stiffness is proportional to proteoglycan content,
47 resistance to 
dynamic biomechanical properties such as resistance to shear (G*) may correlate more with 
collagen content,
52,455,935 and in this study G* shows a strong inverse relationship with thickness 
(Figure 3.17). Appleyard et al. (submitted for publication) have examined topographical variation in 
biomechanical and biochemical variables across the ovine tibial plateaux. Cartilage thickness was 
found to be strongly negatively correlated with collagen content and shear modulus. 
Glycosaminoglycan content was found to be positively correlated with thickness, but negatively 
correlated to G* in unoperated sheep. The thinner, outer zones of the tibial plateaux therefore have 
more collagen and less proteoglycan on a dry weight basis. This increased collagen content may 
account for much of the increase in shear modulus in these areas, despite correction for thickness 
according to the theoretical variation in  as published by Hayes et al. (1972).
331 Zhu et. al. 
(1993)
935 found a similar correlation between G* and collagen content in bovine cartilage discs. 
Similarly, Le Roux et al. (2000)
455 correlated G* with surface collagen organisation (birefringence)    208. 
in canine cartilage, and concluded that collagen governs the dynamic (shear) behaviour of cartilage. 
The increase in G* in the middle and inner LTP of ovariectomised animals is therefore likely to 
reflect an increase in collagen content, in association with the decrease in cartilage thickness also 
observed.  
 
The reduction in cartilage phase lag seen in ovariectomised animals might also reflect collagen 
changes. Lower phase values mark a change in viscoelastic behaviour towards a more elastic solid, 
and reduced dissipation of shear forces. The relationship between the structural components of 
cartilage and its phase properties is complex, but simplistically the collagen network provides the 
elastic response while proteoglycan provides the viscous response. Zhu et al. (1993)
935 found a 
weak positive correlation between  and uronic acid content. However, more complex modelling 
recognises the importance of energy dissipation from both proteoglycan-collagen and proteoglycan-
proteoglycan interactions. Phase properties are therefore influenced by the quantity and molecular 
size of proteoglycans, and the degree to which they form stable aggregates, as well as intactness of 
the collagen network. Therefore, the reduction in phase lag in the OVX group may be due to either 
reduced cartilage proteoglycan content, some change in proteoglycan quality or aggregation state, 
and/or an increase in collagen content or organisation. Analysis of collagen birefringence (Figures 
3.27 - 3.29) shows an increase in superficial birefringence in the LFC and middle and outer zones of 
the LTP, with a similar trend in other regions. This again suggests an increase in collagen density 
and/or organization in OVX animals, specifically localised to the superficial layer of cartilage. 
Ovariectomy is known to induce changes in collagen structure in various tissues. For example, 
ovariectomy of adult rats  increases collagen content of the temporomandilar joint disc,
4 and 
reduces mean fibril diameter of type I collagen in bone and skin
397 The altered birefringence 
patterns observed here, together with regional alterations in  and G*, are highly suggestive of 
similar structural reorganisation of cartilage collagen following ovariectomy of sheep. 
    209. 
This study confirm suggestions from a recent related study
611,769 showing altered cartilage 
proteoglycan synthesis following ovariectomy in sheep. Proteoglycan synthesis was elevated in 
patellar cartilage explants from ovariectomised animals (Figure 3.41). However, greater induction 
of latent MMPs was seen following IL-1ß stimulation (Figure 3.43), suggesting that proteoglycan 
catabolism may also have been up-regulated. Quantitation of toluidine blue staining showed a net 
loss of proteoglycan content in both patellar and femoral condyle articular cartilage (Figures 3.24 
and 3.25). This suggests that despite an increase in proteoglycan turnover, net loss of proteoglycan 
had occurred by six months post-ovariectomy. Ovariectomy induces cellular proliferation and 
increased matrix synthesis in growth plate cartilage in adult rats, a phenomenon thought to relate to 
a concurrent increase in serum IGF-1.
811 In a previous similar trial, cultured patellar cartilage 
explants from ovariectomised sheep showed decreased 
35SO4-incorporation at three months post-
surgery.
769 The reasons for these different results are unknown, but they suggest that chondrocytes 
undergo a prolonged period of fluctuating metabolic disturbance following oestrogen withdrawal. 
 
Patellar cartilage explants from ovariectomised sheep produced significantly more nitric oxide 
compared to entire animals (Figure 3.41). This result is unexpected as oestradiol is supportive of 
constitutive nitric oxide production in most tissues.
36,330,884,890  However, Kauser et al. (1997)
406 
demonstrated that ovariectomised rats experience a greater increase in plasma nitrate levels 
following endotoxin treatment than entire animals, and that this increase could be attenuated by pre-
treatment with oestradiol.
406 This suggests that oestrogen may normally function to suppress iNOS 
induction. As nitric oxide is thought to decrease proteoglycan content
561,801,822 and alter collagen 
synthesis,
110 increased cartilage iNOS expression following ovariectomy may be a possible 
mechanism for some of the cartilage changes observed in this study. Yoon et al. (2001)
925 found a 
similar increase in NOS expression in rabbit clitoris and vagina following ovariectomy, and this 
was associated with an increase in collagen content in these tissues. 
    210. 
Some debate exists in the literature as to whether the effects of the female menopause are created by 
the absolute loss of oestrogen, or are due to fluctuations in the oestrogen/progesterone balance in 
the perimenopausal period.
782 Serial assay of plasma 17ß-oestradiol in this study suggests a rapid 
and permanent decline in oestradiol levels following ovariectomy. Resting plasma oestradiol levels 
are normally very low in sheep, with a peak at oestrus.
103 Serum concentrations of oestradiol in 
women are much higher - reported levels include 74.1±59.1 pg/ml in premenopausal women,
796 
53.4±31.0 pg/ml in the perimenopausal period,
796 and 4.1 pg/ml in postmenopausal women.
120 The 
presence of metabolic abnormalities in cartilage, synovium and subchondral bone (elevated 
urokinase activity) tissues at six months post-ovariectomy confirms that the metabolic influence of 
ovariectomy is prolonged, and therefore more likely relates to long-term hormone withdrawal, 
rather than a temporary ‘perimenopausal’ imbalance. Analysis of serum oestradiol concentrations 
(Figure 3.38) suggests that it is largely the loss of the cyclical peaks which is responsible for the 
drop in average concentration, rather than a decline in the (already low) resting levels. This suggests 
that, at least in sheep, it is loss of the normal cyclical rises in oestrogen levels that disrupts cartilage 
homeostasis. As the oestrus cycles of women and sheep are temporally similar, the same may be 
true of menopausal women.  
 
3.4.2.2    Synovial Changes After Ovariectomy 
 
Ovariectomy had little effect on cultured synovial fibroblasts. A slight but not statistically 
significant increase in MMP synthesis was observed (Figure 3.49). A similar increase in gelatinase 
synthesis was demonstrated by gelatin zymography in a previous study of ovariectomised ewes (see 
Appendix 1). Oestrogen and MMP synthesis are potentially linked via the common involvement of 
the AP-1 promotor element.
420,620 Oestrogen receptor levels were found to be very low (in fact 
barely detectable) in cultured synovial fibroblasts, though levels were slightly higher in cells 
derived from in ovariectomised or meniscectomised sheep (Figure 3.55). A similar modest increase 
in oestrogen receptor expression was seen following ovariectomy in a previous trial, using a whole    211. 
cell uptake method (see Appendix 1).  Smith et al. (2000)
775 recently reported upregulation of 
synovial oestrogen receptors after meniscectomy in sheep, using both a competitive binding assay 
and immunohistochemistry.  
 
While having little effect on synovial fibroblasts, ovariectomy was found to significantly alter 
cytokine release by primary synovial isolates. The increase in IL-6 bioactivity in ovariectomised 
cultures seems contrary to the report by Kawasaki et al. (2000)
411 showing that exogenous 
oestradiol increased IL-6 production by rheumatoid synovial fibroblasts. However IL-6 activity was 
generally very low. IL-1 bioactivity was reduced in cultures from ovariectomised sheep. This is 
consistent with a report that oestrogen (over the range of 1-100 ng/ml) induces a dose-dependant 
increase in IL-1 secretion by rat peritoneal macrophages, whilst ovariectomy leads to a reduction in 
IL-1 synthesis reversible by oestrogen replacement.
361 The greater response to ovariectomy in 
primary over passaged synovial cultures is consistent with studies by Cutolo and co-
workers,
161,163,165 suggesting that synovial macrophages are a more important target for modulation 
by oestrogen than fibroblastic cells.  
 
3.4.2.3    Bone Changes After Ovariectomy 
 
The findings in this study confirm those of a recent report by Hwa et al. (2001)
367 showing that 
ovariectomy results in active remodelling of the subchondral bone region, with net loss of BMD and 
subchondral plate thickness, and increased neovascularisation of the calcified cartilage layer. This 
study shows loss of subchondral bone mineral density (MTP and LTP) and subchondral plate 
thickness (LTP and LFC only). Loss of bone mass is of course expected as part of a generalised 
skeletal loss secondary to oestrogen withdrawal, as is well characterised in the ovine ovariectomy 
model.
581,840,844,845 In this trial ovariectomy lead to reduced BMD at all extra-articular sites 
measured, though this loss was statistically significantly only in first lumbar vertebrae, a site known 
to be useful for measuring post-ovariectomy BMD responses in sheep.
844 Lumbar vertebral sites are    212. 
important sites for assessing postmenopausal bone loss in women; for example, lumbar BMD was 
12% lower versus age-matched control subjects in one study.
592 Turner et al. (1995)
840 has shown 
bone responses to ovariectomy occur slowly in sheep, and only early changes in bone mass are 
observed six months post-operatively. In addition, seasonal variation
581 and the effects of stress
845 
may mask the responses observed. 
 
Other measured parameters failed to show a significant disturbance in bone turnover following 
ovariectomy. Serum osteocalcin and urinary collagen crosslink levels were not significantly 
increased by ovariectomy alone in this trial, as has been shown in other studies.
127,387 Similarly, 
ovariectomy induced no detectable changes in cancellous bone histomorphometric parameters. 
Other ovine studies have reported a lack of cancellous bone responses to ovariectomy within a six 
month experimental period.
127,840,845 It is likely that a longer experimental period and larger sample 
size would be required to demonstrate significant alterations in these parameters. 
 
A significant increase in the number and depth of blood vessel incursions into the calcified cartilage 
layer was observed following ovariectomy. This may be related to the general remodelling 
processes and altered stresses across this layer, or may result from specific biochemical stimuli such 
as cytokine or growth factor release. Several lines of evidence suggest a link between ovariectomy 
and angiogenesis. Firstly, elevated levels of the gonadotropins luteinising hormone (LH) and 
follicle-stimulating hormone (FSH) following menopause or ovariectomy have been shown to 
promote angiogenesis in ovarian carcinomas, possibly by increasing VEGF expression.
731 Secondly, 
ovariectomy influences the IGF-1 axis,
227,811 while IGF-1 also induces VEGF expression in many 
cell types, including tumour cells,
10,72 retinal pigment cells,
655 and osteoblastic cell lines.
269 Thirdly, 
nitric oxide may again be involved, as it is also thought to promote angiogenesis via interactions 
with growth factors.
937  
    213. 
3.4.3  EFFECT OF PRIOR OVARIECTOMY ON THE DEVELOPMENT OF 
FEMORO-TIBIAL JOINT LESIONS AFTER MENISCECTOMY OF AGED 
EWES 
 
Hypothesis: that prior ovariectomy of ewes would worsen and/or accelerate the 
progression of joint changes following meniscectomy. 
 
3.4.3.1    Cartilage Changes After Ovariectomy and Meniscectomy  
 
The development of cartilage pathology post-meniscectomy was found to be significantly modified 
by prior ovariectomy, providing further evidence of the importance of ovarian hormones in 
maintaining cartilage integrity. However, the variety of parameters measured in this study provide 
conflicting information as to whether cartilage integrity was worsened or improved following 
ovariectomy. On one hand, OVX+MX sheep had significantly thicker uncalcified cartilage at all 
points measured, except the inner zones of the MFC (Figures 3.22 and 3.23). This difference in 
thickness was particularly prominent in areas subject to erosion following meniscectomy, 
suggesting that ovariectomised sheep were partially protected from fibrillation and loss of cartilage. 
Lower histopathology scores, and the lack of a significant increase in chondrocyte density in the 
femoral condyles, also suggest that ovariectomised animals showed greater structural integrity of 
cartilage following meniscectomy. 
 
On the other hand, the increase in cartilage thickness in uneroded areas is less clearly a beneficial 
change, as it may represent increased swelling (i.e. water content) secondary to collagen damage, 
rather than an anti-catabolic effect. There is evidence that OVX+MX sheep possessed 
biomechanically inferior cartilage, with greater loss of dynamic stiffness in the tibial plateaux. Loss 
of proteoglycan (toluidine blue staining) was also significantly greater in the LFC (Figure 3.24), 
with a similar trend in other regions. This suggests that the cartilage of OVX+MX sheep, while    214. 
thicker, was structurally inferior and does indeed suggest an increase in hydration. As discussed 
above, explant culture of patellar cartilage was not particularly useful and did not resolve this issue. 
It is worth noting that prior ovariectomy increased cartilage nitric oxide release as it did in non-
meniscectomised animals, though this difference was not statistically significant. 
 
Quantitative analysis of cartilage changes in this OA model therefore suggests that while thicker, 
cartilage of OVX+MX sheep showed greater loss of proteoglycan content, and greater disruption of 
collagen integrity as suggested by the greater decrease in G*. Increased post-meniscectomy loss of 
cartilage proteoglycan has also been shown in a previous trial of ovariectomised ewes, and further 
this was reversed by transdermal 17ß-oestradiol supplementation (Parker et al.,  in press).  This 
evidence appears consistent with the known association between human OA and the female 
menopause,
578 and the protective effect of HRT.
226,758 Numerous mechanisms might explain the 
influence of ovariectomy on the OA process, including disturbance of growth factor levels,
227,811 
nitric oxide synthesis,
406,906, cytokine networks,
161,691 and subchondral bone responses. However, 
greater histopathologic severity of erosive lesions was not demonstrated in OVX+MX sheep. 
Chambers et al. (2001)
122 similarly found that neither ovariectomy or orchietomy had any effect on 
the development of lesions or aggrecan cleavage in the STR/ort mouse model of spontaneous OA. It 
was therefore not possible to confirm the hypothesis that prior ovariectomy would worsen the 
osteoarthritic lesions produced by meniscectomy in this model.  
 
3.4.3.2    Synovial Changes After Ovariectomy and Meniscectomy  
 
In vitro, synovial fibroblasts from OVX+MX sheep showed significantly greater production of 
latent MMPs relative to MX under both resting and IL-1ß-stimulated conditions (Figure 3.49), as 
well as increased IL-1ß-stimulated urokinase activity (Figure 3.50). This confirms the trend towards 
greater MMP production as was seen in OVX cultures. However, synovial fibroblast NO production    215. 
was lower relative to that of MX sheep (Figure 3.47). This result must be interpreted in conjunction 
with knowledge that IL-1ß stimulation significantly reduced in vitro NO production in these cells.  
 
3.4.3.3    Bone Changes After Ovariectomy and Meniscectomy 
 
While ovariectomy induced subchondral bone loss in normal sheep, it had no significant effect on 
subchondral bone thickness changes secondary to meniscectomy. Similarly subchondral BMD as 
measured in intact bones did not differ, though 'cubic' BMD measured in tibial bone slabs (Figure 
3.36) was lower in OVX+MX animals - the latter technique may be more sensitive to trabecular 
rather than cortical bone changes. The comparative lack of post-ovariectomy bone changes in 
meniscectomised relative to unoperated sheep suggests that different processes are responsible for 
bone remodelling in normal and arthritic joints, and that bone responses to the dual stimuli of 
altered force distribution and/or cytokine stimulation following meniscectomy are largely 
independent of oestrogen. This is consistent with the findings of Fazzalari et al. (2001),
219 who 
showed that a different set of mediators may control turnover in OA bone compared to normal 
tissue. However, calcified cartilage neovascularisation and osteophyte growth were significantly 
greater in OVX+MX joints. These changes may relate to alterations in levels of growth hormones 
following ovariectomy as has been shown in other species.
227,811 
 
While subchondral bone was structurally similar, bone explant culture showed that prior 
ovariectomy had a significant effect on the metabolic responses of tibial subchondral bone to 
meniscectomy. OVX+MX but not MX explants showed increased production of PGE2 (Figure 3.45) 
and urokinase (Figure 3.46) relative to control cultures. Both of these mediators are thought to be 
important modifiers of bone metabolism. Urokinase is thought to be important in bone resorption,
695 
while PGE2 has varied effects but is also predominantly associated with bone loss.
24 Hilal et al. 
(1998)
350 used an identical bone explant culture system to demonstrate that tibial bone from OA 
patients released greater levels of urokinase and IGF-1 compared to normal specimens. However,    216. 
the OA samples in this study were derived mainly from aged women (3 men, 6 women), while 
control samples were predominantly sourced from men (4 men, 1 woman). Massicotte et al. 
(2000)
515 recently showed that different levels of cytokine production by osteoblasts discriminate 
two subgroups of OA patients, with a group termed ‘high OA Ob responders’ showing greatly 
increased IL-6 and PGE2 production. PGE2 production was partially responsible for this IL-6 
increase as it could be blocked by NSAIDs. Gender of subjects was not recorded in this abstract. 
Results from ovine bone explants in this study suggest that oestrogen withdrawal has an important 
influence on the metabolic responses of subchondral bone in OA. If extrapolated to human OA, the 
female menopause may have a similar effect and should be considered as a variable in such studies. 
 
3.4.4  EFFECT OF TOPICAL GLYCERYL TRINITRATE ON FEMORO-TIBIAL 
JOINT TISSUES IN NORMAL AND OVARIECTOMISED SHEEP 
 
Hypothesis: that the topical use of an exogenous nitric oxide donor, glyceryl 
trinitrate (GTN), would reduce the loss of bone mineral density following 
ovariectomy in aged ewes, as has been shown in other species.
902,904,906 
 
Hypothesis: that the same dose of GTN which produces the above skeletal effects 
would adversely affect the structural and metabolic integrity of normal articular 
cartilage, in keeping with the known degradative effects of NO on 
chondrocytes.
78,140,322,802,803,822 
 
Hypothesis: given the net effect of NO varies in physiological and pathological 
conditions
381,552 and NO is a key mediator of oestrogen 
activity,
36,329,330,406,666,676,884,890,906 that the response of joint tissues to GTN 
treatment would vary between normal animals, ovariectomised animals, and 
animals with surgically-induced OA.  
 
    217. 
The results of this study reveal that topical application of glyceryl trinitrate to normal sheep for six 
months caused significant changes to the structure and biomechanical properties of articular 
cartilage in the femoro-tibial joint. Uncalcified cartilage of GTN-treated animals was found to be 
thinner, by both direct (needle penetration) (Figure 3.17) and histomorphometric assessment 
(Figures 3.20 and 3.21), in all regions tested. The changes in biomechanical properties of 
NOC+GTN sheep paralleled that of OVX animals, with a similar decrease in phase lag, and 
increased G* in the inner zones of the LTP (Figure 3.17). As with the changes observed following 
ovariectomy (see 3.4.2.1), these biomechanical changes suggest thinner cartilage with an increase in 
collagen content or organisation, and/or a reduction in proteoglycan content or the viscous qualities 
(aggregation) of proteoglycan. Superficial collagen birefringence was increased in the LFC and 
middle zone of the LTP, with similar changes other areas (Figures 3.27 – 3.29), confirming 
reorganization of cartilage collagen. The lower intensity of toluidine blue staining observed in the 
MFC (Figure 3.24) shows that proteoglycan content was also reduced by GTN treatment. Again, 
these changes suggest more an ‘atrophic’ than a degenerative effect, and were not accompanied by 
any detectable gross or histopathological alterations (except neovascularisation of calcified cartilage 
layer). In experimental animal models, osteoarthritis is generally associated with reduced cartilage 
shear modulus and increased phase lag, which is the opposite of that observed here.
33,745 
 
Several of the known actions of nitric oxide may explain the effects observed. Firstly, NO has been 
shown to have direct effects on chondrocyte metabolism, including suppression of proteoglycan 
synthesis, increasing MMP synthesis, and decreasing the level of (and response to) endogenous 
growth factors.
349,561,801 The changes observed might be consistent with prolonged suppression of 
chondrocyte proteoglycan synthesis, or increased loss of proteoglycan due to elevated MMP 
activity. Secondly, nitric oxide is known to influence collagen synthesis in many cell types. NO 
increases collagen synthesis in most connective tissues
925 and dermal fibroblasts in vitro
909, and is 
generally thought to promote collagen production during wound healing.
562,726 However, NO has 
been shown to decrease collagen production in other tissues, including mouse artery
585 and rabbit    218. 
cruciate ligament.
108 In the only published study to examine its effect on chondrocytes, Cao et al. 
(1997)
110 showed that NO reduced type II collagen production by lapine chondrocytes in monolayer 
culture, an effect attributed to inhibition of the key enzyme prolyl-hydroxylase. Changes in collagen 
birefringence observed in this study (Figure 3.27 – 3.29) suggest that GTN increased collagen 
organisation in the superficial zone of articular cartilage in certain areas, though the collagen type 
involved was not identified. GTN treatment had no significant effect on chondrocyte density in 
femoral condylar cartilage (Table 3.4). This result suggests that the pro-apoptotic effects of nitric 
oxide found by some researchers
78,321,481 were not operative in this model. 
 
Alternatively, GTN may have influenced articular cartilage via its effects on subchondral bone. NO 
is known to affect bone metabolism, its dominant role in vitro being tonic inhibition of osteoclastic 
bone resorption.
211 GTN-treated sheep showed a trend towards increased thickness of the 
subchondral bone plate (statistically significant in the MTP) and greater subchondral BMD 
(significant in the LFC). Concurrent increase in calcified cartilage neovascularisation provides 
evidence of active subchondral plate remodelling. Given the hypothesis by some authors that 
subchondral bone sclerosis may be central to the early pathogenesis of OA,
659 and that much 
experimental and epidemiological evidence associates OA with increased bone density,
184,580 the 
sclerosing effects of GTN treatment on subchondral bone might have induced changes in the 
overlying cartilage. However, as discussed in 3.4.1.3, a clear association between subchondral 
sclerosis and cartilage degradation was absent in this study. 
 
In ovariectomised animals, GTN treatment appeared to have an opposite effect, apparently 
reversing of the effects of ovariectomy on cartilage thickness and phase lag (Figure 3.17). It is not 
possible from the variables measured to determine whether this represents a protective effect, or a 
worsened  degradative effect from the combined treatments. The thicker cartilage in OVX+GTN 
animals may be closer to the normal state, or might reflect cartilage swelling secondary to 
disruption of the collagen network. Similarly, the increase in  might represent a more normal state,    219. 
or be due to increased energy dissipation secondary to loosening of the proteoglycan-collagen 
matrix.
745 Importantly,   was significantly elevated in the outer zones of the LTP in OVX+GTN 
animals, relative to NOC as well as to OVX sheep (Figure 3.17). Trypsin degradation of ovine 
cartilage significantly increases phase lag (Appleyard et al., submitted for publication). An increase 
in cartilage thickness and phase is also seen in animal models of OA.
34,746  While OVX+GTN 
cartilage did not show the increase in surface birefringence seen in OVX and NOC+GTN animals, 
birefringence plots were significantly altered relative to controls, especially in the outer LTP where 
a reduced surface peak and elevated intermediate zone bifringence suggested similar collagen 
disruption to that seen in OA (Appleyard et al.,  unpublished data). Such cartilage disruption, 
combined with loss of proteoglycan as seen in the femoral condyles (which was not reversed by 
GTN treatment) (Figure 3.24), might reflect a more severe structural degeneration of cartilage 
compared to OVX alone.  
 
However, there is some evidence that GTN treatment did indeed partially reverse the changes 
associated with ovariectomy. Cartilage histopathological scores were not increased in the MFC as 
was seen in OVX animals (Table 3.2). The increase in patellar explant nitric oxide release seen in 
OVX animals was significantly reduced by GTN treatment (Figure 3.41), though 
35SO4-labelled 
proteoglycan synthesis and MMP activity were not affected. There are several concievable 
mechanisms by which GTN might exert a protective effect after ovariectomy. Firstly, ovariectomy 
has been shown to increase IL-1ß activity in certain tissues.
161,361,605 If this mechanism were 
operating in cartilage, GTN may have an early protective effect similar to that attributed to NO in 
some studies of IL-1ß-stimulated cartilage.
327,793,794 Secondly, ovariectomy leads to disturbance of 
the IGF-1 axis, in a manner that is not entirely clear and may vary between species.
111,227,811,868 If 
ovariectomy disrupts cartilage by inducing cartilage growth factors as is seen in rat growth plate 
cartilage,
811 GTN may be protective, as NO is thought to blunt chondrocyte responses to IGF-1 and 
TGF-ß.
801,803 In this sense, NO may act as a non-specific ‘brake’ on both anabolic and catabolic 
responses.
140     220. 
 
Alternatively, the primary influence of ovariectomy may be in its effect on subchondral bone. In 
this study ovariectomised animals were found to have reduced BMD (MTP and LTP) (Figure 3.35) 
and a thinner subchondral bone plate (LFC and LTP) (Figures 3.20 and 3.21) compared to entire 
controls, as well as a neovascularisation response in the calcified cartilage layer (Figure 3.19). GTN 
treatment significantly attenuated some of these changes, increasing subchondral plate thickness in 
the LFC and LTP. By preventing subchondral bone loss, GTN may have a ‘stabilising’ effect on 
joint tissues in ovariectomised sheep. Similarly, a recent study in dogs attributed chondroprotective 
properties to calcitonin, another agent preventing bone resorption.
496 However, subchondral BMD 
loss and neovascularisation responses were not prevented by GTN treatment. Rather, GTN 
treatment (in common with ovariectomy) was found to significantly promote neovascularisation of 
calcified cartilage. This is consistent with the proposed role of NO in both VEGF and FGF-2-
related angiogenesis.
247,937 
 
Ovariectomy-associated bone loss is well described in sheep.
581,840,843 Wimalawansa and coworkers 
have demonstrated that topical glyceryl trinitrate attenuates both prednisolone- and ovariectomy-
induced bone loss in rats.
904,906 Early results of clinical trials suggest the same effect may occur in 
women,
902 as does the epidemiological observation that intermittent use of nitrates is associated 
with increased bone mineral density in the hip and heel in elderly women.
380 The variables 
measured in this trial failed to demonstrate a significant effect by topical GTN application on 
skeletal bone density. A trend towards reversal of ovariectomy-associated bone loss was seen in the 
tibial and femoral diaphyses, though neither the effect of GTN or the effect of ovariectomy was 
statistically significant. As discussed above (see 3.4.2.3), ovariectomy failed to induce significant 
changes in other indices of bone turnover. It was therefore not possible to demonstrate any reversal 
of such changes following GTN treatment. However, the reduction in trabecular eroded surface 
seen in NOC+GTN relative to NOC sheep (Figure 3.31) is consistent with the proposed skeletal 
effects of GTN. The lack of change in serum osteocalcin is also consistent with both the human
902    221. 
and rat
903 studies of Wimalawansa, which found that GTN treatment failed to negate ovariectomy-
induced increases in serum osteocalcin, suggesting it may have a positive effect on bone formation 
separate to any effect on osteoclasts. It is likely that a larger group size, and/or greater time period, 
would be required to show consistent effect by GTN on bone indices in this sheep model. 
Alternatively, the frequency and dose of GTN treatment may have been insufficient. Wimalawansa 
et al. (2000)
905 demonstrated the importance of dose frequency in their rat model, finding that while 
once daily treatment prevented bone loss in ovariectomised rats, twice- or thrice-daily treatment 
was ineffective. Efficacy trials in humans and rats have used once-daily treatment.
902,904,906 The 
GTN dosage used in this study was limited for practical reasons to twice weekly application. While 
this dose of GTN was demonstrated to have significant effects on cartilage structure, and to 
regionally  increase subchondral bone plate thickness in both control and ovariectomised animals, a 
consistent effect on bone mass was not demonstrated in this study. 
 
3.4.5  EFFECT OF TOPICAL GLYCERYL TRINITRATE ON THE 
DEVELOPMENT OF FEMORO-TIBIAL JOINT LESIONS AFTER OVINE 
MENISCECTOMY 
 
Hypothesis: given nitric oxide synthase inhibitors reduce the progression of 
experimental arthritis,
525,619,792 that GTN treatment would worsen and/or 
accelerate the progression of joint changes in the ovine meniscectomy model of 
OA. 
 
Treatment with glyceryl trinitrate was found to significantly affect the structural alterations seen in 
cartilage and bone following meniscectomy. While there was no grossly visible difference in 
cartilage pathology, other measures suggest that the cartilage of GTN-treated animals was degraded 
to a greater degree compared to untreated animals. MX+GTN animals showed thinner cartilage at 
central testing points in the LTP by the needle penetration method (Figure 3.18), though this was 
not confirmed by histomorphometric measures. This suggests greater severity of articular cartilage    222. 
erosion. The cartilage was biomechanically inferior, with an overall increase in phase lag, and a 
greater reduction in G* in the outer zones of the LTP. Further, histopathological scoring revealed 
greater structural degeneration and loss of proteoglycan in the MFC, and a greater degree of 
chondrocyte cloning in the LFC. Together, these results suggest that topical treatment with glyceryl 
trinitrate worsened cartilage degeneration following lateral meniscectomy.  
 
Glyceryl trinitrate particularly influenced the subchondral bone remodelling processes associated 
with meniscectomy. GTN-treated animals showed a greater increase in subchondral bone plate 
thickness in the middle (in-contact) zone of the LFC, and reduced loss of thickness in the outer zone 
of the MFC, relative to MX sheep (Figure 3.22). Similarly, treated animals showed a greater 
increase in subchondral bone density in the LFC and LTP, and less loss of BMD in the MTP 
(Figure 3.35). Induction of endogenous NO production in bone is thought to be a protective 
response against cytokine-stimulated bone resorption in pathological conditions.
362,483,664,665 NO is 
known to inhibit both osteoclast function,
88,405,486 and osteoclast differentiation from precursor cell 
types.
88 GTN, as an exogenous donor of nitric oxide, appears to have had a similar bone-promoting 
effect. It is interesting to note that the effects of GTN were more pronounced in the disturbed 
subchondral bone of meniscectomised animals, compared to its slight influence on remodelling 
following ovariectomy. This may again support the hypothesis of Fazzalari et al. (2001)
219 that a 
different set of mediators might predominate in the remodelling processes of OA subchondral bone, 
compared to those operative during normal homeostatic turnover. It also suggests that endogenously 
generated nitric oxide may be a prime mediator in the subchondral bone plate sclerosis that occurs 
in OA joints.   
 
GTN treatment also promoted osteophytic remodelling, increasing the cross-sectional area of 
marginal osteophytes especially in the femoral condyles (Figure 3.26). Van den Berg et al. (1999)
858 
found reduced growth of osteophytes in iNOS-deficient mice, an effect possibly linked to TGF-ß 
production. Serum osteocalcin levels were similar to NOC animals, and significantly lower than    223. 
that of MX sheep. Urinary collagen crosslinks  showed a similar trend, with GTN reversing a 
meniscectomy-associated increase in deoxypyridinoline excretion (Figure 3.40), though this was not 
statistically significant. This suggests that GTN treament attenuated the increase in bone turnover 
observed following meniscectomy. In vitro, NO has been shown to reduce osteoblast proliferation, 
activity, and viability.
170,171,362,665 However, topical GTN treatment did not affect the ovariectomy-
induced increase in serum osteocalcin levels in human and rat trials.
902,903  
 
In the combined OVX+MX model, there is also some evidence that GTN-treated animals 
experienced greater cartilage deterioration. The strong trend towards lower body weights in 
OVX+MX+GTN sheep may be secondary to increased disability and joint pain, leading to altered 
grazing behaviour, as was proposed in Chapter 2. This difference in body weight was unfortunately 
a confounding factor on other variables, as cartilage thickness and bone mineral densities were 
found to be positively correlated closely with body weight (data not shown). However, 
OVX+MX+GTN animals showed a significant increase in phase lag not observed in OVX+MX 
animals, as well as greater decrease in G* overall. As the dynamic biomechanical properties of 
cartilage should be mostly independent of body weight, this suggests that the OVX+MX+GTN 
group experienced greater cartilage degeneration relative to the OVX+MX control.     224. 
CHAPTER 4 
 
CONCLUSION AND SUMMARY 
 
These doctoral studies make important contributions to the scientific literature in three main areas. 
Firstly, understanding of the ovine meniscectomy model of osteoarthritis has been importantly 
extended. Novel computerised image analysis methodologies were shown to provide improved 
quantification of the structural changes affecting cartilage and subchondral bone in this model. 
These methods offered distinct advantages compared to traditional qualitative or semi-quantitative 
outcome  measures, and were able to confirm subtle structural changes associated with various 
interventions (ASU, GTN, OVX) where no gross changes were evident. Further, bilateral lateral 
meniscectomy was shown to induce significant structural and metabolic changes in synovial and 
subchondral bone tissues, in addition to the well-characterised cartilage changes. Both gross and 
microscopic synovitis were confirmed to be a feature of this OA model, with an increase in intimal 
hyperplasia, inflammatory cell infiltration, vascularity, and fibrosis demonstrated following 
meniscectomy.  
 
Meniscectomy was also found to induce a significant elevation in plasma oestradiol levels. The 
observation that an increase in circulating oestradiol can occur secondary to an induced OA-like 
process is potentially very important, given the suggestion by some authors
68,838 that local 
production of oestradiol within OA joints may represent a potential source of circulating hormone. 
Further studies with this model should include analysis of both blood and synovial fluid levels of 
oestradiol to further examine this possibility. 
 
However, the in vitro responses of cultured ovine synoviocytes to both meniscectomy and IL-1ß-
stimulation were modest and showed some inconsistency with previous studies in other species. It    225. 
seems likely that true species differences exist with regard to the in vitro responses of arthritic 
synovial tissue. Alternatively, these results may reflect the inherent flaws of monolayer cell culture 
as a model of investigating synovial tissue changes. Cultures of passaged synovial fibroblasts fail to 
model the Type A/Type B synoviocyte interactions and cartilage/synovial interactions that are 
likely to be important in the synovial responses in osteoarthritis. In addition, the extremely rapid in 
vitro proliferation of intimal fibroblasts, a cell type which normally has a low mitotic rate, is highly 
artifactual.
337,339 Ex vivo methods such as immunohistochemistry or in situ hybridisation may have 
yielded different results regarding the nature of synovial activation in this model.  
 
 
Secondly, this study demonstrated significant changes in joint tissues secondary to oestrogen 
withdrawal by surgical ovariectomy. Ovariectomised sheep were shown to have thinner articular 
cartilage in some regions, with altered dynamic biomechanical properties related to reduction of 
proteoglycan content and reorganisation of superficial collagen structure. Patellar cartilage explant 
studies showed an increase in both proteoglycan synthesis and MMP activity, with a net loss of 
proteoglycan. This confirms the findings of previous studies (see 1.1.4) showing that ovarian 
hormones, principally oestrogen, are important regulators of chondrocyte metabolism and cartilage 
homeostasis. Cartilage events may also have been influenced by subchondral bone processes 
occurring simultaneously. While generalised skeletal bone loss was detected, bone remodelling was 
particularly prominent in the subchondral region, with loss of subchondral plate thickness and 
BMD. These changes were accompanied by neovascularization of the calcified cartilage layer as 
described by Hwa et al. (2001).
367 However despite regional thinning, cartilage of ovariectomised 
sheep was not obviously biomechanically  inferior to that of normal animals, and the changes 
observed were more atrophic than osteoarthritic. More time may be required to observe any long-
term degenerative sequelae of these cartilage changes, though some early histopathological changes 
were observed. 
    226. 
Prior ovariectomy was also shown to significantly influence the development of joint changes 
following meniscectomy. However, as the increase in cartilage thickness observed might be due to 
reduced erosion, or due to increased disruption and swelling of cartilage, it was not possible to 
conclude whether the cartilage degenerative process was improved or worsened by ovariectomy. 
The greater biomechanical disruption and proteoglycan loss in some areas suggests that cartilage 
degeneration was worsened in these animals. This is consistent with the observations that (i) prior 
ovariectomy significantly increased synovial fibroblast MMP and urokinase activity following 
meniscectomy; and (ii) prior ovariectomy significantly influenced the metabolic responses of 
subchondral bone to meniscectomy, increasing urokinase and PGE2 release by bone explants. 
However, prior ovariectomy had little effect on the structural bone alterations induced by 
meniscectomy, though osteophyte growth and calcified cartilage neovascularisation were also more 
pronounced in ovariectomised sheep. 
 
 
Thirdly, this study is the first to show that the nitric oxide donor glyceryl trinitrate, a ubiquitous 
human medication used for symptomatic treatment of angina pectoris, is capable of inducing 
structural and biomechanical changes in ovine articular cartilage. Topical treatment of ewes with 
GTN was found to produce cartilage changes similar to those induced by ovariectomy, with reduced 
thickness and altered biomechanical properties of femoro-tibial articular cartilage. Regional loss of 
cartilage proteoglycan, altered collagen distribution, and calcified cartilage neovascularisation were 
observed. These findings are consistent with chronic derangement of chondrocyte metabolism, as 
might be predicted from the known deleterious effects of nitric oxide in cartilage. GTN treatment 
also induced calcified cartilage neovascularisation, and increased subchondral bone thickness and 
BMD in some joint regions. If these findings were applied clinically, the safety of NO-donor 
compounds may be questioned. Indeed, some epidemiological evidence of an association between 
nitrate use and hip OA was recently presented.
450 However, it should be noted that the cartilage 
changes observed in this study after GTN treatment are not necessarily degenerative, since minimal    227. 
evidence of cartilage pathology was observed. In experimental animal models, osteoarthritis is 
generally associated with reduced cartilage shear modulus and increased phase lag, which is the 
opposite of that observed here
745.
33,745 Additionally, ovine knee joint cartilage is less than half the 
thickness of the equivalent human cartilage.
47 Nevertheless, the current findings indicate the need 
for further epidemiological investigation into the cartilage effects of glyceryl trinitrate and other 
nitric oxide donors. 
 
While the topical use of glyceryl trinitrate did not significantly reverse skeletal bone loss in 
ovariectomised ewes as has been shown in rats
906 and women,
902 it did attenuate post-ovariectomy 
thinning of the subchondral plate in some regions. In addition, GTN treatment increased 
subchondral bone plate thickness and BMD during subchondral remodelling following 
meniscectomy. GTN treatment was also found to slightly but significantly worsen cartilage 
degeneration following meniscectomy. This suggests that clinical use of GTN may accelerate both 
cartilage degeneration and subchondral bone sclerosis in patients with concurrent osteoarthritis. 
 
In this combined trial, either ovariectomy or GTN treatment were found to induce very similar 
structural and biomechanical changes in articular cartilage. The observation of increased in vitro 
nitric oxide production by patellar cartilage from OVX sheep, presumably the result of iNOS 
induction, suggests that this similarity may be due to the prime involvement of NO in both 
processes. However, the apparent reversal of the effects of ovariectomy by GTN treatment suggests 
otherwise. While there are plausible reasons why GTN might be protective in this case, this paradox 
may in fact be an illusion created by greater structural deterioration of articular cartilage in the 
combined OVX+GTN group. It was not possible to confirm whether articular cartilage was more 
normal, or instead showed a greater degree of disruption with the combined treatment. Either way, 
results confirm that ovarian status has the potential to influence cartilage responses to GTN 
treatment. If extrapolated to human usage, these results suggest that oestrogen (i.e. menopausal) 
status may influence cartilage responses to clinical nitric oxide donors.     228. 
 
 
Further studies will be necessary to confirm some of the extended hypotheses in this study. In order 
to confirm the biochemical basis of the cartilage changes observed, more direct biochemical assays 
on cartilage tissue (e.g. collagen content (as hydroxyproline), proteoglycan content (as sulphated 
glycosaminoglycan), water content) could be included in future trials. Immunohistochemical studies 
might be used to confirm the induction of cartilage iNOS following ovariectomy, and to resolve the 
exact nature of the association between ovariectomy and the IGF-1 axis in the sheep model. 
Cartilage collagen changes should be investigated with particular reference to the collagen types 
involved, as aberrant chondrocyte expression of types I and III collagen is noted in disease states 
such as OA. Double immuno-staining of synovial tissue may confirm that macrophage-like synovial 
cells are a more important target for oestrogen modulation than the (here relatively inert) 
fibroblastic cells. In addition, this study intentionally used a fairly crude bone explant system to 
examine changes in subchondral bone metabolism in an attempt to replicate the findings of Hilal et 
al. (1998).
350 To further these investigations, more sophisticated culture methods (e.g. osteoblast 
culture) or immunohistological methods should be used in future studies. 
    229. 
APPENDIX 1 
 
SELECTED RESULTS FROM ANOTHER TRIAL OF 
OVARIECTOMISED AND MENISCECTOMISED EWES 
 
The following results were obtained from synovial fibroblast cultures derived from a previous, 
related trial of ovariectomised and meniscectomised ewes conducted by the Institute of Bone and 
Joint Research, University of Sydney.
367,611,769,775 A number of aged (8-10 years old) Merino ewes 
were used for this study. Six of these were ovariectomised by midline laparotomy (OVX), six were 
subjected to bilateral lateral meniscectomy (MX), and six served as non-operated controls (NOC). 
Animals were euthanased six months post-operatively. Synovial fibroblast cultures were derived 
using identical techniques to those described in 3.2.7.3. 
 
1.   Synovial Fibroblasts – Oestrogen Receptors (Whole Cell Uptake Method) 
 
Method:  Oestrogen receptors were measured by a whole cell uptake method.
208,704 Briefly, cells were cultured to 
confluence then incubated with 10nM [2,4,6,7-
3H]17ß-oestradiol [Amersham, UK] in the presence or absence of a 100-
fold excess of non-radioactive oestradiol. After incubation for 30 mins at 37°C, monolayers were gently washed three 
times with warm PBS, trypsinised, and harvested onto filter paper discs using a cell harvester. Specific binding was 
determined by subtracting non-specific from total binding, and expressed as molecules bound/cell. 
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2.   Synovial Fibroblasts – MMP (Gelatinase) Levels  
 
MMP-2 and -9 levels in conditioned media from confluent primary cultures, as determined by 
quantitative gelatin zymography
391,424 (mean summed density of all relevant bands (as % of NOC 
mean) and percentage active form, n=4 per group) and corrected for cell number. 
* differs significantly from NOC, p=0.027; † differs significantly from MX, p=0.019 
 
GROUP 
(n=4) 
Total MMP-2 
(% of NOC) 
% active  
MMP-2 
Total MMP-9 
(% of NOC) 
% active 
MMP-9  
NOC  100.0 ± 14.1  42.5%  100.0 ± 29.2  8.3% 
OVX  178.9 ± 95.6*†  33.0%  213.3 ± 157.1  5.5% 
MX    92.2 ± 17.0  41.8%  131.4 ± 125.8  7.7% 
 
Method: Conditioned media were diluted 1:5 in dilution buffer (50mM Tris, 0.15M NaCl, pH 7.2) before mixing with an 
equal volume of Tris-glycine SDS PAGE application buffer (0.0625 M Tris-HCl, 10% glycerol(v/v), 2% SDS(w/v), pH 
6.8 with 0.0025% (w/v) bromophenol blue) and incubated for 30 minutes at 37°C to allow formation of SDS-protein 
complexes. 20l samples were loaded into 10% homogenous polyacrylamide gels containing 0.1% gelatin [Novex, USA]. 
A standard solution of MMP-2 (6U/ml) [Boehringer Mannheim, Germany; from human fibrosarcoma cells] and a 
molecular weight standard [SeeBlue, Novex, USA] was run in each gel. Electrophoresis [XCell II Mini-Cell, Novex, 
USA] was conducted at 125V for 120 minutes in Tris-glycine buffer (0.025M Tris-HCl, 0.192M glycine, 0.1% (w/v) 
SDS, pH 8.4).
443 Following electrophoresis, SDS was removed during incubation in 2.5% Triton X-100 (30 minutes, room 
temperature), with gentle agitation on a platform rocker. Gels were then incubated for a further 30 minutes in 50mM Tris-
HCl, 20% glycerol, pH 7.2 to promote protein renaturation.  Digestion of the gelatin was allowed to proceed by incubation 
(18 hours, 37°C) in 50mM Tris-HCl, 100mM NaCl, 20mM CaCl2, pH 7.2. The gel was then stained for 1 hour in 
Coomasie R250 solution (0.1% (w/v) in 40% (v/v) ethanol and 10% (v/v) acetic acid) and subsequently destained in 10% 
(v/v) ethanol, 7.5% (v/v) acetic acid. To quantify the density of the digested bands, each gel was scanned at 300 dpi  on a 
flat bed scanner. An inverted greyscale image was analysed with the gel plotting macro in NIH Image [NIH Image 1.62, 
National Institutes of Health, USA], using the areas under the density plot for each lane. Values were corrected for 
standard values and the results presented as percentage of control mean. 
 
Sample gelatin zymogram.  
Lane 1- MMP-2 control; Lane 2 - media blank; Lane 3,4 - NOC: Lane 5,6 - OVX 
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